var title_f35_46_36576="Dentinogenesis imperfecta";
var content_f35_46_36576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dentinogenesis imperfecta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked discoloration and severe attrition of the primary dentition are seen in this child with dentinogenesis imperfecta type II.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright WB Saunders 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36576=[""].join("\n");
var outline_f35_46_36576=null;
var title_f35_46_36577="Twin peak or lambda sign";
var content_f35_46_36577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Twin peak or lambda sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 247px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD3AZoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDnNA/Zf1fWdF03U4/EdhHFe20VyFaByVDoGx15xmvn27gNtdzQMwYxOyEjocHFfpH8ObkDwF4XTb/zC7QZz6wpX5xawc6ten/pu/8A6EaAKdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFOxxTakzlQOKAOuj8DrPbW32TxR4alvpIo5ZbV74Q+SHAIBkkCxswB+ZVYkEEYODWJb6HcXfiaPQ9Pmt7y5luhaQywMTFKxbaGUkAlT2OOlej6f8WxbabZ2rzeKyLeGOICPVbVUGxQvyqbQkDjgEk+5rz+PX5IPGa6/bCQyxXwvYxO4diQ+8B2AUE8ckAZ9B0rmput73MvQ1l7PSx3Oi/Cax1W/Onx+OdDTUslRa7JGcsoJYYA7AH8q8tlQRXEiK28KxUNjqPXFeo3PxP0dfECaxpHguz0y9Ek8kksd68jymWKRHBZgR1kzwB07ZrhbDQ7y/voWktpoLa4Q3KyOuA0W9l3KTwfmVlHuD6VOH9um1V2t5b632+RVX2drw/Xb5lq6sNPutB0iTRLe/wD7S/eJfmdk8p23fIYQOcbc53d+lc7LE8UrRyoySKcFWGCD9K9XOiuts5sLd5oo1w9vIcOg6D5RnK9t3WqNxDp95DH58QEu/bsmXdjPXB4746EV1mB5nSV3cvhK0uplS2W8t5Cm4qgE4XB544YDGT1NZV54Su7ZNwntH+TeBuZM+w3qM9ulAHM0VqtoOpKBttGlycfuWWQ+2dpOOtIugauxwumXh/7Yt/hQBl0VsReHdWeUxmwljYLu/fYiGPqxAqe28MXczukktrbsn3hJJuwcZA+UHk9qAMCnKpY4HJ9BXZ23hfT4IzcXd4blVwPJRhEznI4A+ZiPwH4VqReRYQMltYfZd4AVnUo0id/V25HqB7UAYcmhWy+CjO9pfR68tx5p3SJ5RtNnUJjduDdc9v05MjFd1c8hhmbBIEalcZPqT+ea5zVNKuIrdr9LdvsRkWJ5EX93HKwLCMnsSASB6A+lAGPRRRQAUUUUAFFFFABRRRQAV0Nr4P1q6ttKlt7VXfVZRFZW4mTz58kgOsWd/l5VhvxtypGawERpHVEUszHAAGST6CvoZrjxX/ZWhQt8PvFF1d2dtHZSJLprItrbi1e2lW3kC7iZlfed6kI6jAfOQAeXWvwx8S3V2ILaPTJN/liCYapbeVctIzqiQyeZtkctHINqknKkHFcZNE8LskilXUlWVhggjqDXvHhHwyPDd3qH2Lwd8QIrx1gW01Z9CSe4iALGVo4mISFj+7AfdIw2sQV3YHmk/wAOPG7SsV8I+JGDMcF9Ol3Hnv8AL1oA5vSbFtSvltkkWMlHfcwJHyoW7f7uKpV6F4Z+H3jK01hJbnwnr8UYimUs+nygZMTgDJXucD8a4rV9L1DRr02er2N1Y3aqGMFzE0TgEZBKsAeRQBSopetGDnHegBKKXtQQR1FACUU7a3oaTB9DQB+jPw9uMeDfCsewc6bZDOfWGOvzw1X/AJCl5/12f/0I1+gHgG42+GvCkewf8g+wGc/9MY6/P7VOdTu/+uz/APoRoAq0UUUAFFLijafSgBKKXB9KCCOooASiiigAooooAKKKKACiiigAoopR1oAltoJLmVIoEeSZ2CoiDJYnoAO9e8+DfB1vp9jDbwbriaQK88sWGEnGSFyAcgj5fXk4rhPCNhbE22pJYCB4oAMGQtvYZJm5GVJ+UADjg+teuWV5aPbxJckSzFDK8wcq8b5LZbs2MZ9zxntQBnalps0G2CVfLn2ZVrdwQcDkFjnBIzn8ada2kcokSZLfYI3ZpbchgqnnodwYDnjr2GeldMbqxuIRLcWbLA0QDkkLIOeWx0bI7deap6voNssJFokiwzjdtY7QfRdgByTjGD0OffABzyaOYoLe4i+yXcWBvVXNuyJkKAnpncCSf0rJ1W1YSrHY2+qmSN9uzzFkCENjAJHy5yCPUV2cWmsUZrv7SXaVnEqHBYjGVHPC4AHHXqM1DfW06qUYo6TOqoiSDgdQnHRm2jk9Nv4UAefTbLiVbe/N3F5ZYK2xWOT97gDIA75zjHGRmnvaebG81jZR3MBysrR3KhzuwMoCB8p7YHGa6mdmdhuKli67rtsrKqEdBgDnIx1/OkuFvJrkwTKrSIxijWQCOTy88MCMDaFA/XrmgDmjbypdIr2Vmm3KeXJKxdRjoAOcArj69etSR2V3IDMbQzzABCrRs7F8/wAQHGcdiQOGrejiYu0UFvAG3SbJZk27/ukjqf064FSOkzFA9xLEqoZYog/kBjtzyOpIBHtyKAMaHQLrSrlvltrbyoczC5OJkR+hAxtbGPu5OMjrU1ho1utyt4dTlv50O77QkuwRr6ZOTt7EjH071b1W1Lyy29gy5Q7dpHmnaygnaCeeec5P4VX02waWQROWkt4wSpQfcdgNrY4zn0H91qAKl5ptrLIs90gCyAyRxxLtR3wdyhicgYDc55788Vi+III9aEVsU8qBU/dWdrGE2HHGRj5m5Bz35ruZdISezMapBaKzDdc3b5dlbBBVgPkAwSAP72MZFU30ZU8uORZ7S3cEfLGMvwc8kg8gZ56Z6GgDwXUbKWwunguFw6ng44YdiPY1Vr1fxZoEF1pTpbWKpeQAG2YyEu0a7iybQPmOD1PQrx9415Uw5PagBtFFFABRRRQAUUUUAXdFONZsCTgC4j/9CFfSnjPw1ql9dSJfrevpTajrUiw2mkNNLaqb+F9zrvHnJIFyB8p2hsbsYr5lsUMl7boswhZpFAlJwE5+9ntjrX0lBJeX/iDXNMg8SeL7JtBv5dMkuLjX7iT7aRBdss5VVBVla3VtqZynGCQWYA6BbdD4X0zTrnw/JbaVDra3uo29jp08UN7pod0Fw0HLKXcQsbfLMAivt29OP03wb4juvB/i9tVuPEFjfJpdpHJZIhP9pBYGMSMSCS0ZEYO0kgZQ4JJrz7xprnjbwvq0VufHGvXlvcW8V9Z3UeoXCCaGVdyPtZtyEjgg9Mdxg1z4+IPjMYx4u8Q/L0/4mU3H/j1AHvrR+IdCsLbUof7VfyrfWhZ2unaUDcW8kl9HtV2cOHWQfNkoCqBioYjNeMfGqS8l8YQSareNfag1hbG4uWtWtTI+z/nkyqygcKMqu4ANj5qTwr498YT+J9Ihm8WeIJIpLyFHRtSmIZS4BBG7kY4rj9W1S/1i9a81a+ur+7cANPdTNK5AGACzEngUAUwcGvR/COp6ZP4Dh0rxFc28Olp4n0+WZEjUTfZjHcCdztG9wAVHO7bkAYzg+b0oJHSgD6TOtWD+I5p4tX0+z1aY2LTWj6lby29hp8c8vnWsE6hY2iaMwv5K/NtypDkNXPSaV8ObplT7NYJJcCD9/HqpjA8+G5dnKE4UxmKEbOgaQBsghK8NzSUAe16xo/w9awvYbG3s4bxLW98q4i1cuN8NrbzRsFLEEvLJJGBnGFZQCw3L4zyedhqOkoA+9/At266F4VAROLCwA/78x18I6l/yEbr/AK6v/M19seCrt10XwyNseBY2IHX/AJ4x18Tah/x/3P8A11b+ZoAr0UUUAdh4QtoJvB3juWaCKSWDTbd4XdAWjY31upKk8glWIyOxIrovBngfSNV0TRv7Q/tE6hrjX6W9xA6rFYm2i3jehUmTcfvfMm1eea4HQte1bQLiS40PVL7TbiRPLeSznaJmXOcEqRxkDj2qceKNcEOowjWtTEWpMXvUF0+Lpj1Mgz8xPvmgD0q3+Hnh7UoNJs7GTVLbUZbjQorq5llSSE/2hAZGCRhQRsIyMsc5IxwCeV8faFotj4Z8Paxodlq1h/aU97FLb6jMspUQtGoKkImR8zZyPvBl/hyeaj12/HyT3Vxc2zGDzbeWZ/LmWEbYkbDA4VcqMEEA8YrW8feOtU8ayWX9pJDFDZq4iiieWT5nILOzyu8jMdqjliAFAAFAHJ0UUUAFFFFABRRRQAUUUoGTgUAJW/oehPcXlo10YTbPGLghZVcsm8rtIU5ViVb5Tg457jOPa20tzOsUCF5G6KPpk/pXrfhnT7aysRaxtPFhQ/mAE7nIwW2+hGOO2BQBf0+x+yXxlZljRRtUpkl14wyj2xj8/TNaQZJN8c8G2R0wWjYsY8DJP5gcdsjmq+iQFb9FgaQyqCckk4RR9zP8JJzx+VbCYW4EEjW7Qoxxuk25Ug7FLEcHnt+tAFWG5gtwytNFHIp8shtzdfvYB64x39sdKS1u3VEbeAjJho4nz0zkcnO7oevf1NNvrN7e8BdVfMaruVCu4jqCx4B54IxVBZWtozsUxq6kPwPu5+7k/wD1jQB6Na6jJKpM2biUIPLeHB3EA/eBGcfN9cZ9aklfSpbYbZwJJGXPmlh5ajkk9uOQAPzriradpGt4HMsYIO4Pnf8AdBAOf4sEHHXipbq/b7RsLpGqqhLpwhIIbJ6ZY8jnBGe9AHU3Vuk/kra+dnzTIWeQSZIJxk/xZGMnp8opp05g0yhdys+5HAUD73UhiQowOufyNcub5zKt1NBLgEkeWwJwvJVQBzjJ5IFX57tfLRk2rGVWSQE7sZyMkqSOe/09aANF10hVjEW6KSFgiyI+xXP3st6kHIUkk4PPaom/sqBmSO0tZd0oMZ3lpHbgctj0Zeh7dMiqsOq3GCJQsMiqsiLtH3ghHpnHNRzapdR7RaXDqD8wQ42gYIwFHRjx74zQBvX7XLSRn7J5Uo8uMiRyEUE8qQQDjGMgelVbmylmkmihW3ktxKFcyOI1V8/dLHAOTnpnORnrWFfXbBJI2+0bJP8AWt5uSh4z3OT0Gfc9OlV5dSaSKKdSjIcxDeSw6Y4B9AMe4oA6J3uo/tCW9rZSKDtKKS5QjIwR6EnI47+tUbp9QDvNc26RyzLhJ5Y9jk55ZMk9xgjHINY8t6zXKyRzpJb7NxaAbPLk/ToeeMjpQdbuZDbjyYnZCyNj5dw+9nOMKCTyD7YxQBm3IubncILNUiJ82SVwRISM8E8YH5elea+MdF8kS6paGI2zSLHKquoKyMCQQuclTtY5AwDgEgkCvStX1W8vpZZbpw10w8sosfI7EY6AYB9c9c81yGoraNHMyRFFlHluv3yScZ9Mf0oA84oq1fWrWtw0Z5A5U+o9aq0AFFFFABRRRQA+KN5ZEjiRnkchVVRksT0AFera4njWz1LS9NtfGsur69p8z6emnWV1O1xZSlXVwCyqGATcpkUnb0yABXlUMrwzRyxMVkRgysOxByDXqz/Ge7eaIjSIVt5Zrie/gNy8iStcKyzCFZNwhVt5crhhv5+78tAHH69o3izUhqWv61Y6rc+XM0d7fXEbNskVljKOx6EEqu3twOlNfwF4pS5u7dvD+pia0iWe4XyD+5jZWYO3YLhG5PQqR1GK62b4w3hllmi0/wD0kPO8E81x5jR75bV0z8oDbBaInQAg9sAVS8YfE0+INJ1DT4dNezt7yOFdv2kMsRWaSZ9qqija7SA4OSCgOSaAK/gvwPra6lY6tfWVxYWMCR6lDLdQui3aLJGdsTYwSVcMO2O/SuAr2Oz+Kja5qUVjJokENxqlz/pVylxI2+ebyVeUI2Qv+qUhRgDOOgGPHKAEooooAKKKKACiiigD7L8IXci6R4dACYWzswOP+mSV8eX/APx/XH/XRv519WeFbqVdK0ADZgWloB8v/TJK+Ur3/j8n/wCujfzoAgooooAKKKKACiiigAooooAKKKKACiilBwQfT1oASlX7w+tdX4fvPDKeHdRs9aXUje3ADwS28EbCCRc7SCXBKkHDD8eoBq9pvhKOJtJvTqFhqFtcW63EkcDk+TIWI8qQMMFgMEqPp3zQBo6DpXn2ccjWkFte/Z1hMcCMGKjne2c5c55xgcAYFdvYQmyfeAG82IeXGq4LHuT3Qgj8fejTDHbpAFKueh8lizgnnPqe2M9MjNbiWsj3DOXaSQNsc428ckjaPvYHfr0AoAitYybMfZ1G5CGLO5BLEA4APJC8YLHqe9S29lItuyOGt5WV+JcYOfu4HJwT0zwPY0kzPCz3R8vcGB8wPtK5GCBngg9z15x1qzfJLHJ5bsH42pHkPt+UnBbsuCSDj+VAGHcQNAVMqFW3dF+bDf1OF7eh44qRLIJMNjLLG371XhTGfl6gcY7E56cVGYRukRiYLuFQu1BlAOzZx9MnsKsxJbwRn7MT8ju3DHawA4PvnONvXjvQBDYRsjCaARkqwIRm3kbhkYPdvcdiMUkqSwzCN40iBXLtkkdieMdPvDJ6GribRcMBA8MfDGPZ+8QgY+8OAO/v1xWePJkupJYCot5MDC5CjpyM5wM+nf60AWxhLqWMloHQsELAHbgkANgfd78ZzkE1VltQtwTcvNAq4aQxZDKAcnb1BzjIHTBrVsIokAld1gwrBT5ZBOAQRjrhs9OepzzUcrMMHYzsOcgBSWI+864+UdBt79qAMyy8l3mRGQzKoeMKGBbnuCQM9Mn8quX0DNbskaDzHDgASkgAE5yD1HQZzwKtabaJdHz/ADI1l3spc/IEJGO4Hz98dx060upRIbSOURymHLC3ZGLb1zuwwOAOeaAKsVpE1uvy+dIqkN5DbPlJwcDjjGPrg1SayWedEMsSEAh3HRFB4I5wevsa17CFn34L7lHCMDtwexPRc5AyOD045qrdKzTJNkzBh8+RtBAXOAQOByP5UAZo09UNv5sRMc0vzyqAxwOCMduMHPWp4EuYriSeMSu7OoYErsQdhtH3uwBPXtV0I1vF5b+YkUK7XxISzgjOAOhxxz1wOait7KCVSXhZN7iEOwAWSUjjHcAf3f5UAYxs3ZpZ7obiHbzABgsOM57HH1rM1HTSXfeytEDiIsPKWPngD2I57117xwo0YEkDJHKzPKy4UsB0wCOhwoIwOuaz9Rt1nMSTQbUjXc20ZwCCdpyeP/rUAea6tBDJYXNtFHbv5hWSOV48yRFc8BgeN+eQQfur078OwKsVYEEHBB7V6pq+nuiHJxJjcFTJK9un9a5fVPD8T6Bfar/aVlHc2s0cJsWLCedWBPmqMYIGMHn1zg4BAORopaSgAooooAKKK+h/DmgaMmieHrtvDYvmiihMSW+nrObx5bKZ5fLLOv20rKqM8Z2eSUKKW5yAfPFFfRumeA7K+8S3mo6rZR3cltCiDT9P0yK1jtN1o0qyX8AJ8o5BUqM/Op56Bub+OPhu2sfDmlX9jpEOmpbzpavJ9h+y/aBJbRuvlkEidVZJd0pwcyKMYANAHlvhAqvi3RC7Kqi+gJZiAAPMXkk9Ky5EaNyjqVdTgqRgg0+2yt1FhgpDjknAHPr2r6L1/QbV/ivpsd94V0yC01G31RYbaawe2uYvLEjq8sSyGORlxhJRuV1JJ+ZRtAPm6iu3s7Cx0vwLBLqiW633iKdY7eaaPzDZWcUg8ycAHcGeQbBgZ2xSj+IV09toHhjTPFuv6Vo9xY+JbA+HLu6ivZAzNazLaSSfJghC24A8g7cgcMpoA8hor1nwP4fMI8L6ZFo+man4i12Y6okWoxu8UFnDHKE3Ko3NvIklKKTuWKIYbftq94gsdK0/xFrfiK68OtZWekWMFstlf6f9kXUNRljZEk+zHIjj+WSbaOMRAcF8AA8Yor1bwvofhmf4Q+Jrz7ZYXHib7H57C4Lq9giXUKqsahCrNIGIMm7ILIuACzHywjntQB9O+G7uRdN0QBUwLW1HQ/8APNK+Zbz/AI+5v99v519B+H7uRdP0gDZgW9uB8v8AsLXz3df8fM3++f50ARUUUUAFFFFABRRRQAUUUUAFFFFABRRS0AWLC3a7u44FZVLnBZjgKO5r1bT30u3EVlvNtbWuShkOQGI5YE5zk4yK8+a7uZ0g87y1lSJIFMcSR/u16BtoGT6sck9zUpuC27PBGMNv6D0oA9lsdTtfLlkmvLYQ3J5RI1XJH3SOpUg/0rRtYYkhbzZN0Ehy86lT8pGex78cdh6V4jHeNGo2tkcqFBwR6mr9lqb2UZVY8gD926PjYeu4YGD9CKAPZdSePAtpI23xbplEcocBMcMueozjK8YFZ19Oly22N4C82cPsYk56c/wgA4J6elefad4subNpYJoF+zzfeyASr93GRwcdhjNdRb+INOlQQwSvZ5CxZ8sMqjgll5yDweO2e+aANxbNpXVXlia4UFFSMYZlOBkYPzDO3r/Prfl3rcAzH7PEGj+QOFRjjgjPJbrgDpzUNk8FzEs0DR+TuKxqqszHA5IB+7uzj61flVnhklYQwHAIgJwzdd4DZxgcEn6+poAqG3FzZMiyJ9mDFGld1PnAc7l9F6/jgYqu8UEX7tpbe0dmVsKANw5ztIyMDIx2+6OoNakpQMzw/Zo8j526h2A5AyuM856Y49qlsmaMwrIEmmCs4ATAdRklW9CDnpj8sUALp1kkauAzMnlSEseTFt5BPXksRmqV7ah1kYlI4mcXMrI4+d2U4IxjK5/U4FaqwMAk8Eiom4xlVBJlOTjGPu/d4wccjJqDUmtJrU3DTKsQZV8yWXywWb+EAZwAykYOMdKAM6WDyLlmnUlpejg5YAcEHPy7xj2qy0YuHdpY1aVWzFFsKjndwxHYDGd1Ou7u1hWZZ5S7ytuOCApJbOFBBwMYHHPNOFykcMkismzazg4LrvGcBhkZPP0xQBAgMkkdsgzHCxKrOdhCAgZH9773TsTVh7TebhCzi4kbEbLhSMYPPQAYxwT6U3SI3gAffH5khVjswskoPQ8Z/i43DPTPFXZISuqLE8aG4uJVJdULYIGFCkjnOCMjBGM0AZSKt7axzwI7K42/MCp2k/MSRwMED29xUNwlxBIiYYxsC/z52B+p59+w9O5roBDIqSea5l3qXiPL7Dwx6DoDnA4+6frWfPFHbNE1w6yTozeQxUhUH3yyKeeD65zk0AMk0+OOB7pEdYREvnKAAVIHUEnoCc8nsM81V1WFLWUGRGjt2cN5ZIIK9G3A9Bnv3CnFW4fMGpNZtawuZI85ZS6RJ1B2k85P3R14yRWreWVtFaebdJiXaCkkibuhwEB4LA4zgdD7UAcBqGnE2m0fu1lDukqIVOAeA2T8o9en06V53qls5jJ8hkBBKhPmVlPuevNexa0kk8S7po/PLlnIXaqZPzAnr7fnXGeKrcF5I2gCzyfccDBZRgYX/HigDx/UbQ2s2M5Q/dP8xVKu9vrGWHT7i13Qi2uZFBcxAHemcFWYblHJzjAPfOBjhpo2ikZHGGU4NAEdFFFAEttC9zcRQQjMsrhEGcZJOBXqOt/DOaC7g0/Q7rV5rm2uri2mu760Fpp6mAv588dwZCAiGPB3AE4z1O0eVqSpDKSGByCO1d2fir4iNzBNt0sNveW7VbCMLqDurI7XC4w5ZHZT0z9773zUAay/CnxFN5MNs8Sas7sl2Zb+FYiHaARhZA3zEtOoOeCSNu6uT1LQLmPw1BqtxrGlyoG2Cw+3BruI7ipBhPK42c+xU+lbg+LfiTz45tumiRJ4bgbbRVG6J4XXhSABm3j4GBjIGM1zV54s1y70NdFm1O7Ojq5kSx8w+ShLFvlXoOWJ/GgC74M0Oz1Ww8QX017JFd6RaLfw2yw7luAJFVwzZ+XG5eMHOT0xz2Xjb4bapbazYw280sutXktxLeO88S2unoB5hjeXflGSMln3hRg/LuHJ4PwZqF1BqUmm2hhVdZjXTJ2kXdiN5YySPQ5RefrXQ3fxW16XUY7mL7INsrvP5lsjnUFYOgF3xibETtHyBwSepJoA6nxJ8M47fwtfX154hvby+021VIFDJPEVjtreYxx/PvaP/SH2tGpVVXc20HNeMeY0bHy2K5BHB7HqK7+7+LOu3MF1G1losbTLJHFLFZKr2ivbpbusPOEBijVcY+lefMQegxQBYkvrqe5Wee5nknVFjEryEsFRQiqCTnAUBQOwAFdZe+F/EMV7pGja1qENhDqNoNXtjqN75duFePhyW4VysYX1yAPSuPs5xbXUM5jjl8tw/lyruRsHOGHcHuK7bW/ij4g1K9try3FnpV9b3NxdrdaZEbeVpZwBKxYE53bRn6UAaFr4E0xfC+uXU2s3AurBJQ13AkbaZLIuGS3WfeDLI4wQFUkEjIwCa85BOBhv/Hq7C8+I+r6j4fbStYtdN1TPnlby9t/NuY2mILurk8NkLg44CgdBXGbh/tfnQB7hot1KtlpYUrxBBj5R/cWvELj/AI+JP94/zr1jSriVbWwAcYEMOOB/dWvJ5/8AXSf7xoAjooooAKKKKACiiigAooooAKKKKAHKATzWm1raRJbTQXDXAaIPKPKK+VLk/J33DG07uMk47VRghMkoXt3+ntWosTJIWVgABjA6fQigCNV3kucjB+Yg5GKnIVFIAIU4GYz8re/0oeMjB2DCnpgALTlVgu1Y0DMBgJwfp6UAECgy7l2kNyNxwT7Gnx7WdQcrhucDAx6Dt/8AWqUxHyi4EZQ5VwOCpHXp29xxUUhCRDYrlF+bHp6c/wBaAGJKGVTGqbsEDJ6/h7VNHMVYOwAKAjIGCR2571VHzNjgkdB1wKWNQFCrkAsAxxkD6elAHYaF4mksX2xyRtC4w8fYd89jkdjmu8sfFem3NtEIZXgynljzUUCT5TuUnngjgZrxc8gn7rbjjjI+vtVmOQCMo7MPmzgYwG/3fp6UAe7TSx+RavIk0UJKw4LfuVAxjrkdsE+vYVoWcwujAzoyb8OrFwqxcEA9DnIUdeDn5uK8N07XbuxkHlXDRRjO5FHmL+XbNd94a8bWRaKe+sruNrYqGuLSAPHDvcKGkAwSCD3PJHANAHTeIdSFlMmm3KSI5YM8e4FlUrkMGztGcYB5HX2rgZbOV7oPdWV0AwyCjIFk9NxbjJx24xXXeIoz4hj87T7iKfDs0ITCGPJyQw/hJ9P8K4xrDxVcwtLDZXstpbbiQq5VCOTknrx39KANSa7bS2RbzTZriOMkpELiN9pwBuZlBzkce3aqkPiaG6dVms7qDJVQIJTtVPU7vvNjPJwa5557q2t5Q/mYDZAlyoIJycDuf0rOuohIpliZvLfnyycYPXkfnigD09buS4S4FhfSWSIwAkkeNW4xyOpY4x6ZrXi1K10aC3j1bVLOeVgFaMs8jMud6sw9+uOPevE5ziP5QpKjJwvHXsO9SRsFWJY+ZOcgEhuT1z3P+NAHsA8e2STb5Yolh+bzPJ2iRw/AHzYGOoAPAB6GmX/jiyuLZmWZ7ds7o4VTzXaQcAGXgKPU4+leSO6SfeVk5w2BncM4yfTNSKHeF1Zh5KlTvx/FjAA/zigD1fSvFVvvjVFhSIndKrsTuYjkswyzcZ5J57VZudcjfVhbW+p2/wBnkYN5jNkKM5+VOQAB0z6e9eRxxyyIWmEhjAwCBgnHp6/0qxG8UaIGRCh4CPnGP89DQB6bfeI9Es4SLeYi83/62Bt4AyRz0GcenUn0Fcffa9aRyER27vCx+bzN3zHH3gxPT2Ax+NYaFSgMUS7o+m9ScHPQDtzVm10G7uTk2soVsjcwIDEc/wCRQBX1fW0vyZZw7ErhFX7pPbA649q5jU7OKeymu5LhlvRIqxW4iyJY8NvfcD8u3C8HruOOmK6ZtCuUlEk6SEZ2gBDktnAA9M+tZV3ZLbyMXZkxkhDgEHPQ5/pQBxxpKv6haeW3mxjMLHGR0B9KoUAOjRpJFSNWd2IVVUZJJ6ACuqb4ceN1zu8H+IhgZ/5Bs3/xNc5pyltQtlHnZMqgeT/rOo+77+nvX034f03ULKDRJNF0zULf+z9W2gvYSwDUZ209kRp4pd5hYyAQSyIQhMhfI2qwAPBP+FeeNP8AoUfEP/gtm/8AiaP+FeeNP+hR8Q/+C2b/AOJr6L8N6n451rU9Gs7291HTrG5uWW41GTRoopE223mTQ+W6kBUkAjSQgbi7ff21u/DbWfFmo+KdStvFdolpbwqx8nyHX7PKJtqokmxUZGjOfvykkBgQCwAB82eGPAPjC18SadcXPhTXo4radbh9+nyrwh3kDK4ycYGepI9ay/8AhXnjPAx4R8Q9M/8AINm/+Jr6K+F934rjn0Cy1ITxaLj7I1k2mLEIVFgJvM8wAEfvsqB0yWHPAFPUvFHjfzvEo0g3lzFZ313bIf7JUpbLHeRxxGNwD55KtIrKRkKhPGNxAPAP+FeeNP8AoUfEP/gtm/8AiaP+FeeNP+hR8Q/+C2b/AOJr6h1G88b6Z40/sqwWTW4Yo1EIuLGOK3vk8mRpLh7hCBG6zBYxGNo27Tglix5rwb4j8X+IPFVro8uualbW6vGL+6bRoYpLT/RmleMoyEId67FY8kDgHuAeB/8ACvPGmcf8Ij4h/wDBbN/8TVHWPCniLRLMXes6Dqun2pcRia6tJIkLEEhcsAMkAnHtX0WfEvxFOla/LPbCzurMq32eOwkkkhYTsvkwMIGQh48AOxmHG7cA5xzfx11HXbrw1q1trUdytnDq1nLZ77MQJAGgnzCTtBaUdWKtIh/hK4AIB8+0UUUAei6fcTC3swJDgRx46f3RXnsv+tf6muttJ5RDbgSMMImPbgVyL/fb60ANooooAKKKKACiiigAooooAKcilmCqMknAFIBk4rrrTRYo/LvLWO58iWBGi+0oN24qA7jbxt37wvfbyeaAKcj3sohF5PcXEkcKRK0zlgkajCopOflUcADpTIo/mONqlsck52j3HpWwmkXCFQ21imGwrcYPf/8AVmn29pukSWZQI3zGWRdv4kH/ACaAMpUeKYu4RjtxnaMN9Kkk8uUqIwgQjbhB/wChVdl06ZFDoPOsySAgODz1IH+cU7SdPlvLryrVQFVduFbaze2DxmgCmsAO6ORQGwRvB5Uj1H+cdaZHpstxOwjxu+8EB7Y/I17Z4Q0eCTwhZ6Le21sNT1KfUbe3WawDeZIixNGzXKjfCEO7GMq2TngGsKy0q2urCSQ2ixIRlNwCLJx95excZwelAHkzWziRkmj8vABBAHI7UeXKkIEYAUntyD+Hauy13w89kSDDNJC3yoXJJDDHQgY7/oa5qe0VJBti5Ayy4x9RQBAiuqbwV+7yFHX1A96dtTG4scDH4e49PpToLfeSQAyjksDz7ZFDAAF5A0RIxnacY7YH/wCqgC/4eSzn8Q2NvewXl7bTSojW1iwWadjgKqEgjknHr7jrXufxr1bwzB8MdC0TwNDaw2T6jL9ojtznD26bXDv/ABHdLGd5JyNpBIIryKyz4X0RNRLbNc1OJksBj5rS1OVef1DSfMiei72HVTWEkE0cccr7lT7sRU4JHuPTigC3YX91abnhuXjMg2nDjDD0IPXmu70PUdP1+xaDUkdbwh4xJGkmZc9yEI78/hXmZETSDzNoCAYXbgfQHFPtrqeKRpI5HiduAYiVJ/8ArUAega34S1eHzJZbZp7QIr+ZGrOTkdT6f45rjbuOS1Q2xiKsnJV1+YdscjvVqx8UavaeUYL+4R1OAHkZ1H0Gf/1VuWHjAXIEWt2FrdxOgQSYCyRDPJVjkj1z3yaAOPFuSyOdw2nk4GCR0H5U4W8m5RtQKV4JbkdznvXazaFb3tu82lXsUgV2b7OSd0SgDB3EAHJ4AFcxeW32eUiQt5m37oYfLk/xY5zQBWmijiiVopUkz/Aq4ZB6knjvjvTWUplGAHlfcOeOnHHarCJvlVMKu3B2q/UD3xQuHYks+/1TGD/9f36UAJF804V5yxA2g7uo9OelWEEy/L5Ug3HJAUFQoH3sH+lRLC4TIBZGcgKOcH396vRRMpQGIERt8wyW5xnHrge1AHpfw78GWd7CmpapctHp+CvkudpmPr8vQD681svJZX9032Z9sSHyowQEVyADufrgADoMk4pdH1O1u/BtvbrdRxGOMAoib8OAcZyeWwc49+fWuPs7acXayxiWCdQxYsDIzMvOcn88Dj60AX/GVjNHKbtuqIDOSeDnJ3DjjA4J7cVxOn2EeqT+dqTr9mRSqgdCB79wOK09Y8RXtxbpCZsAkNIGU4IHQE9RjggflWUI7y7uN0sYRFJEW3henQc9PUjpQBjeJ76OP7Tpen3E502Vh5yg7RMVOVJxwdpPA6CuBuIWglZHHI7+o9a9Mn8PTMytNEsFmqjdOyFMf7K5PLewqnrXhrzNOnL21wk4UGxVArF2yNyyd8bc4x/F7GgDzxGZGDoxVlOQQcEGunPxE8asST4w8RkkY/5Cc3T0+9XMOpRipBBHBBGMH0ptAHUn4h+NCOfF/iLpj/kJz/8AxVJ/wsLxntCnxd4i2jgD+0psD/x6uXooA7/QPH3jCU6hJc+LPEDww2UrkvqMzBWICofvdd7IAexIPHWsO08ceLLJZBZ+KNdtxJK87iLUJU3SOcs5w3LEkknqar6QoTQtenJyGgit8DqGaZHz9MRH8xWJQB1A+IXjMLt/4S7xFj0/tKbH/oVU9I8XeI9Fsvseja/q2n2m4yGG0vJIULHGWIUgE8Dn2rDooA6kfEPxoNuPF/iIbeB/xM5uPp81UdY8V+Itbs0tNZ17VtQtUcSLDd3kkqKwBAYKxIBwSM+5rEooAKKKKANmKWUJGBI4AUd/asdvvH604SOBw7DHvTKACiiigAooooAKKKKACirbWFwumpfmJvsjyGFZRyvmAAlT6HBB569uhpNPs5r+7itbVDJPK21VH8z7Ack9gKAOt8MeA9VuPENva6vpN5HCLdLxoiPLeWJwSm0n+9g++FbuK9cFnbtFcIbMLdqgwoiIBPTaAp44xitPwJLpul6ZaabPdSyvHGqzSSrvlJAwGXIyABgAc4UDiutZLO8it0mmCXxBS3mZQfNOf754PHY/nnigDym/8PT2kTTafFDMCBI0G/LJjrgdCOc9sc1zE1gLhSgUWxVtrpK5MfJz8v8A+vFexa6jRpOL7ZHf252xykfu5gxwMuAD/gevFYsug2+otAJilo0KeW75wxY8lQpOMdwRxQB5WY7mynAni2K+djkghwD1U9D06da1TZW2rwG5txAl0oCbtn3zwOp4/ka74+Cha2U0DwfaLQnJVHCkHOd0f91v09a56PQ2tZCsIMMuQ6xtIFYj6c8+vagB3h/WfEGhQjTbq8mfTWDLJYT5w6MMEFc5K/nXR6fDHeaXPHYKY135aJVMsLehXB4OOD0wO1VdPka/V0mhh8wAg21zhMtjGRngnHocd63NGtrSyeCexhmtiqMDFI7ZTnjryGwevQjtQByWrW32GzaBITJCABEqyZVm7Af7QGcDvXE6tbwm8meFkCnAwVCgsOpI/WvTrWWHWPtCzx/Z484ViQVLFjgnb908YBIxzWD4j00xRiZ4mgm+bbKEJ5GM5Kkhv97jNAHnF02SzOgkBI3MCMn6rWj4d0+1uTcahqiSf2LYYe4RflNzIwPl2yn1cjkj7qB27Ci4jhjACMBukKuVPUjk4/8Ar1nPGuxMxRtMuc54bB6A464z1oAfrN7capfXGoXssZkuHG4hNqqBwI1XOAqqFUDsABiqSIJSTgeXHwAM4B9fXmns2WVG3Ag43lcq2O2Ov1NSfZ4hKY1wMJz8+MY74oAhZSrx+RGozwVUHIA+tRlH8rl+CRk5yR6fh1qW68wGRVCHccZAxkfXg/0qIEcIAjYO5gD0yMflmgCRFK7kA81hgbVJIY9vYGnoU807ISoJxuXGFx19qgjUujqUIYEZHmYTmpYTkqjEqp53Ekj8cUAamnalJZEGGIt84KmRNwPt7V0D+VrFqLh40jKljmMACPHAC9zz61yhElrCu5FQt8x3Llh7AnpWr4cv4rd5kuxvt2I3FQWJ57e/NAFWSykt7go27eP4UyAcHk5Pc8cUyON42RLgcnJ5AZh9T2rptdAvSskVuCjYJzxvB5zg89BTdI8G6nqNi1zcCysbNC2Zp32NIR/Cq8knGM8UAc2EDMkksr7Opwvy5z2HvW/4ftGmkdBtEq5bLR8jPAx6A9Aafe6HaabIIjem8O7YhiXdDtIyGA6+uRg4xXTaBYJM0MFsXIZyGCnC5653HheB7UAbPhfwpqU1lczTSsiMECvb5YcdQce3U57VqT+HRbT+XeXjMmGCh1ZCxZew5H0Bro9YurTQtOjRpMSxNvEcY+ZW25IzkkDGOtcpqesNql3hJobVY8vJtRgiDqQfVvY0AZes6ZpcbR/2Y/nyAFGVFVm3HAznvj16dhUOgabFp+l3H26GPzDh/KEmZG54HT5U713ugvbTW9wuh2F3JaSPFZm5gUvKrPyZS3UogwSBgc4yOteR+O9TuNL1qK3lUJdJp9pFIXP8SwKCM9WGc44AINAG3qH2fSx/aGtKGumQ/ZLUEN9mBxtOOx98Hr0FZVtFbxW0t9qeqIt6+fLtlYuIx7n+I/oDXMJq8lxKbmQPNdL/ABFQEj4xk5rPnn/tIzTahcHagwEjxlgPf/GgDK8R6Fd6gup67plrLNp9uym8mQZWJnOAxPuevofqK4+u5m1CQRCziDQ6bcACdI32rIo6BscHHr2Nclqdr9kuSoB8tvmjJ7r/AI9qAKdFFFAG3E3leD7kn5GubyONf9tY0YsPwLx/99CsStvUR5fhjRkX7sklxMc/3iUT8sIv45rEoAKKKKACiiigAooooAKKKKACiiigAooooAKKKWgDo7XxdfQeGrnQRbac9hcBd+60QPuX7rhxg7hzz15IOQTXp3hDwxPoGnpr0Vmtu99aoDZyy+ZLFEVX588Y8xgX2kcKVGec1wXgzw5H/bMU+ueXHaxxJPGNyyLO7IHjQkEgcMGYHkfdIBNe1nWkhmDNNPPE6YlRv3kqN1yhPUDkFT07UAYy/aJ7yN4dv747o4wBlGPY857djxW/ZXVw1oBahhFH/pG6fIEe84Knt7jn1rCX+zbi9aayiwsmE+RiCf8Atn/Ce+PbrXReGNkqxrdq4kkWQbcNyAcY6cHoccgigCX+1oms47S5IjRWbCTJtR2PZWHQ/iBxSWlhODGNRMiRncDKcmFSAc7mUcDng9KfcGA3KAlLW3CFlYYKyMDjb6Nk8ZH0pl4stqY7OW5YDcrQhMEMxHyxlATgdsjjOOKANKzaS2h2zGVJJW81JIyXVFAxztwMccEYPPerEGrJe2cls9h9oVlEh+UbVBODkH5lHuCO9ZOmrJDI32hoWErmSZ14UjGCpjHXt82RnPtW1BfRtbNJcWMNzd+WEg8vO+JOgbjOPcHJoAyJ4LRYYLqK0jtoQCCvm+bHDj+Dk9x0ySR71f8A7Os7iCGV57gW5G1o5jlnbsCR1GcHkDj6U3VkSSHZcJCkca+UAAAFbI5Dcb3AJx0qCC9ktLqGCeZ54FQRM8pCeahzgnk9CO4oAhTQ/IvEj81IpxEJSZFChT2AAHXPcnmqeuafb2M8MUVvcIyKRGGlJJJPZcnrnucY6VrRahbxyufOkiG8SSluWPHyhQPvH1PXHas3xVJ9qt5UkiiV0YOd0wUZP3SgYhuehAwKAPMNWtBEZ5PKLjcQu6PAx05+n58Vz00DuysETzeBjGCf8Poa6jWLtfOC3EUOSuChc5XsPY/Subu8tOYpgSCBtGwjge/OP1oArvuZfK38AjDZKE+2DViAeXcql1aTRQAZ2KocgY+8Af8AGoFkUZ+UHGSM45PYdOvtTSYniG64y7dFx82D29KAEvCkbkLNJ5R5DyRDp0OPQ/pVZxgMYxuaQhssVGCOlJLOF2Km1lI2oqpkbvUf/XqGN5HfbIBlTgjbtxjsaALIIjeRmIUN8m44KjjkAH3/APrUOx3bkk5QjDqMDH+GcVEx3NucbCw+8AOD9D396V2+Yt5bkAj5tw5PrjpQBf2Nbp5qxB45RxK7g49fw+lRBpjtKeWqgZ+Uc47U3hkVlgd5G6gud2OxweP5VXZmSRiS6Beijg5/LqPSgDsvDNwzQ7IEZhEQpdiFAB9GPJzk8DOPSteUnVpbezu3eA52sYEaWTPOAEx94gc1xOi3C22Q4eTjKkE4yfQDnNdJHc3ZuoXa6ulC8yvAuHHPc8c44zQB1etaQLLSona4aAPJ5UQv8C4VVxuO0dPoAR71N4OSyuNVjEUjFDlBtlCmQjkMQePw61h3EmiW1qFS1ea/aQubm/nO8qegVAcZrovCEKR3Mc0k0kayofJSKPdx3JHUd++aANbxRKt9PEkDJcwq3kFlQqy7upAz39T25qrZWDBIQkUjbg6uHQDzGz949icAdTRf2b3OpX91LI8NsoUB/KALdNi8ZC49hnFasKTNYxNLLJI54MUnCt29/wAuvegDjvFkpn0i3sL4nyEd5JUY7mViFBBYDnIVenGAOK5bxlq/9vXz311gXtzFDFI6qrPcNHGqBjgAAtsBwAAK63xGI5tQkt7RoZII4yNrJhSwHJGe3YZz9K8/u1FuXklXKKCM7T/LtQBhmbZMrShSAM7RkheeuOxqe/ZpLWAzW/lwjlIzwFX1x1JPqetRO37wTpGihctvYDYO3fvR9qllDrIWf5sjzDy31Hf6UAV3EjAyZZRuG3IAC+2P6UycW8tncW9zbyS3rKPIcSbfJfcCzEYO4FQVxwBnPbFXVllidVgiBnbgEYHl57gdj7nmqU1qVQ8gszZfnA496AOYcYYgjGDjB7U0DNdHqmkmewnv7VFH2ZVa4BdVwrNtVgCcsSeOM8DOAOa51aANnxH+7TSrXq0FhFuYdD5haYfkJQPqPpWJW54vx/bLbP8AU/Z4DD/1z8lNmM89PXmsOgAooooAKKKKACiiigAooooAKKKKACiiigAq1p1q95dJDHwTyzYztUdW/AVWA9eldZa+UZTcrZw2bssalIQxRSFA/iJOTjeecZJwAOAAdTB5On2NvZCCGWyMZEc7KVz3LA9mJ5/TjFdR4e8u4jDTyvJFGVf7UCN0QB5JHQ/X864m2c3EaRjKSMx+XHU+h9R05/wrq9I+2WbRTzJcLCSdwVV2tgdz0IHTtnNAHX/2Hc2pW+00i6iBLLGqgvIg6gnuMZ4xmtaS8uPKZI4YBbld+GjyY0I6lQRge+cisvT54VCXVhZpbxZHyNkgH0VhgL6jPT0rfaFXsi8C7o/KaaRWP+sJP3mHOCD3U4PQigDNsLG9jNuUlt5XuQQhjcOk59Cc8ZH1PGMdDWbI9486xxqqRYdVWByyKAcNubnHr2+lXdTvXs5EjhVFieMss6xBQTjphR+FYMs1vDG0dvemGTZtJBwr9TweBuz680Ab2n3uo28k1xJK8sSII185Vwwxnr37EE5+tUdU1y9eF7q7RftDMcXUSYhZT3Zx0PTrgfjVfTdVnWa1kikknykcDGMBdkfOc8H5evOcVo3ur6cDckSRRRAARwld0UijjcwGMHsexwDQBf0/ULa908WV+tuZZcrHEiDZu4B54CnOM4OOfxrJuIJjeGyvEjTc3yjkNFHt+YAdxxgkjr61Wt7jTw7/ANniKGTas0Z42Mwx3P3B2zir3kPqJY30FuE+YqkUm55cj7ykkjGe2exHFACWhW6jlglYxkBIFiGQGI5CYHIwOc+uRWTr+sQ7nQTujBGUDy8EHPPP9RgH0pk89zYW7hGKTiP5kY4G08cf7Q7+/rXC6xfNO7ptdif3f7w85A4/OgCnqdwkSsdsKmThtgGOT1JHGfamR4mtSYbyFpuFKglS3YAHHp1FRQyYAZbWDLrsBOfm9SDnmle3jWBC8kBMm4bUypGD33D096AKsoldnWWQvt2l1DHLY6Dmms69G24+8ACeQD09x61ZaNliZkhACMMOCMcencfrUZTdNvZW3lQ28/LkHr16/WgCpcyKgO0MmSTtBwMH6Yx/WmLKJjHCDKwwC3PJI7+pq3KksqBQGK871wMe2DVZIplJHl+SxBzvG3aPrigCvGyokgYktnkEcAdjz1FWGhT5Q3ygtuUZPT/CnKrxIJgi7G+UMV79+KWOMyT7N+FAzgKTx7+lADmQQjGwLKrZGG5+vXn6GoWiUIFAOVPABzjNX5obSEIY5x5gHDKD8x78kDiqcLKGGB9wHJB4f8TQBYtJWi+YBFcdGUnjn1rdW6u5LcyuY4gD85Lhd3b7p/DArm3jyh25Dd1UEkf7WanSN5J0CuzSD/YJbd9PXigD0XQNf0/SHXyrO0uLry9mXj4RT2DdcHvg966Oy1n7a4u2nW3cMwURIUijOMLhOrYHAznNeVW5JYmRGUNyhYgfMD16da9L8MQ4kgUmOSJJDIXDA53Dkbj0x360AaGptiIzRG6SckmaVcfvMDq2PfsOaj0DWF8iafY32mAMuwsBGi/xZyepP0/GtaTS7eRBNaC5FyA5giKBsEn5mGex9ePpXFz2KwyTlt0UyqG2hSpyO5PT6jJoAfcaibtW+0BzH5nmt5cZITIx9O2Ocn0FYfiCExpAqiERMxaKNjhCcenB4xiumaFp40kuWktVkwIgV/1wx94lfmwPQkfjWRrFpCpEqx7rkqd27nPud3AA7d/agDi73dOyPIMqoyvA9Ovt7VkplTIFIL53Pj5jj2Pb610etJEZlQhZA43bEyh+gJ7fhXOXu22RMbVAzhUXAUfTuaAJIUaZCX3FT/DyCT6n2qKaIRxLGZEK/ewf4vce1WLN45ImZt0jbdqR4659OenvUBEaoSuI5AQCVTIGOwB6/WgCN9nmJ5sfykHavccVh6jaNbsj7NsUuSgznHqD71032NIkVpWZd53bipP61L9nS6trqKSG3eJotsU0hIaMhgd0YyOTjByCME8ZwQAYWvgy2OjXZBZpbMRu+CAWjd0A9MhFjHHsTySaxK3tSRj4ZsN6gva3M1uwX+BWCOhP+8TJj1Cn0JrBoAKKKKACiiigAooooAKKKKACiiigApQM0lXdLsnvroRLkKBudgM7VHU4oA1YtE+y3tx5lxa3UcDBVkgfdHKT3UkDIGcfWtLyk2B3L5QbsN9eg9RUyRIkXlReXHtAAU84HXv3qeG2kLKWQHnAz/F/9b0NAGnYSQM4Ex2xuAN0aglV7/iK9KtYjY6JDeWlyby1c7ZJUfcUA6eZHg5x64zzzmvLdKvRYXiecizggrJGchuT7d+K7azv3hjmfT5Vw3MltKAgK9s85J9DQBtWyWrWYuYI4Ynu18txC3yPnkbo+x44YcH0FatxdedNbvatNcQfLFtUBdwx3P1/lxXEG9jnu5LmKMWqMAZIwuA2eMDjpnnOMitrRGBtncSJcuitm3jfBKHqQD97tQBevrtXmupJJBEBlcFiqBs9CvGT7jFZFxKHtwt7axwRSAl5IyAWI6HHOfyqis+4ywWojIR1Izkf99Due1UzdBLpFjQSeWWxvJyh74PFAEN3YSRvFJaXBQYYKoc7eRkgEdM+nOat20aqsBlSNFdgjEngMvovUcfhWYktxJqDGFt46OlwoYMPTHb2NbsGlQwafJNKAqMdqO4Zt59UI6YPGTigCrqFylt/y2tmXzONq5y3QMx/QgcVPLrl2lp5cKKsCTKFEZUEYXB68+nbt1qn4l06K0ignS7kllk+Wa3YAknHI3A8+vSuavHs4Fk+yw/vXAHy8j3+Vv50Aaesa7PPMLZpPNO7DMWYnHdT2H1rnpDI6BfMACE4JjDZGOMjr+NL5TRxZO4KMFl+8Mdv8ipxGJ5VVrXbIq5KRdSvrjOKAKMRQbY2YKCP4BknnHy4/lVmOIkIjKuU+TcQQMDqCPWtjTtBuZ5Y/LglEbsAcDdtzxgkYBz+dd3pvhC5sYB56Wz4AZhIocD0HHJX2ODQB51badfFfmgkwoHyRhWcjsT14qO+0m527btSM8iLJzj05H6Zr263s7O0hK2sEFtdOMrAgADHvtznaPYn8aLe2tri2u1vLeJQ7iTh1+RjwSpbnHtnFAHgT2s3mbPLlDL9+L7xIHHpjHv6VUkj8tiCrxKxxuYkn8CeMV7he6NpGxrSAPMTkEHblz2wQOue2fzrn9f8Gy6jZxvaQ3RZEwwZAqAjOflwOMelAHlcBkBaSINvAKqTgYB79MVYhPyIFRCuN23JG5vfqT/Kp9R0ye1kkiAKCM/NkGMrxxgHn8aq+VgnyQ8RC4BxyD7k9qAFfHnYZlhYjAOA3H402KE7+N3lg8mWQAflUqLIpAwIyh5DnjIqS1sLuWeOFYQzlsptTO7Pf1oAaluQwEUg2g8FucKO/OOPpXU+FrC0ihubm5jSVkiyDck7CTnbgLyRx/EaNL8Bavd6kI7tktozkEzPwp/uqBy34Yrsr3wPbRRSW19rpW1ZVKx20eDKegGTx1zQB5vDcQGR7jyt7M+QAhIAx0XsB9a6bQNVigh8u7dYLPcWWOJQ0shI6A9qt3nh/QNLjKlS8vlkHcWZo/qGwv6GuWu7vTDcHyYZHjHO4ja2emB2FAHpOra0pjtJYwbfcBC0KPiR1HTIXkcY5rldb1OOXUJEeVysg3NH94lR0X3+mK5xLja5SN5ZORkAgbiOgJ/nUv2cRXBN1cKGblDG24K3oWHt6UAb9rPFewS7Ibve5wNrbGI9OuMDHOevQVoW0EkuoJbxRFI48qfNILKuO5LYGfT0FcxZXCwlVWJxCWO0sB8zdmOefpmuiW5W3tng0wy+e2HMrADLHuOSEH15NAHP63axteXCW6yyQqT+9kOC2O6gD19a5maF3c7/AJEY9iuCe+6uu1CW5QCK5kjkmkJBXlnz7k1z00IRNuI4+C2Vyc96AMwQrsdQpUqSQ453D1/wqyEhjQECNnKj7/OD3yD1qJppFy8BUscZ6YA9frTF83axYhxt++xB4PtQAxWVSUBEhwSBng/X/CnS7pTsnPOckDBIGOnsKcYfMQAyMVXA+ZOh9KlRgSEkAIbtGAS59B3NADRp5vvC2sKjW0H2V4bpWkfDT43x7F/vN82QOOjegria9B03czasm7Ak0+T5k6rsKSY/8h7e3XviuQ1axFqyyoymNyRtzyp+nvQBmUUppKACiiigAooooAKKKKACiinKQDzQAsSNI6qilnY4VVGST6Yr1W/1K4v7h7/UIbSC/mEYn+zQLDERGgVQFXpgD8SewFcxoGmaeNUvvst6t8ICRbzIpi3AYzJsYZ74ArZfYkimEx4A5BJIJ9vSgC7aWMF6gEDgSEEqoXBXHr/nmqa7o3EN15Z3cg7ScMP5ZHatKx+yzxCKZzEwO+Nugz6N/wDWrejj821ddXhCxXCfNKpONv8AC2Rnp6/z6UAcu0EYAkV4SkijYVfdn1yOoxxwadbzSRZMpDxMSF+XcrAdvb2q7dWJt7kxoGKYCqxXAcevPUfSltViRFXYYmG7KjapH1zQBUmvFcJiPyQeqscH8OeasSXyG0jhYyzkcoJF5jb2cdfxFSppqRhGmtY5bfHySr8xHrjH8sVVuLMJErWgE8Ui4ZdxO1f7wwefcY+tAFvTNYFsDCBIyYI+deAfx5zVOe+DF3F0ZgQP3TDGw5+735qK4jVjwYJI1AVWAwQfYk8n2qs9k6KCEIZmwcLwvsTjrmgC49z5ZUllMm7d5bjIX+orodJ8R/YcGMb5ooyi7x84z0AHoPyNcrDYtGR5yJvUfKp+/wA9/pWt9nhj2FFcRhlBDvnaSOQSOR+VAEt9HPq0yTwrN5kWAWRtsit1OAQAy+wqO30OadreOdBhicq0ZVsg/eJz+FbWnWsjz26OgSBpA2WQnAPbPuPXrXVaNNBBNJO0MluyZUFyfkOcbQQcc9wf1oAwNP8ACNv9jWW7ufJtWzsJzsUg8qQeMj2xnNbln4egSCVWDI9ri7CpHwwPGQwP9faty2lsn04ho3TblUKwHIIOSVVcn8TV3T74XxhDB/scaF5N7iNWI4w3OD+h9jQBBY6ZOIQN7CLoqW8n7sd9zEHapPpU7aZDaxwmFvtFy7eXDGNqHJPOSCVJHuMUJOklpDcW0d01w2MLKh2lQcchQBx2INO+zyOqTbbudZHwrMzLITnIRskkD0HT3oAsLaRWwuYY28uKNP3qxqCcgdQAeCO4GRTZbSWZYZYo7fAQbGaNWkkBPIGBxn36U2W6MiItq3lTsxKsZOEA6jOMY49TmomkSW9t2sbeUCTLOUV2RyP+eZC9++TQBLd2xgvVggsoTbxSgLz8u5hyCe5POcdvSqEEBgEi2sMMUMsmPtBEgVWByc5PTsOxqa/d5lCx28yzAZiYLho+f4QDjH159arTme9EHy3SMXZSJU3gDHzOQTu7cHpQBieKNCs9UtXJuvtE8UgVScPvJ6gDrx27Y6V5rqPhSa0N2ZZJnRWEZCplc+hPqPavbrFo1jiW3lknCYl+YhCFBwFPTg9eOaZd6dbzkwuLkuRlWGwqq8kbAp5BPGTzQB4HDZhpishhRlH+rY7twH93rg1v22oQwBTDO62yqMxxR7tpHfJx79K6vWvBrW0JltY2VHJInXEgAxyp6YI79MVzlv4d1KUvOsbtawgEyAeWEXHOOm4/nQBsWVy890srtMscg+8jF2VRyCQPbqc1BJqemves2pC4EPQiCTqOxOScewFZEkc1orG3aV4umVGzA9SOuaxMGWQqER0UEsp+c/lmgC4+oabFcXM9tZoyZIxPI0u3PTk9/wAKyCbmZsJDDGVy6Lkhm9fX8KcYQGJIYZJkTK/MPoOv4VcstG1DVHZrS3CxlflmlQxAKOuW/mTQBmqgki2on75T824ZGe/tmllgBZnEMgQEBSOCD3FdxZ+CYY7dXvNWeQhQQLWDCn0ALHkD2rTsfCWnQQRJbpbyzyDexnIcx/7WTx79OvHNAHn0E8Z3KkQZm+YYU7VPue9XrC7WKNooCd4Bdzt2lvYY/nXV61oNxDdLEJGRCNwbYUXpyzdwPwFQW4jsGyIIo3HQzKMKvd+mCT2GD70Ac0JDKGeKFxHwGLMM4926n8Kx7pZLhW3tCgjYhBgDOTxnnpXbT31ncTPLbJZqEO4s6EM2erc965zUbW3uZmnTzUZ2x93aqjqTnHP5UAYdyoRHYbGmfgDZgDHfb2/GoGyATFuCt94E+nXPt7VeWDZuSFR0yu/t7n/9WahG9t0YZDnDMZF4B7YAoAhiVPlQFti4Ziv3j/n0qQ7ZJQr7VzklmGHOenT+VWf7OLqfIYsEUl2LBFx7jr1q1Hc6fpajEEd1cYyWkXABPTA/xoArWcYjmvysckIOnXJxJ1b92fTis+y1q7sINXtoYrV01O2+yT+fCsjIgYMChI+U5HX+oBDrW4mn1DUWlHJ067PLZwPLrGIAADYUZ5JGc+2KAMWaMxOVb8D6j1qOt2WK0uRKbm8S3EcDPExiLGaQYxGMfdzzgngYrDNACUUUUAFFFFABRRRQAUUUUAPikeKRZImKupyGBwQa6XS/EKyOU1Xox+aVVzn/AHl/qK5eigD0q2RJYGurXc6huRDztB7+4/8A1V13h/xN9gs2t7m3DwONmCAPo6+jD06HpXi2k6re6TcedYXDwv3A6N9R3rrNP8Wx3jsL2OOCaTAJU4Rv6CgD0mK5hEcZNwqWrHDQKS0StnsD93NWreCzXMssSw3JJxgHLL2Hoa5TTEN7EGDRiXZ8qqpJYDqfQ/5PNbFm7eW0UguN7KFVAeo/3T/TBoA2Li0C3RZLe3mL/MHtl3BiOzDgg/nXPalbwXEkk1oZLdt2XjKBcn3wcEfhWzb3ktonlbpo/L4WSM53D/a6HI9f/wBdZupXaXEaSOwMoJ2SMgbJ/mp9qAOemn2ODGsT7QRhV4XPQH/63SrlvC948ksPmoyYLRuxI/A9CKZLjakgVGVThgRySf8APQ1rWIa5OBIkX7shB8oJx26nn2oAmttFUQpOy/uQcq4XcFPc7Rz+B61pxaSJrjc21rhVyqXBDb/RTtHBx0zxT7PcsSP9iKg7czQzbtx7A88D2zVVZ5o7+4giwZWIBjdsg/Q9fxFAG/ZaP50kbGLzAEBSSSYsA2eAuwYJz+XetmKyVZAk1jNIyHyyAQURj1yQQQD6kY96wTcy2V1HGVlR3G5SSp575GBgdsjmrA1poLsxgKsjKEUg5Lf75A6emTjtzQB0DadYWkIgkkWB5DIFwXwr5yM+g7daS6XR4AiNcTxJJt3MIlIjI7ndnI965ufUI3KGOQtKFw74I2E9iDkD6iq4hkndUSJfJIOxJXALjofvEBqAOig1fTrUo2meety+Iyvm7lX0OcYwfTityx1YO5W1tWa6ZCoMn35PXG1hg56jpivPJoI+LeJZIp1QbQFIUDvjHBX0yat2Vs9sAunuGaQgys45Qjk5PH5DpQB2J+13cm2G2ngmHyFIoOpHfIH3c9aLqSaF7cSzmWMqwjGCrFsfNgqMmqdxqV5BGViW4jhSMN5s3BfJ4IIOT+NNex1aR1ma7Z5JTgRrKJTjHJA428elACm+aWJpLidV8v5GjtkA2ntggc8dc4pRf2DXTN9rgBAXz8x4zzxtIAOfftVWbRZHmVYNRv2j8plZ1QISf4RywJ/Lmqqaa6zxwPcypNFhpfOhEZb0AAP3fXpQBsX8N3cXLzQMqjZlUgkClFH97gnn0Oai055Gicw2bxSyAebiQESHpwwA2AfWobSxurO4lkaRFLsFZoiuV/u4AOcU77bOGSO9t4ppjnfJt2LJjoMcAn2I5oArzSSTNJJcWtxParmNQsYcO3XGDk4HT175rMntxewyOiTK8ABVOFZVP8AGc/TNbMFuk8Zmtp5GIYL9mciKQRZwcKOwPc4xSSRsJphBPLDEieWJolXIAPdiOWPTA/KgDlLnwZIkRaOHUGnYbxFIuyMcdCxP865K+0+aJvJmjHmbyqyRnK9M4yPSvT7nUQkcsVzaxbAVBadGDFe7EMfvH0xiqF9ZWeoyjPmWxkX5VUIgx2X5cnPHtxQB5tFZXnmJln+RgmVUAZ9RnrxXT+F4WQSMt2C6nJDMArjoAA3X6YNM1HSJLeaBYmFwNu4ebJkKD2we5PoapWiCxIUAJhSGaRtgAzzjtk+2aAOpuLsrOyJLG0Cny3JwoBAztVuOh9KkvNU+zJFPBAyuYvLkCAlsdeXb73+elcq0sSGJI9rAAuIZgCqZ78d8dOfwq/Pfl9OixIqxoQEHOB6jJyM980AVb7xI7eZPcY8xxgRs25gB0X0UevWuSuJp53luJ3Wdy+8/McDPYE9TW5epETIy2yCJGAZmQHc31HGPxzVGGECYEPEke0lmwMj2GQcfUUAVZ5JbksbiSTcD9/GCD2AB4FD2k1xFJtWcr03MCzLjucetbSXcNq8eYY0AB4B3sT2Y55P4YqW78XXCPEFViFAMhdV59MjHAHvn1z2oA5eOxupAotba6kC9Asfyr/vN3NRpCtpEyXTCJGy7FRgg/gf0rR1LxLdTygG4kmXJaPHyxr+BHP1Nc3e6hJcXDSzszDscY59vagBLq+YoYUYxLwAnVseh96z3kZn/ANWAAfmAOP8AJpWkIOFADclsDqPr6VTur2GJFRAHkXqRgg0Aa2igiW/I+Vf7OusDPX92awri8SNdkA3HoWYcYq54dnkmur7eeBYXOAOB/qzWBQA53Z2JY5PrTaKKACiiigAooooAKKKKACiiigAooooAKXPFJRQBp6LrV9pFwsllMVAIJRvuH8P8K7/SPiBYTqP7UtPst2BkTwEhS3r6rk9sEV5bRQB7xcalDfRJIpQqy7vOh2yLL2+bGBkfTNc1cXYjeZDEvlA8sfl5/Hp/KvNrW9uLQk200kZPUKeD9R0Nalr4gfCrdx7wBtLR8Ej3HQ/pQB3Fi3nHeGKPtOQp+ZvTHY/rW5ZXyxxb8qvPEixglfZxjp71w+napEzAW1wjbv8Aliw259sdv5VvW05QtGGNu45xwWI+p7f5xQB1byQT2busSs6AOZI/lBXoV2ngH9KikkEls1s6/IykqiqB5uOgz0BH1xWKL1Y5jOspWRV2lhw3Tr6c/lWlpDmSFgzt+86rEBz78nA/CgDTtrV3Xy2tWWBVzhWPUDoc8ZHcDpThpkriVbeESWr7cMxIKk9evT69DU9pb+WEMyKoVCqsJPLQEd+M8/X9K6eTyYLV82kf2ZUGJJDlSfYjk0AYA0dI714raWKSdI+c4I5HO3nP5Vajt7f9ybm6SK4cABLaUpjHBJz0Yj6fSpdTvYlAuGuI3kXkNCih+n3cjkY+lZa6k0lsnmyzZVd4kkQspYdF5/mMUAdnDaQWVrC1qUMcRKKjqV3g9txJBOT071Be3qrbxwxSGSSNvm25JU+m3nJx2IrHjn83ymaK1hZVB8xGwZR6hfX6CoLu7fezQORI4JMoXbux7j72B34NAG8bxIFZLV7guo3BHKqFQdBt+8MHv29KrT6y0dussNrcxyptkfypApYnqTjGVx0PeuXE3nFmhMdr5QwTOASB65OSQR9PrUFvbvPAiwuNqn5ZYv3e7HQEdKAOnu/FEd5/HfXG9vMhCg7SemZD1wP/AK9QRatJc3bW800pgCsJJRl0bHQhickVx484xyrLJLmNuYxGNp+ucYNI801uPMhkJTo3AAT8AOcUAd7ZayLJ3R5PNTBMMm3EUbd2bPU+lXWvVvRb3TX9sJAQMscfvOmcjnnsB+Neb/23O4RjJHI6NvB8pVebsBt6H8R+NX4L+6kZpVP2eVFLeZGqqETv8oxz2zQB38FjexWpma8kjBctJKSFcDPGScg/lVh9Smjkkku4XgtZHCiSWbHmHGO3IPfAGPU1xUd2kP2dIJ7ZZJSPMkfJLNjrkDlcelWheiRpUS6gkBH+qhkZ2b2JOB74oA6mH7E67ZLYRwO2CXfEhPY8g8n1qhe2Ni8QWS3+xZl2sfNdjuHquckY79Kr2epxR3kRW9c/u9m6FDGwB+nJOeMioDcRPdmSOOea6AP7xj5uPTCjI3fWgClf2n2eNN955sTyAJGQD5Y6DJ9fQGqd5YQ2ccCRKZA4J82UfMDn05J/LFa+oeaBHOY1SSMoWKQhST/tc9R9MGrFkjS2xE1vFvkOGkuB8zDOcYxtA9hzQBxhhkmlLB4LYf3S25x2JGcn88VYmsbSGIW8bzXNz5ZycFYuTgKAef5VtahHbOrfZUdkSQpvz5caEHgDJ4wOMdTWBemKO5OZYo2A3jG7r06dG57DmgDPnSXyfK+zw28ceVYKCWj5xkHOM/nisa+VrCXZaEvx87sATz646Ctu6kSRiG8yZU+UvDFsjyfUEfmaxZrSVJJUtgWRznzIsEn645H0oAyZGW2l3q2+TOclcc+lNZWuGwiQpv7tlQPz4NR6tNaW0pE1xFHJtyQTk+wwOfxrm7rXi3FvGQcY3O3b0xQBuzKIfMeSZXQHBxgZ9x2xWJfX9opxGWmJHOPlH51jT3Ms5zK7NjoOw+gqGgCea5klGCQFx0HA/wDr1BRRQBt+Fh/pN/8A9g+5/wDRRrFrb8Hn/ieRgf8APCf/ANEvWKTnFADaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApc0lFABV+y1S7sxiGdgmMbW5GPTB6fhVCigDrLLxYB5aXdtiMdTCcY98Hr+YrptN1rQbhYyLmOCVQf9buTjjr2yPrzivLaUdaAPpKxtLOdGWO5EtkzqEcthZH7hh04zxVyJJLZvs8V3JbKCSgYB0yO7A9R9DXzRbXlxasWtZpYHI2lo3Kkj047V0UHjzxBGFSa7W6iD7ylxErZIGAN2NwHsCKAPWb6+vGu5FkntpyPmYAbV3D146nsRgVBY3AbdL/qnJxiVcpn9cV5wfH91Lzc6faFgDhosoQfxzV2HxrZhVbyLmF41yoGHBPfnIx9aAPU7e5klBigiinZV5PmAMP93HIHsaivdRDnZNCyzqAuyMDyvbGeM+pB59BXIp450ua3WI3Ebs3zSLLFtUHH8Jx1+tMXV7Kb/V39rFFzz5i4PtjIx/KgDpLi9KXKxwRRQiNcvjnd6jnINRS3437Y4l3AbmQKFYD2yeR71hSbsRgXTmA/OCZQEI9uScVBI0ssSqPNcKTnBDIw+vf6UAbInYTExKURgSRtzu/PPT2rPui7SKJwFdPut/CB2HTrVALhTGxK+YQS4Q7foDjj6UrM8TmKQu24HcuTsA7ZPGT+VAEUd/crJIzmRmXkIrAZ9884HtVqO5lLkyuksu3cWJO5B+JGSajmCNZbll+c9SkfDe2c8UyxSJ4zFM8cDDkMUJX+XH40AbcV7DJ5TILgSryMfP8ALjB7k/pViPUp0VWZpV3Aoscoxkf3gAOT9awiqrcAsQpjQ7ZAwP4gccfWoG1OwQbpry2lkcZaV5AWA9BjjNAHVnUS8Kx2VqXG7AkfP7xu4AwAKfY6lK9wYw8ttdINmyKYEt6qykfy5rkh4j0REdprtVmC4TylZs8/kDRp/wARNMsSjDTZJySdwOFx756k/lQB6WftkskdrMpV9gTEMe18Z6Hv/KnxXzWFzHGkVxFEmfMaRxIzEenVVz69a801f4wTTiOLS9EtbK3TPBkZmb0O4YI9+TXHXvjXWrliVnjtw2M+REFzg5HPJ/XmgD3eW7ivIpLxpDcgMQ6SsXCE9HctgD0471h6x4k8KQWSSNqdst4doaK3jJZRnHDJkDGMkE59BXhF7fXN9L5l5cSzyc8yOWxk549Krk5OaAPVNS+JenQSbNF0h7gKCRLfynG4gc+Wp6derHPtXCar4l1TUnkM1x5SOclIFEYPsccn8SaxaKAFzSUUUAFFFFABRRRQBt+Dv+Q9H/1xn/8ARL1inpWv4OP/ABVmjD+FryFGH95S4BB9QQSCPesgnIFACUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALRRRQAlSLNKqhVkcKOgDHAoooAd9quMY8+XH++aDczkYM0pHpvNFFACCeYYxLIMDA+Y9KQzSlSpkcqeoLHBoooAjpaKKADmkoooAWkoooAKKKKACiiigAooooAKKKKACiiigCexuZbO9t7q3cpPDIskbAA7WByDzx1FRNjPGMe1FFADaKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow points to a triangular projection of chorionic tissue emanating from fused dichorionic placentas and extending between layers of the intertwin membrane. This is characteristic of a dichorionic diamniotic twin pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36577=[""].join("\n");
var outline_f35_46_36577=null;
var title_f35_46_36578="Inspiratory effort triggering";
var content_f35_46_36578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inspiratory effort and triggering of ventilator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recordings of tidal volume, flow, airway pressure (P",
"    <sub>",
"     aw",
"    </sub>",
"    ) and esophageal pressure (P",
"    <sub>",
"     es",
"    </sub>",
"    ) in a patient with chronic obstructive pulmonary disease receiving pressure support ventilation. Approximately one-half of the patient's inspiratory efforts do not succeed in triggering the ventilator. Triggering occurred only when the patient generated a Pes &lt; -8 cmH",
"    <sub>",
"     2",
"    </sub>",
"    O which was equal in magnitude to the opposing elastic recoil pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Tobin, MJ, Jubran, A, Schwiez Med Wochenschr 1994; 124:2139",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36578=[""].join("\n");
var outline_f35_46_36578=null;
var title_f35_46_36579="Superficial veins of leg anterior view";
var content_f35_46_36579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial veins of leg, anterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 682px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36579=[""].join("\n");
var outline_f35_46_36579=null;
var title_f35_46_36580="Triamcinolone (topical): Patient drug information";
var content_f35_46_36580=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Triamcinolone (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/30/32229?source=see_link\">",
"     see \"Triamcinolone (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14500?source=see_link\">",
"     see \"Triamcinolone (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9606513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kenalog&reg;;",
"     </li>",
"     <li>",
"      Oralone&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; TA;",
"     </li>",
"     <li>",
"      Trianex&trade;;",
"     </li>",
"     <li>",
"      Triderm&reg;;",
"     </li>",
"     <li>",
"      Zytopic&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9606514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kenalog&reg;;",
"     </li>",
"     <li>",
"      Oracort;",
"     </li>",
"     <li>",
"      Triaderm",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to triamcinolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696418",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral paste:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected part with a cotton swab. Do not rub in.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12330 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36580=[""].join("\n");
var outline_f35_46_36580=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606513\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606514\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024620\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024622\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024621\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024626\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024627\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024629\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024624\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024625\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024630\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024631\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/31/19955?source=related_link\">",
"      Triamcinolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/36/16963?source=related_link\">",
"      Triamcinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31768?source=related_link\">",
"      Triamcinolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/11/27831?source=related_link\">",
"      Triamcinolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/30/32229?source=related_link\">",
"      Triamcinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14500?source=related_link\">",
"      Triamcinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_46_36581="Disseminated NTM skin lesions";
var content_f35_46_36581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Cutaneous lesions in disseminated nontuberculous mycobacteria infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Disseminated nontuberculous mycobacteria with generalized cutaneous lesions in a boy with acute lymphoblastic leukemia in remission.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: American Academy of Pediatrics. Syphilis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering, LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Copyright &copy; 2012 American Academy of Pediatrics. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36581=[""].join("\n");
var outline_f35_46_36581=null;
var title_f35_46_36582="Phototoxic eruption new";
var content_f35_46_36582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Phototoxic eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36582=[""].join("\n");
var outline_f35_46_36582=null;
var title_f35_46_36583="Clinical features, diagnosis, and treatment of Bartonella quintana infections";
var content_f35_46_36583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and treatment of Bartonella quintana infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36583/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36583/contributors\">",
"     David H Spach, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36583/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36583/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36583/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36583/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/46/36583/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartonella quintana is a species of Bartonella, which historically caused \"trench fever,\" but more recently has been associated with a variety of infections including bacteremia, endocarditis, and bacillary angiomatosis.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of B. quintana infection will be reviewed here. Endocarditis due to Bartonella spp, Bartonella infection in HIV-infected patients, bacillary angiomatosis, and bartonellosis (or Carrion's disease) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8182?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/56/26503?source=see_link\">",
"     \"Bartonellosis: Oroya fever and verruga peruana\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartonella quintana is a small, fastidious, gram-negative rod formerly known as Rochalimaea quintana, Rickettsia quintana, Rickettsia weigli, Rickettsia volhynia, and Rickettsia pediculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/1\">",
"     1",
"    </a>",
"    ]. Early in the 20th century, B. quintana infection emerged as a major source of morbidity and mortality among soldiers and was commonly known as trench fever. During World War I, an estimated one million soldiers developed trench fever, and military physicians reported on the wide range of clinical manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/2\">",
"     2",
"    </a>",
"    ]. They identified the human body louse Pediculus humanus variety corporis as the vector. During World War II, a significant, but less extensive, trench fever epidemic occurred. Subsequently, endemic and sporadic outbreaks of trench fever occurred in the middle part of the century in multiple regions of the world, including Ethiopia (1946), Poland (1949), Mexico (1954), USSR (1960), and Tunisia (1961) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the 1990s, sporadic B. quintana infections have reemerged in the United States and Europe, most often manifesting as bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], or bacillary angiomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Contemporary B. quintana infections have disproportionately affected indigent or homeless persons who often have chronic alcoholism; these infections have been reported mainly in France and Seattle, Washington [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. One study from France noted intraerythrocytic organisms in a small proportion of erythrocytes from 9 of 18 homeless individuals with B. quintana bacteremia; the authors speculate that infection of erythrocytes could allow body lice to efficiently transmit B. quintana [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although investigators have reported scattered outbreaks of contemporary B. quintana infections, serologic studies suggest that exposure to the pathogen among certain at-risk populations is more common than overt clinical disease. In studies of indigent or homeless populations in the United States and France, B. quintana antibodies were present in 8 to 53 percent compared with 0 to 2 percent of healthy blood donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. The frequency of current infection, as determined by blood culture, was assessed in a report of 930 homeless patients and 217 sex-and age-matched controls: B. quintana was isolated in 5.3 and 0 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lice generally have been considered to be the major vector for B. quintana in classic trench fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/1\">",
"     1",
"    </a>",
"    ]. Although three lice species, Pediculus humanus var capitis (head louse), P. humanus var corporis (body louse), and P. humanus var pubis (pubic louse), can potentially transmit B. quintana, available data suggest the body louse is the predominant vector. Since B. quintana propagates in the intestinal lumen of the body louse, not in the intestinal epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/17\">",
"     17",
"    </a>",
"    ], infection probably results from contact with contaminated louse feces. One study from 1939 documented the presence of B. quintana in ticks that had fed on humans who had a trench fever-like illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts also believe that lice serve as the source of contemporary B. quintana infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, B. quintana infection occurred among a cluster of homeless, HIV-infected persons, most of whom had head or body lice exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series from Russia, 33 (12.3 percent) of 268 body lice samples from homeless men were positive for B. quintana using polymerase chain reaction (PCR) testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/19\">",
"       19",
"      </a>",
"      ]. The same investigators found a similar prevalence of B. quintana-infected lice in Burundi [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The most convincing evidence implicating lice in contemporary B. quintana infections was the isolation of the organism from lice extracted from three patients with B. quintana bacteremia in Marseilles, France [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In San Francisco, investigators used PCR techniques to identify B. quintana in lice pools from homeless persons infested with head or body lice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/21\">",
"       21",
"      </a>",
"      ]. They identified B. quintana in 33 percent of pooled samples of body lice and in 25 percent of pooled head lice samples.",
"     </li>",
"     <li>",
"      B. quintana could be cultured from 15 of 161 body lice obtained from homeless persons in Marseilles; PCR-based tests detected B. quintana in 41 of these 161 body lice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an experimental model, investigators provided a blood meal containing B. quintana to body lice and then analyzed the bacterial replication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/23\">",
"       23",
"      </a>",
"      ]. B. quintana became detectable in the lice within four days, and the lice had continued excretion of B. quintana in the feces for at least three weeks. On day 15, the lice were excreting millions of B. quintana per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transmission of B. quintana has rarely been associated with exposure to cats or their fleas in contrast to Bartonella henselae infection, which generally results from cat exposure (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    ). In the Seattle outbreak, three patients reported a recent cat scratch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/4\">",
"     4",
"    </a>",
"    ], and in a separate case report, a cat owner developed bacteremia and lymphadenopathy due to B. quintana, but did not recall a scratch or bite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, B. quintana has been isolated from cat fleas and cat dental pulp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humans are the only known host for this organism. In both classic and contemporary trench fever, B. quintana occurs in situations that foster very close contact of humans, particularly those with poor hygienic practices. In rare instances, B. quintana may be transmitted by cats in a mode similar to transmission of B. henselae, which causes cat scratch disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with B. quintana can lead to an array of clinical presentations that generally depend upon the immune status of the infected individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Classic trench fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic trench fever includes a variety of clinical manifestations, ranging from a mild influenza-like illness to a moderately severe, chronic, debilitating disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/2,18,26\">",
"     2,18,26",
"    </a>",
"    ]. Most persons who develop these symptoms presumably have bacteremia with B. quintana. Clinical observations from persons infected during the two world wars suggest a typical incubation period of 15 to 25 days (range 3 to 38 days). However, data from controlled studies in human volunteers inoculated with B. quintana-infected louse feces indicate a more narrow incubation range of 5 to 20 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms and signs of the acute disease typically include malaise, fever, headache, bone pain (particularly of the shins), splenomegaly, and, in some instances, a maculopapular rash. Investigators have observed four major fever patterns associated with classic trench fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An isolated febrile episode",
"     </li>",
"     <li>",
"      A single febrile episode lasting four to five days",
"     </li>",
"     <li>",
"      Three to eight recurrent febrile episodes, each lasting four to five days and punctuated by asymptomatic intervals also four to five days in duration",
"     </li>",
"     <li>",
"      Persistent fever lasting two to six weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term \"quintan fever\" derives from the recurring five day attacks. Among the four fever patterns, the episodic pattern occurs the most frequently. In some instances, patients may develop persistent bacteremia without fever. The primary clinical episode can be followed by prolonged bacteremia lasting weeks to months. Death, however, rarely occurs in either the acute or chronic illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Contemporary B. quintana infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary B. quintana infections were first described in HIV-infected individuals in the early 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/10,27\">",
"     10,27",
"    </a>",
"    ]. In a study of 46 HIV-infected persons, B. quintana predominantly caused bacillary angiomatosis, manifesting as cutaneous lesions, subcutaneous masses, or bone lesions, but not lymph node, liver, or splenic lesions (as commonly seen with B. henselae infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8182?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of contemporary B. quintana infections among immunocompetent persons have differed from those in HIV-infected patients and have more closely resembled classic trench fever. Among the 10 patients involved in the cluster of B. quintana bacteremia from the 1993 Seattle outbreak, seven had a temperature greater than 38.5&ordm;C and one had hypothermia (median temperature 38.5&ordm;C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/4\">",
"     4",
"    </a>",
"    ]. Three had weight loss that exceeded 20 pounds (9.1 kg), and two had splenomegaly. Six of the 10 patients had three or more blood cultures positive for B. quintana, and 4 of 10 had positive blood cultures separated by at least 10 days.",
"   </p>",
"   <p>",
"    In the 1997 study in Marseilles, France, B. quintana bacteremia occurred in 10 (14 percent) of 71 homeless persons evaluated at an emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/5\">",
"     5",
"    </a>",
"    ]. Most of those patients with B. quintana bacteremia had an illness characterized by leg pain, headaches, and thrombocytopenia; only one had the typical shin pain described with classic trench fever. Two of 10 patients had a temperature greater than 38&ordm;C, and several of the patients had chronic bacteremia with few or no symptoms.",
"   </p>",
"   <p>",
"    In the Seattle outbreak, 2 of the 10 patients had endocarditis. Similarly, in a report from France, three patients with B. quintana bacteremia developed endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/6\">",
"     6",
"    </a>",
"    ]. In a subsequent multicenter international study from France, England, Canada, and South Africa, investigators evaluated patients with blood culture-negative endocarditis and found 22 patients with Bartonella endocarditis, including five with B. quintana infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although contemporary B. quintana infections have not generally been associated with lymphadenopathy, there are several case reports of patients with B. quintana bacteremia and adenopathy. One 30-year-old woman developed cervical adenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/24\">",
"     24",
"    </a>",
"    ], and a hemodialysis patient had generalized lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of Bartonella infection is made by isolating the organism from a culture of blood or tissue. However, more frequently the diagnosis is based upon a combination of findings from supportive diagnostic tests, including serology or the polymerase chain reaction. Histopathology does not typically play an important role in the diagnosis of B. quintana infections, except in HIV-infected persons who have cutaneous bacillary angiomatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartonella quintana is a fastidious gram-negative bacterium that requires specific laboratory conditions to enhance the yield of culture. Preferably, blood culture samples should be incubated in pediatric or adult isolator tubes or by using EDTA blood tubes. In some instances, Bartonella species have been isolated from BACTEC bottles.",
"   </p>",
"   <p>",
"    Isolation of organisms from subcultures is enhanced by plating samples onto either chocolate agar or heart infusion agar supplemented with 5 percent rabbit blood. Optimally, the microbiology lab should use fresh agar plates and incubate them in 5 percent CO2 at 35 to 37&ordm;C for a minimum of 21 days (incubation periods as long as 45 days have been documented). Identifying B. quintana within erythrocytes has led one group to recommend freezing blood samples prior to plating to release intracellular bacteria and thus enhance the yield of blood culture samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard histologic hematoxylin and eosin staining of bacillary angiomatosis lesions from any site characteristically shows lobular vascular proliferations composed of rounded vessels lined by variably protuberant plump endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/29\">",
"     29",
"    </a>",
"    ]. Clusters of neutrophils, neutrophilic debris, and lymphocytes are also scattered throughout the lesions, especially around eosinophilic granular aggregates. Warthin-Starry silver staining of these aggregates reveals masses of small, dark-staining bacteria. Electron microscopic examination, if performed, shows pleomorphic bacilli with a trilaminar wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody production in response to B. quintana infection appears to be variable. As an example, patients with acute trench fever typically develop significant titers of anti-Bartonella antibody, whereas those with chronic B. quintana bacteremia have little or no anti-Bartonella antibody response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/5\">",
"     5",
"    </a>",
"    ]. When individuals recover from chronic infection, they typically generate detectable, but low antibody titers. By contrast, persons with endocarditis due to this organism often have high antibody titers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two serologic methods, indirect fluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA), are available for the diagnosis of B. quintana infections. These serologic tests generally distinguish Bartonella from other genuses of bacteria.",
"   </p>",
"   <p>",
"    Problems with the B. quintana IFA serology tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant cross reactivity occurs at the species level between B. quintana and B. henselae, especially for IgG assays.",
"     </li>",
"     <li>",
"      The sensitivity of the test does not appear to be optimal, especially with IgG assays.",
"     </li>",
"     <li>",
"      The prevalence of positive Bartonella serology in the general population is 4 to 6 percent, which creates difficulties with false positive tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although both the IFA and EIA serologic tests have undergone study, most commercially available assays use the IFA test.",
"   </p>",
"   <p>",
"    In general, IFA IgG titers &lt;1:64 suggest the patient does not have a current Bartonella infection. Titers &lt;1:64 could represent past infection. Titers &gt;1:64 but &lt;1:256 represents possible Bartonella infection and repeat testing in 10 to 14 days is generally recommended. Titers &gt;1:256 strongly suggest active or recent infection.",
"   </p>",
"   <p>",
"    Bartonella serologic testing should not stand alone as a means to diagnose Bartonella infection. A positive serologic test can be used as supportive information in the appropriate clinical setting. A convincing diagnosis of Bartonella infection generally requires a positive culture or histopathologic findings consistent with Bartonella infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR)-based tests have played an important role in studies and reports of Bartonella-associated infections because of the difficulty in culturing Bartonella species from tissue samples. The PCR test generally can distinguish B. quintana from other Bartonella species. A semiquantitative, species-specific, PCR-based enzyme immunoassay has been developed that appears to be a rapid, sensitive, and specific test for B. quintana; larger scale testing, however, will need to be performed to confirm the effectiveness of this test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, a rapid single-step PCR assay for Bartonella that amplifies the 16S-23S rRNA intergenic region has shown promise in preliminary findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PCR test on tissue or blood samples is available in some commercial laboratories",
"    <a class=\"external\" href=\"file://\">",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antibiotic therapy for B. quintana infection is problematic for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data on the efficacy of treatment are sparse.",
"     </li>",
"     <li>",
"      In vitro data have not correlated well with clinical responses.",
"     </li>",
"     <li>",
"      A true clinical response to antibiotics may be difficult to judge since some patients with B. quintana bacteremia have minimal or no clinical symptoms.",
"     </li>",
"     <li>",
"      Long term follow-up of treated patients has been limited, making it difficult to judge treatment responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of antibiotic therapy was directly addressed in a randomized trial involving homeless patients with B. quintana bacteremia who were assigned to either no treatment or a combination of 28 days of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    plus 14 days of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/33\">",
"     33",
"    </a>",
"    ]. Using intention-to-treat analysis, bacteremia was eradicated significantly more often with antibiotic therapy (7 of 9 versus 2 of 11). Among those who completed the protocol, eradication of B. quintana occurred in all seven treated patients compared with only two of nine untreated patients.",
"   </p>",
"   <p>",
"    A benefit from aminoglycoside therapy was also suggested in a retrospective analysis of 101 patients with endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients who received a regimen that included at least 14 days of an aminoglycoside had a greater likelihood of achieving full recovery and surviving the infection than those treated only with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal therapy of B. quintana infection is uncertain given the limited published treatment data, and, inadequate data exist to guide the duration of therapy. The following recommendations are separated by the clinical presentation and are based on available data and expert panel guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36583/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have acute or chronic B. quintana bacteremia without endocarditis, expert guidelines recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      200 mg orally once daily (or 100 mg twice daily) for four weeks plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily for the first 2 weeks.",
"     </li>",
"     <li>",
"      Patients with chronic B. quintana bacteremia should undergo careful evaluation for endocarditis, since endocarditis requires a longer duration of antimicrobial therapy and closer monitoring and long-term follow-up. The treatment of endocarditis caused by B. quintana is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"       \"Endocarditis caused by Bartonella\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of B. quintana in HIV-infected patients with bacillary angiomatosis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18469?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of Bartonella infections in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8182?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      , fluoroquinolones, penicillins, and first-generation cephalosporins probably do not have reliable activity and thus are not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234332289\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bartonella quintana is a small, fastidious, gram-negative rod that belongs to the species of Bartonella. B quintana historically caused \"trench fever,\" but more recently has been associated with a variety of infections including bacteremia, endocarditis, and bacillary angiomatosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since the 1990s, sporadic B. quintana infections have reemerged in the United States and Europe and contemporary B. quintana infections have disproportionately affected indigent or homeless persons who often have chronic alcoholism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although investigators have reported scattered outbreaks of contemporary B. quintana infections, serologic studies suggest that exposure to the pathogen among certain at-risk populations is more common than overt clinical disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lice generally have been considered to be the major vector for B. quintana in classic trench fever. Available data suggest that the body louse is the predominant vector and infection probably results from contact with contaminated louse feces. Humans are the only known host for this organism. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In both classic and contemporary trench fever, B. quintana occurs in situations that foster very close contact of humans, particularly those with poor hygienic practices. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection with B. quintana can lead to an array of clinical presentations that generally depend upon the immune status of the infected individual:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Classic trench fever includes a variety of clinical manifestations, ranging from a mild influenza-like illness to a moderately severe, chronic, debilitating disease. Most persons who develop these symptoms presumably have bacteremia with B. quintana. The symptoms and signs of the acute disease typically include malaise, fever, headache, bone pain (particularly of the shins), splenomegaly, and, in some instances, a maculopapular rash. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Classic trench fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contemporary B. quintana infections were first described in HIV-infected individuals in the early 1990s. In such patients, B. quintana predominantly caused bacillary angiomatosis, manifesting as cutaneous lesions, subcutaneous masses, or bone lesions, but not lymph node, liver, or splenic lesions (as commonly seen with B. henselae infection). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Contemporary B. quintana infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of contemporary B. quintana infections among immunocompetent persons have differed from those in HIV-infected patients and have more closely resembled classic trench fever. Most patients have had bacteremia, and some have had endocarditis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Contemporary B. quintana infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A definitive diagnosis of Bartonella infection is made by isolating the organism from a culture of blood or tissue. However, more frequently the diagnosis is based upon a combination of findings from supportive diagnostic tests, including serology or the polymerase chain reaction. Histopathology does not typically play an important role in the diagnosis of B. quintana infections, except in HIV-infected persons who have cutaneous bacillary angiomatosis. Bartonella quintana is a fastidious gram-negative bacterium that requires specific laboratory conditions to enhance the yield of culture. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive antibiotic therapy recommendations for B. quintana infection are problematic because of limited treatment efficacy data, relatively poor correlations of in vitro data and clinical responses, and difficultly judging treatment response in the subset of patients with B. quintana bacteremia who have minimal or no clinical symptoms. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have acute or chronic B. quintana bacteremia without endocarditis, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      200 mg orally once daily (or 100 mg twice daily) for four weeks plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily for the first 2 weeks. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic B. quintana bacteremia should undergo careful evaluation for endocarditis, since endocarditis requires a longer duration of antimicrobial therapy and closer monitoring and long-term follow-up. The treatment of endocarditis caused by B. quintana is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"       \"Endocarditis caused by Bartonella\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of B. quintana in HIV-infected patients with bacillary angiomatosis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18469?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of Bartonella infections in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8182?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/1\">",
"      Foucault C, Brouqui P, Raoult D. Bartonella quintana characteristics and clinical management. Emerg Infect Dis 2006; 12:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/2\">",
"      Relman DA. Has trench fever returned? N Engl J Med 1995; 332:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/3\">",
"      Vinson JW. In vitro cultivation of the rickettsial agent of trench fever. Bull World Health Organ 1966; 35:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/4\">",
"      Spach DH, Kanter AS, Dougherty MJ, et al. Bartonella (Rochalimaea) quintana bacteremia in inner-city patients with chronic alcoholism. N Engl J Med 1995; 332:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/5\">",
"      Brouqui P, Lascola B, Roux V, Raoult D. Chronic Bartonella quintana bacteremia in homeless patients. N Engl J Med 1999; 340:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/6\">",
"      Drancourt M, Mainardi JL, Brouqui P, et al. Bartonella (Rochalimaea) quintana endocarditis in three homeless men. N Engl J Med 1995; 332:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/7\">",
"      Raoult D, Fournier PE, Drancourt M, et al. Diagnosis of 22 new cases of Bartonella endocarditis. Ann Intern Med 1996; 125:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/8\">",
"      Spach DH, Kanter AS, Daniels NA, et al. Bartonella (Rochalimaea) species as a cause of apparent \"culture-negative\" endocarditis. Clin Infect Dis 1995; 20:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/9\">",
"      Koehler JE, Sanchez MA, Garrido CS, et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med 1997; 337:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/10\">",
"      Relman DA, Loutit JS, Schmidt TM, et al. The agent of bacillary angiomatosis. An approach to the identification of uncultured pathogens. N Engl J Med 1990; 323:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/11\">",
"      Rolain JM, Foucault C, Guieu R, et al. Bartonella quintana in human erythrocytes. Lancet 2002; 360:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/12\">",
"      Jackson LA, Spach DH, Kippen DA, et al. Seroprevalence to Bartonella quintana among patients at a community clinic in downtown Seattle. J Infect Dis 1996; 173:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/13\">",
"      Brouqui P, Houpikian P, Dupont HT, et al. Survey of the seroprevalence of Bartonella quintana in homeless people. Clin Infect Dis 1996; 23:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/14\">",
"      Guibal F, de La Salmoni&egrave;re P, Rybojad M, et al. High seroprevalence to Bartonella quintana in homeless patients with cutaneous parasitic infestations in downtown Paris. J Am Acad Dermatol 2001; 44:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/15\">",
"      Brouqui P, Stein A, Dupont HT, et al. Ectoparasitism and vector-borne diseases in 930 homeless people from Marseilles. Medicine (Baltimore) 2005; 84:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/16\">",
"      Comer JA, Flynn C, Regnery RL, et al. Antibodies to Bartonella species in inner-city intravenous drug users in Baltimore, Md. Arch Intern Med 1996; 156:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/17\">",
"      ITO S, VINSON JW. FINE STRUCTURE OF RICKETTSIA QUINTANA CULTIVATED IN VITRO AND IN THE LOUSE. J Bacteriol 1965; 89:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/18\">",
"      Raoult D, Roux V. The body louse as a vector of reemerging human diseases. Clin Infect Dis 1999; 29:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/19\">",
"      Rydkina EB, Roux V, Gagua EM, et al. Bartonella quintana in body lice collected from homeless persons in Russia. Emerg Infect Dis 1999; 5:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/20\">",
"      Raoult D, Ndihokubwayo JB, Tissot-Dupont H, et al. Outbreak of epidemic typhus associated with trench fever in Burundi. Lancet 1998; 352:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/21\">",
"      Bonilla DL, Kabeya H, Henn J, et al. Bartonella quintana in body lice and head lice from homeless persons, San Francisco, California, USA. Emerg Infect Dis 2009; 15:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/22\">",
"      La Scola B, Fournier PE, Brouqui P, Raoult D. Detection and culture of Bartonella quintana, Serratia marcescens, and Acinetobacter spp. from decontaminated human body lice. J Clin Microbiol 2001; 39:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/23\">",
"      Seki N, Kasai S, Saito N, et al. Quantitative analysis of proliferation and excretion of Bartonella quintana in body lice, Pediculus humanus L. Am J Trop Med Hyg 2007; 77:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/24\">",
"      Raoult D, Drancourt M, Carta A, Gastaut JA. Bartonella (Rochalimaea) quintana isolation in patient with chronic adenopathy, lymphopenia, and a cat. Lancet 1994; 343:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/25\">",
"      Ohl ME, Spach DH. Bartonella quintana and urban trench fever. Clin Infect Dis 2000; 31:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/26\">",
"      Vinson JW, Varela G, Molina-Pasquel C. Trench fever. 3. Induction of clinical disease in volunteers inoculated with Rickettsia quintana propagated on blood agar. Am J Trop Med Hyg 1969; 18:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/27\">",
"      Koehler JE, Quinn FD, Berger TG, et al. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992; 327:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/28\">",
"      Drancourt M, Moal V, Brunet P, et al. Bartonella (Rochalimaea) quintana infection in a seronegative hemodialyzed patient. J Clin Microbiol 1996; 34:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/29\">",
"      LeBoit PE, Berger TG, Egbert BM, et al. Bacillary angiomatosis. The histopathology and differential diagnosis of a pseudoneoplastic infection in patients with human immunodeficiency virus disease. Am J Surg Pathol 1989; 13:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/30\">",
"      LeBoit PE, Berger TG, Egbert BM, et al. Epithelioid haemangioma-like vascular proliferation in AIDS: manifestation of cat scratch disease bacillus infection? Lancet 1988; 1:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/31\">",
"      Sander A, Penno S. Semiquantitative species-specific detection of Bartonella henselae and Bartonella quintana by PCR-enzyme immunoassay. J Clin Microbiol 1999; 37:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/32\">",
"      Jensen WA, Fall MZ, Rooney J, et al. Rapid identification and differentiation of Bartonella species using a single-step PCR assay. J Clin Microbiol 2000; 38:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/33\">",
"      Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother 2003; 47:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/34\">",
"      Raoult D, Fournier PE, Vandenesch F, et al. Outcome and treatment of Bartonella endocarditis. Arch Intern Med 2003; 163:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36583/abstract/35\">",
"      Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5517 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36583=[""].join("\n");
var outline_f35_46_36583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H234332289\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Classic trench fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Contemporary B. quintana infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234332289\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/56/26503?source=related_link\">",
"      Bartonellosis: Oroya fever and verruga peruana",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18469?source=related_link\">",
"      Diagnosis, treatment, and prevention of Bartonella infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=related_link\">",
"      Endocarditis caused by Bartonella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8182?source=related_link\">",
"      Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_46_36584="Rosacea: Pathogenesis, clinical features, and diagnosis";
var content_f35_46_36584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rosacea: Pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36584/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36584/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36584/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/46/36584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H394012116\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosacea is a common, chronic skin disorder that presents with a variety of clinical manifestations primarily localized on the central face [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The disorder is divided into four main subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea.",
"   </p>",
"   <p>",
"    Persistent centrofacial redness is a characteristic feature of the erythematotelangiectatic form of rosacea, while papulopustular disease presents with acne-like inflammatory papules and pustules in a similar distribution. The less common phymatous form of rosacea may demonstrate marked skin thickening and distortion of facial contours. Ocular rosacea, which often presents with eye redness, pruritus, or irritation, can occur in the presence or absence of cutaneous disease.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of rosacea will be reviewed here. The treatment of rosacea is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29066?source=see_link\">",
"     \"Management of rosacea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394012123\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosacea is a common disorder that is most frequently observed in fair-skinned individuals (skin phototypes I and II) (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"mobipreview.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ). People of Celtic and Northern European origin appear to have the greatest risk for this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The prevalence of rosacea is difficult to assess due to its variable clinical manifestations and the wide variety of skin disorders that exhibit similar clinical features (see",
"    <a class=\"local\" href=\"#H394012195\">",
"     'Differential diagnosis'",
"    </a>",
"    below). Estimates of the prevalence of rosacea in fair-skinned populations range from 1 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rosacea occurs in people with darker skin complexions, but is less frequently diagnosed in such populations (",
"    <a class=\"graphic graphic_picture graphicRef53889 graphicRef63008 \" href=\"mobipreview.htm?38/53/39769\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. It is unknown whether factors such as masking of facial redness by abundant skin pigment, protective effects of melanin against ultraviolet radiation (an exacerbating factor for rosacea), or genetic differences in susceptibility to rosacea contribute to the lower rate of diagnosis in people with dark skin.",
"   </p>",
"   <p>",
"    Adults over the age of 30 are the primary age group affected by rosacea, and the disorder occurs more frequently in women than in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Phymatous rosacea is an exception; the vast majority of affected patients are adult males.",
"   </p>",
"   <p>",
"    Rarely, rosacea occurs in children. Children may exhibit all subtypes except the phymatous form of the disease, and symptoms may persist into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394012131\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathways that lead to the development of rosacea are not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Proposed contributing factors include abnormalities in innate immunity, inflammatory reactions to cutaneous microorganisms, ultraviolet damage, and vascular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433190\">",
"    <span class=\"h2\">",
"     Immune dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innate immune system plays a key role in the cutaneous immune response to microorganisms and to insults such as ultraviolet radiation and physical or chemical trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/19\">",
"     19",
"    </a>",
"    ]. Dysfunction of the innate immune system may contribute to the development of chronic inflammation and vascular abnormalities in rosacea.",
"   </p>",
"   <p>",
"    The process through which aberrations of the innate immune system may contribute to rosacea may involve the production of abnormal cathelicidin peptides that have vasoactive and inflammatory properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/19\">",
"     19",
"    </a>",
"    ]. Increased levels of abnormal cathelicidin and kallikrein 5 (a processing enzyme for cathelicidin that is also known as stratum corneum tryptic enzyme) have been detected in skin from patients with rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subsequent discovery that toll-like receptor 2, a component of the innate immune system that interacts with environmental stimuli, can stimulate release of kallikrein 5 from epidermal keratinocytes offers a potential explanation for a link between environmental insults and cathelicidin-mediated abnormalities in rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/21\">",
"     21",
"    </a>",
"    ]. Moreover, a study in which the injection of mouse skin with cathelicidin peptides from patients with rosacea led to inflammation and vascular dilatation provides additional evidence in support of cathelicidin as a pathogenic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433233\">",
"    <span class=\"h2\">",
"     Microorganisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulation of inflammatory reactions by microbes in or on the skin has been proposed as an inciting factor for cutaneous inflammation in rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433276\">",
"    <span class=\"h3\">",
"     Demodex",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Demodex folliculorum",
"    </em>",
"    is a saprophytic mite that resides in sebaceous follicles. Although",
"    <em>",
"     Demodex",
"    </em>",
"    mites can be found on normal skin in almost all adults, increased density of",
"    <em>",
"     Demodex",
"    </em>",
"    mites in patients with rosacea has been reported in multiple studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. In a meta-analysis of case-control studies, a statistically significant association between",
"    <em>",
"     Demodex",
"    </em>",
"    infestation and rosacea was detected, with the degree of infestation being more important than the rate of infestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/22\">",
"     22",
"    </a>",
"    ]. The role of",
"    <em>",
"     Demodex",
"    </em>",
"    mites as an inciting factor for rosacea remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433283\">",
"    <span class=\"h3\">",
"     Bacillus olenorium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knowledge that papulopustular rosacea improves with antibiotic therapy led to an in vitro study investigating",
"    <em>",
"     Bacillus olenorius",
"    </em>",
"    , a bacterium that was cultured from a single",
"    <em>",
"     Demodex",
"    </em>",
"    mite, as a potential cause of inflammation in rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/26\">",
"     26",
"    </a>",
"    ]. The study found that antigens from",
"    <em>",
"     B. olenorius",
"    </em>",
"    stimulated proliferation of peripheral blood mononuclear cells from 16 out of 22 patients with rosacea (73 percent) versus only 5 out of 17 patients without rosacea (29 percent). Additional studies are necessary to determine whether",
"    <em>",
"     B. olenorius",
"    </em>",
"    is a common colonizer of",
"    <em>",
"     Demodex",
"    </em>",
"    mites and whether the organism is involved in the pathogenesis of rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433290\">",
"    <span class=\"h3\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between gastrointestinal",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    infection and rosacea is uncertain due to conflicting data on the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection among patients with rosacea. While some studies have reported increased rates of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection in patients with rosacea, others have not found an association between the disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, studies conflict on whether treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    improves rosacea. It is conceivable that antibiotic therapy to eradicate the infection could simultaneously ameliorate rosacea through unrelated mechanisms.",
"   </p>",
"   <p>",
"    Proposed pathogenic mechanisms for",
"    <em>",
"     H. pylori",
"    </em>",
"    infection in rosacea include the promotion of inflammation due to reactive oxygen species produced by",
"    <em>",
"     H. pylori",
"    </em>",
"    and bacterium-induced cytokine production by gastric epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433297\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Staphylococcus epidermidis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/28,29\">",
"     28,29",
"    </a>",
"    ],",
"    <em>",
"     Chlamydia pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/30\">",
"     30",
"    </a>",
"    ], and small intestine bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/31\">",
"     31",
"    </a>",
"    ] have been linked to rosacea in a few studies. Additional investigation is necessary to determine whether any of these organisms have a significant impact on the development of rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433400\">",
"    <span class=\"h2\">",
"     Ultraviolet radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun exposure is often cited as an exacerbating factor for rosacea, based upon the distribution of lesions on chronically sun-exposed skin, the detection of signs of solar elastosis on skin biopsy specimens, and the preferential appearance of the disorder in fair-skinned individuals.",
"   </p>",
"   <p>",
"    Several theories on the mechanisms through which sun exposure could promote rosacea have been proposed. Ultraviolet B radiation has been shown to induce cutaneous angiogenesis in mice and can stimulate the secretion of vascular endothelial growth factor (VEGF)-2 and fibroblast growth factor (FGF)-2 from keratinocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Ultraviolet radiation may also stimulate production of damaging reactive oxygen species and may incite activation of the innate immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, study data confirming an association between all subtypes of rosacea and ultraviolet radiation are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/35\">",
"     35",
"    </a>",
"    ]. Fewer than one-third of patients with rosacea report exacerbations of symptoms with sunlight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/35\">",
"     35",
"    </a>",
"    ], and a retrospective study in Korea of 168 patients with rosacea found that although high daily sun exposure correlated with increased severity of erythematotelangiectatic disease, it did not appear to have a significant effect on papulopustular, phymatous, or ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, a study of 1000 adults in Ireland found no difference in the prevalence of papulopustular rosacea in subjects with high sun exposure versus those with lower sun exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/6\">",
"     6",
"    </a>",
"    ]. Further studies are necessary to explore the impact of ultraviolet radiation on the various subtypes of rosacea.",
"   </p>",
"   <p>",
"    As noted above, extremes of temperature can be an exacerbating factor for rosacea. Thus, aside from ultraviolet light, infrared radiation (radiant heat) from sun exposure could contribute to exacerbations of rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433473\">",
"    <span class=\"h2\">",
"     Vascular hyperreactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequent and prolonged flushing is a common feature in rosacea and triggers of flushing (eg, spicy foods, alcohol, and extremes of temperature) have been anecdotally associated with worsening disease (see",
"    <a class=\"local\" href=\"#H432985\">",
"     'Exacerbating factors'",
"    </a>",
"    below). In addition, increased blood flow has been detected in the skin of some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/12,36\">",
"     12,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest a role for vascular hyperreactivity in the pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/19\">",
"     19",
"    </a>",
"    ]. Dysregulation of thermal mechanisms has also been proposed as a contributing factor to flushing in rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433494\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with a family history of rosacea may be more likely to develop the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/13\">",
"     13",
"    </a>",
"    ]. However, specific genetic factors associated with increased risk for rosacea have not been identified. Further studies are necessary to explore the impact of family history and genetic background on risk for rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432867\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four main subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients may present with features of one or multiple subtypes.",
"   </p>",
"   <p>",
"    Although lesions of erythematotelangiectatic and papulopustular rosacea classically involve the central face, involvement of other sites such as the ears, lateral face, neck, scalp, and chest occasionally occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394012146\">",
"    <span class=\"h2\">",
"     Erythematotelangiectatic rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent facial erythema and recurrent episodes of facial flushing are characteristic features of erythematotelangiectatic rosacea. A summary of common features of the erythematotelangiectatic subtype of rosacea is below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Persistent centrofacial erythema",
"      </strong>",
"      &ndash; Patients exhibit chronic redness of the nose and medial cheeks (",
"      <a class=\"graphic graphic_picture graphicRef77020 graphicRef56083 \" href=\"mobipreview.htm?23/52/24391\">",
"       picture 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Flushing &ndash;",
"      </strong>",
"      This can be wet (accompanied by sweating) or dry, and may be associated with subtle transient facial swelling. Examples of triggers for flushing are provided (see",
"      <a class=\"local\" href=\"#H432985\">",
"       'Exacerbating factors'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <strong>",
"       Telangiectasias &ndash;",
"      </strong>",
"      Telangiectasias are visible enlarged cutaneous blood vessels (",
"      <a class=\"graphic graphic_picture graphicRef71614 \" href=\"mobipreview.htm?13/22/13667\">",
"       picture 3",
"      </a>",
"      ). In rosacea, telangiectasias are predominantly located on the central face, especially on the cheeks.",
"     </li>",
"     <li>",
"      <strong>",
"       Roughness and scaling &ndash;",
"      </strong>",
"      A dry quality to the skin is often present.",
"     </li>",
"     <li>",
"      <strong>",
"       Skin sensitivity &ndash;",
"      </strong>",
"      Stinging or burning sensations in affected areas are common in patients with rosacea. Skin care products may irritate the skin and aggravate symptoms.",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema congestivum &ndash;",
"      </strong>",
"      After an exacerbation of facial redness, the appearance of patients with rosacea returns to baseline more slowly than individuals without rosacea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432928\">",
"    <span class=\"h2\">",
"     Papulopustular rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papulopustular rosacea is marked by the presence of papules and pustules primarily localized to the central face (",
"    <a class=\"graphic graphic_picture graphicRef67890 graphicRef53889 graphicRef78747 graphicRef63008 \" href=\"mobipreview.htm?39/25/40346\">",
"     picture 1A-D",
"    </a>",
"    ). Lesions may be mistaken for inflammatory acne vulgaris. Unlike acne vulgaris, comedones do not occur in rosacea and inflammation may extend outward well beyond the follicular unit to form plaques. As an example, in occasional patients the whole nose may be tender, swollen, and red.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394012163\">",
"    <span class=\"h2\">",
"     Phymatous rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phymatous rosacea exhibits tissue hypertrophy manifesting as thickened skin with irregular contours (",
"    <a class=\"graphic graphic_picture graphicRef61822 \" href=\"mobipreview.htm?0/32/514\">",
"     picture 4",
"    </a>",
"    ). Involvement most commonly occurs on the nose (rhinophyma), but may also be seen in other sites such as the chin (gnathophyma), forehead (glabellophyma), and cheeks. Patients who develop this subtype of rosacea often have prominent sebaceous hyperplasia and very oily skin. The vast majority of patients with phymatous rosacea are adult men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394012175\">",
"    <span class=\"h2\">",
"     Ocular rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular involvement occurs in more than 50 percent of patients with rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/38\">",
"     38",
"    </a>",
"    ] Ocular rosacea may precede (20 percent), follow (50 percent), or occur concurrently with cutaneous disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/37\">",
"     37",
"    </a>",
"    ]. Both children and adults may be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/14,39\">",
"     14,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations of ocular rosacea include conjunctival hyperemia, anterior blepharitis, keratitis, lid margin telangiectases, abnormal tearing, cicatricial conjunctivitis, and chalazion or hordeolum (stye) formation. Potential symptoms include dry eye, foreign body sensations, stinging, burning, pruritus, photosensitivity, and blurry vision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34761?source=see_link\">",
"     \"Ocular rosacea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433591\">",
"    <span class=\"h2\">",
"     Granulomatous rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship of granulomatous rosacea to other forms of rosacea has been debated, but in 2002, a committee of experts recognized this disorder as a variant of rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/37\">",
"     37",
"    </a>",
"    ]. Granulomatous rosacea presents with yellow-brown or monotonous pink papules that are usually distributed on the cheeks and perioral skin; background facial erythema and flushing are often absent. A granulomatous infiltrate is characteristically present on biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433610\">",
"    <span class=\"h2\">",
"     Pediatric rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, children develop erythematotelangiectatic, papulopustular, or ocular rosacea. The clinical features of pediatric rosacea resemble those of rosacea in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/14-16,39,40\">",
"     14-16,39,40",
"    </a>",
"    ]. Phymatous rosacea does not occur in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432985\">",
"    <span class=\"h1\">",
"     EXACERBATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors have been anecdotally associated with exacerbations of cutaneous signs and symptoms of rosacea, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure to extremes of temperature",
"     </li>",
"     <li>",
"      Sun exposure",
"     </li>",
"     <li>",
"      Hot beverages",
"     </li>",
"     <li>",
"      Spicy foods",
"     </li>",
"     <li>",
"      Alcohol",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Irritation from topical products",
"     </li>",
"     <li>",
"      Psychological feelings, especially anger, rage, and embarrassment",
"     </li>",
"     <li>",
"      Certain drugs such as nicotinic acid and vasodilators",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, phymatous rosacea was perceived by the lay public to be a consequence of heavy alcohol consumption. However, definitive evidence in support of an association between alcohol and phymatous rosacea is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2005836\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical assessment of the patient is usually sufficient for the diagnosis of erythematotelangiectatic, papulopustular, and phymatous rosacea. The histopathologic findings in these subtypes are nonspecific, and skin biopsies are rarely indicated. When the diagnosis is uncertain, biopsies may be performed to rule out other disorders or to provide support for a diagnosis of granulomatous rosacea. No serologic studies are useful for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394012187\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimens from erythematous facial skin in erythematotelangiectatic rosacea usually show dilation of superficial blood vessels and a low grade perivascular lymphohistiocytic inflammatory infiltrate with occasional plasma cells. Solar elastosis is often present.",
"   </p>",
"   <p>",
"    Histopathologic examination of papular lesions usually reveals prominent perivascular and perifollicular inflammatory infiltrates in the superficial and mid-dermis composed of lymphocytes, neutrophils, and plasma cells. Superficial accumulations of neutrophils are present in pustular lesions. In contrast to acne vulgaris, inflammation often extends well beyond the follicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/41\">",
"     41",
"    </a>",
"    ].",
"    <em>",
"     Demodex",
"    </em>",
"    mites are often detected in follicular orifices.",
"   </p>",
"   <p>",
"    The histopathologic findings in phymatous rosacea include sebaceous gland hyperplasia, follicular plugging, telangiectasias, pronounced dermal thickening and fibrosis, and large amounts of dermal mucin. Increased numbers of Factor XIIIa positive cells may be present in the dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Granulomatous rosacea is characterized by the presence of epithelioid granulomas adjacent to hair follicles. Caseation is present in approximately 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1419957\">",
"    <span class=\"h2\">",
"     Referral to ophthalmology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have ocular symptoms or who are found to have visible signs suggestive of ocular rosacea should be referred to ophthalmology for further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H394012195\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of skin conditions may present with clinical features that resemble erythematotelangiectatic, papulopustular, or granulomatous rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433678\">",
"    <span class=\"h2\">",
"     Erythematotelangiectatic rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions share features with erythematotelangiectatic rosacea:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ruddy complexion &ndash;",
"      </strong>",
"      Some fair-skinned patients, particularly those of Celtic origin, may have a naturally ruddy complexion to the skin. In contrast to the ruddy complexion, redness in rosacea primarily involves the central face.",
"     </li>",
"     <li>",
"      <strong>",
"       Sun-damaged skin &ndash;",
"      </strong>",
"      Telangiectasia may occur as a manifestation of sun-damaged skin. Dyspigmentation and skin wrinkling are often also present. In contrast to rosacea, which primarily affects the central face, sun damage is often most evident on the lateral face and neck. The presence of other characteristics of rosacea, such as persistent facial erythema and frequent flushing, also support a diagnosis of rosacea.",
"     </li>",
"     <li>",
"      <strong>",
"       Seborrheic dermatitis &ndash;",
"      </strong>",
"      Macular erythema and scale involving the perinasal area is a common finding in seborrheic dermatitis (",
"      <a class=\"graphic graphic_picture graphicRef56410 \" href=\"mobipreview.htm?33/58/34721\">",
"       picture 5",
"      </a>",
"      ). A greasy quality to the scale and involvement of other sites such as the scalp, retroauricular skin, and brow suggest this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21961?source=see_link\">",
"       \"Seborrheic dermatitis in adolescents and adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acute cutaneous lupus erythematosus &ndash;",
"      </strong>",
"      The centrofacial redness in rosacea may be confused with malar erythema of systemic lupus erythematosus, particularly in patients who lack papulopustular lesions (",
"      <a class=\"graphic graphic_picture graphicRef75781 graphicRef55875 \" href=\"mobipreview.htm?36/46/37608\">",
"       picture 6A-B",
"      </a>",
"      ). In lupus, the color of the skin has a violaceous quality and may show a more abrupt cutoff, especially at its most lateral margins (resembling a butterfly wing). &nbsp;",
"      <br/>",
"      <br/>",
"      Serologic testing for antinuclear antibodies in all patients with classic features of erythematotelangiectatic rosacea is",
"      <strong>",
"       not",
"      </strong>",
"      indicated. Patients should be clinically assessed for signs or symptoms of systemic lupus; the need for laboratory work-up should be based upon the presence of mucocutaneous or systemic findings suggestive of this disorder. Skin biopsies of acute cutaneous lupus erythematosus usually demonstrate interface dermatitis, a feature that does not occur in rosacea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link&amp;anchor=H3#H3\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Acute cutaneous lupus erythematosus (butterfly rash)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatomyositis &ndash;",
"      </strong>",
"      Dermatomyositis is an idiopathic inflammatory disorder that can affect skin and muscle tissue. Violaceous erythema involving the periorbital skin and central face can occur. The dusky, violaceous color of the facial eruption differs from the bright erythema that is typically seen in rosacea (",
"      <a class=\"graphic graphic_picture graphicRef56879 \" href=\"mobipreview.htm?29/6/29793\">",
"       picture 7",
"      </a>",
"      ). Examination for muscle weakness and other cutaneous signs of dermatomyositis is useful for diagnosis. Like acute cutaneous lupus erythematosus, skin biopsies reveal features of an interface dermatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other flushing disorders &ndash;",
"      </strong>",
"      In addition to rosacea, facial flushing may occur in a wide variety of disorders. Examples include medication reactions, menopausal hot-flashes, neurologic disorders, carcinoid syndrome, mastocytosis, pheochromocytoma, medullary thyroid carcinoma, and serotonin syndrome. The possibility of such disorders should be considered in patients who present with flushing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12857?source=see_link\">",
"       \"Approach to flushing in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2005723\">",
"    <span class=\"h2\">",
"     Papulopustular rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following disorders share features with papulopustular rosacea:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acne vulgaris &ndash;",
"      </strong>",
"      Acne vulgaris is the most common skin disorder in the differential diagnosis of papulopustular rosacea. Individual inflammatory lesions of the two disorders may appear clinically identical. A key distinguishing feature between acne vulgaris and rosacea is the absence of comedones in rosacea (",
"      <a class=\"graphic graphic_picture graphicRef68412 \" href=\"mobipreview.htm?5/18/5413\">",
"       picture 8",
"      </a>",
"      ). A prominent centrofacial distribution also suggests a diagnosis of rosacea. Acne vulgaris and rosacea coexist in some patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Topical steroid-induced acneiform eruptions &ndash;",
"      </strong>",
"      Topical corticosteroid use can result in the appearance of monomorphic inflammatory papules on facial skin. The patient history is valuable for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link&amp;anchor=H17#H17\">",
"       \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Cutaneous'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Perioral dermatitis &ndash;",
"      </strong>",
"      Perioral dermatitis presents with numerous small papules with fine scale in the perioral area (",
"      <a class=\"graphic graphic_picture graphicRef73779 graphicRef64577 \" href=\"mobipreview.htm?5/53/5977\">",
"       picture 9A-B",
"      </a>",
"      ). Sparing of the skin adjacent to the vermillion border of the lip is characteristic. Lesions may also occur in periorbital and perinasal distributions. In patients who have erroneously attempted to treat the eruption with topical corticosteroids, acneiform eruptions may also be present.",
"     </li>",
"     <li>",
"      <strong>",
"       Keratosis pilaris rubra faceii &ndash;",
"      </strong>",
"      Persistent, rough, 1 to 2 mm follicularly-based papules on the face can occur as a manifestation of keratosis pilaris in children, adolescents, and young adults (",
"      <a class=\"graphic graphic_picture graphicRef77270 \" href=\"mobipreview.htm?19/23/19828\">",
"       picture 10",
"      </a>",
"      ). The condition presents with a rough, red, symmetrical, triangular patch of skin on each cheek that lacks papules or pustules. Typical keratosis pilaris also may be present on the backs of the arms and fronts of the thighs (",
"      <a class=\"graphic graphic_picture graphicRef60786 graphicRef68488 \" href=\"mobipreview.htm?33/22/34152\">",
"       picture 11A-B",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Demodicosis (",
"      </strong>",
"      <strong>",
"       <em>",
"        Demodex",
"       </em>",
"      </strong>",
"      <strong>",
"       folliculitis) &ndash;",
"      </strong>",
"      Demodicosis can present with numerous inflammatory papules on the face and is difficult to distinguish from papulopustular rosacea on clinical examination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/45\">",
"       45",
"      </a>",
"      ]. Potassium hydroxide (KOH) preparation or skin punch biopsy may demonstrate numerous",
"      <em>",
"       Demodex",
"      </em>",
"      mites crowding the follicular orifice. However,",
"      <em>",
"       Demodex",
"      </em>",
"      mites are also commonly detected in rosacea and in normal skin. Immunocompromised patients are at increased risk for this disorder. Multiple therapies have been reported to be effective for demodicosis in individual patients. Examples include topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      , topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/45/13011?source=see_link\">",
"       crotamiton",
"      </a>",
"      , oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      , and topical or oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/45-49\">",
"       45-49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"       \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2149662\">",
"    <span class=\"h2\">",
"     Granulomatous rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The features of granulomatous rosacea overlap with other disorders described in the literature that present with numerous, small, monomorphic facial papules and granulomatous infiltrates on biopsy. In adults, lupus miliaris disseminatus faciei, which presents with multiple red-brown 2 to 5 mm papules on the face and caseating granulomas on biopsy, has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Rarely, B-cell lymphomas and chronic lymphocytic leukemia present with facial cutaneous lesions that resemble granulomatous or phymatous rosacea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, granulomatous facial dermatoses identified as childhood granulomatous periorificial dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/54-56\">",
"     54-56",
"    </a>",
"    ] and facial Afro-Caribbean childhood eruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/57,58\">",
"     57,58",
"    </a>",
"    ] have been described in children. The status of these disorders as independent entities or forms of rosacea is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2149672\">",
"    <span class=\"h1\">",
"     PYODERMA FACIALE (ROSACEA FULMINANS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship of pyoderma faciale (also known as rosacea fulminans or rosacea conglobata) to rosacea also is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients present with intensely inflammatory, purulent facial plaques and nodules with draining sinuses on a background of erythema (",
"    <a class=\"graphic graphic_picture graphicRef57401 \" href=\"mobipreview.htm?35/55/36724\">",
"     picture 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36584/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. A history of rosacea may or may not be present. Young women are most commonly affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2149788\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rosacea is a common skin disorder that may occur in adults of all ethnic backgrounds, but is most commonly diagnosed in individuals with fair skin. Rarely, rosacea occurs in children. (See",
"      <a class=\"local\" href=\"#H394012123\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of rosacea is poorly understood. Factors such as abnormalities in the innate immune system, inflammatory reactions to cutaneous microorganisms, ultraviolet radiation exposure, and vascular hyperreactivity have been identified as potential contributing factors. (See",
"      <a class=\"local\" href=\"#H394012131\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rosacea is divided into four main subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. Granulomatous rosacea may be a variant of rosacea. (See",
"      <a class=\"local\" href=\"#H432867\">",
"       'Classification and clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent facial redness, recurrent facial flushing, telangiectasias, and skin dryness and sensitivity are common features of erythematotelangiectatic rosacea. Lesions of papulopustular rosacea closely resemble inflammatory acne. Features of both subtypes are primarily localized on the central face. (See",
"      <a class=\"local\" href=\"#H432867\">",
"       'Classification and clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients, clinical assessment is sufficient for diagnosing rosacea and excluding other disorders that may resemble rosacea. Skin biopsies are rarely indicated, but can be useful in cases in which another disorder with specific histopathologic findings is suspected or for supporting a diagnosis of granulomatous rosacea. (See",
"      <a class=\"local\" href=\"#H2005836\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H394012195\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular rosacea may present independently or in association with cutaneous subtypes of rosacea. Patients may exhibit features such as conjunctival hyperemia, blepharitis, and ocular irritation. Patients with signs or symptoms of ocular rosacea should be referred to an ophthalmologist for further evaluation. (See",
"      <a class=\"local\" href=\"#H394012175\">",
"       'Ocular rosacea'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1419957\">",
"       'Referral to ophthalmology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/1\">",
"      Webster GF. Rosacea. Med Clin North Am 2009; 93:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/2\">",
"      Powell FC. Clinical practice. Rosacea. N Engl J Med 2005; 352:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/3\">",
"      Elewski BE, Draelos Z, Dr&eacute;no B, et al. Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/4\">",
"      van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev 2011; :CD003262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/5\">",
"      Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatol 1989; 6:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/6\">",
"      McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol 2010; 63:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/7\">",
"      Khaled A, Hammami H, Zeglaoui F, et al. Rosacea: 244 Tunisian cases. Tunis Med 2010; 88:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/8\">",
"      Rosen T, Stone MS. Acne rosacea in blacks. J Am Acad Dermatol 1987; 17:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/9\">",
"      Browning DJ, Rosenwasser G, Lugo M. Ocular rosacea in blacks. Am J Ophthalmol 1986; 101:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/10\">",
"      Bae YI, Yun SJ, Lee JB, et al. Clinical evaluation of 168 korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype. Ann Dermatol 2009; 21:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/11\">",
"      Alexis AF. Rosacea in patients with skin of color: uncommon but not rare. Cutis 2010; 86:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/12\">",
"      Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum. J Am Acad Dermatol 1992; 26:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/13\">",
"      Abram K, Silm H, Maaroos HI, Oona M. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol 2010; 24:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/14\">",
"      Chamaillard M, Mortemousque B, Boralevi F, et al. Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 2008; 144:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/15\">",
"      Kroshinsky D, Glick SA. Pediatric rosacea. Dermatol Ther 2006; 19:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/16\">",
"      Lacz NL, Schwartz RA. Rosacea in the pediatric population. Cutis 2004; 74:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/17\">",
"      Mc Aleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol 2009; 144:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/18\">",
"      Dahl MV. Pathogenesis of rosacea. Adv Dermatol 2001; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/19\">",
"      Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci 2009; 55:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/20\">",
"      Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/21\">",
"      Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011; 131:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/22\">",
"      Zhao YE, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol 2010; 146:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/23\">",
"      Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol 1993; 28:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/24\">",
"      Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993; 128:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/25\">",
"      Erba��ci Z, Ozg&ouml;zta��i O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol 1998; 37:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/26\">",
"      Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 2007; 157:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/27\">",
"      Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges 2011; 9:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/28\">",
"      Whitfeld M, Gunasingam N, Leow LJ, et al. Staphylococcus epidermidis: a possible role in the pustules of rosacea. J Am Acad Dermatol 2011; 64:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/29\">",
"      Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 2004; 50:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/30\">",
"      Fernandez-Obregon A, Patton DL. The role of Chlamydia pneumoniae in the etiology of acne rosacea: response to the use of oral azithromycin. Cutis 2007; 79:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/31\">",
"      Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008; 6:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/32\">",
"      Brauchle M, Funk JO, Kind P, Werner S. Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1996; 271:21793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/33\">",
"      Bielenberg DR, Bucana CD, Sanchez R, et al. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol 1998; 111:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/34\">",
"      Longuet-Perret I, Schmitt D, Viac J. Tumour necrosis factor-alpha is involved in the contrasting effects of ultraviolet B and ultraviolet A1 radiation on the release by normal human keratinocytes of vascular permeability factor. Br J Dermatol 1998; 138:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/35\">",
"      Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/36\">",
"      Guzman-Sanchez DA, Ishiuji Y, Patel T, et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol 2007; 57:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/37\">",
"      Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/38\">",
"      Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003; 22:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/39\">",
"      Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol 2004; 137:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/40\">",
"      Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol 1992; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/41\">",
"      Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol 1969; 100:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/42\">",
"      Tope WD, Sangueza OP. Rhinophyma's fibrous variant. Histopathology and immunohistochemistry. Am J Dermatopathol 1994; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/43\">",
"      Aloi F, Tomasini C, Soro E, Pippione M. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol 2000; 42:468.",
"     </a>",
"    </li>",
"    <li>",
"     Ioffreda MD. Inflammatory diseases of the hair follicles, sweat glands, and cartilage. In: Lever's Histopathology of the Skin, 9th ed, Elder D, Elenitsas R, Johnson BL, et al..  (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.469.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/45\">",
"      Hsu CK, Hsu MM, Lee JY. Demodicosis: a clinicopathological study. J Am Acad Dermatol 2009; 60:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/46\">",
"      Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol 2002; 82:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/47\">",
"      Karincaoglu Y, Miman O, Kalayci B, et al. A demodicosis case which responded to systemic ivermectin. Eur J Dermatol 2009; 19:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/48\">",
"      Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 1999; 41:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/49\">",
"      Aquilina C, Viraben R, Sire S. Ivermectin-responsive Demodex infestation during human immunodeficiency virus infection. A case report and literature review. Dermatology 2002; 205:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/50\">",
"      Al-Mutairi N. Nosology and therapeutic options for lupus miliaris disseminatus faciei. J Dermatol 2011; 38:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/51\">",
"      Esteves T, Faria A, Alves R, et al. Lupus miliaris disseminatus faciei: a case report. Dermatol Online J 2010; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/52\">",
"      van de Scheur MR, van der Waal RI, Starink TM. Lupus miliaris disseminatus faciei: a distinctive rosacea-like syndrome and not a granulomatous form of rosacea. Dermatology 2003; 206:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/53\">",
"      Barzilai A, Feuerman H, Quaglino P, et al. Cutaneous B-cell neoplasms mimicking granulomatous rosacea or rhinophyma. Arch Dermatol 2012; 148:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/54\">",
"      Lucas CR, Korman NJ, Gilliam AC. Granulomatous periorificial dermatitis: a variant of granulomatous rosacea in children? J Cutan Med Surg 2009; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/55\">",
"      Zalaudek I, Di Stefani A, Ferrara G, Argenziano G. Childhood granulomatous periorificial dermatitis: a controversial disease. J Dtsch Dermatol Ges 2005; 3:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/56\">",
"      Knautz MA, Lesher JL Jr. Childhood granulomatous periorificial dermatitis. Pediatr Dermatol 1996; 13:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/57\">",
"      Williams HC, Ashworth J, Pembroke AC, Breathnach SM. FACE--facial Afro-Caribbean childhood eruption. Clin Exp Dermatol 1990; 15:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/58\">",
"      Cribier B, Lieber-Mbomeyo A, Lipsker D. [Clinical and histological study of a case of facial Afro-Caribbean childhood eruption (FACE)]. Ann Dermatol Venereol 2008; 135:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/59\">",
"      Plewig G, Jansen T, Kligman AM. Pyoderma faciale. A review and report of 20 additional cases: is it rosacea? Arch Dermatol 1992; 128:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36584/abstract/60\">",
"      Ormond P, Rogers S. Case 3. Pyoderma faciale (PF) (rosacea fulminans). Clin Exp Dermatol 2003; 28:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13621 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-C5D28A4D55-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36584=[""].join("\n");
var outline_f35_46_36584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2149788\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394012116\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394012123\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394012131\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433190\">",
"      Immune dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433233\">",
"      Microorganisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H433276\">",
"      - Demodex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H433283\">",
"      - Bacillus olenorium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H433290\">",
"      - Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H433297\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433400\">",
"      Ultraviolet radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433473\">",
"      Vascular hyperreactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433494\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H432867\">",
"      CLASSIFICATION AND CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H394012146\">",
"      Erythematotelangiectatic rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432928\">",
"      Papulopustular rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H394012163\">",
"      Phymatous rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H394012175\">",
"      Ocular rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433591\">",
"      Granulomatous rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433610\">",
"      Pediatric rosacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H432985\">",
"      EXACERBATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2005836\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H394012187\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1419957\">",
"      Referral to ophthalmology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394012195\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H433678\">",
"      Erythematotelangiectatic rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2005723\">",
"      Papulopustular rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2149662\">",
"      Granulomatous rosacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2149672\">",
"      PYODERMA FACIALE (ROSACEA FULMINANS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2149788\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13621|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/30/21989\" title=\"picture 1A\">",
"      Rosacea papules on face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/49/37653\" title=\"picture 1B\">",
"      Rosacea in dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/52/41794\" title=\"picture 1C\">",
"      Rosacea papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/54/7011\" title=\"picture 1D\">",
"      Rosacea papules and pustules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/49/37649\" title=\"picture 2A\">",
"      Rosacea erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/61/32722\" title=\"picture 2B\">",
"      Rosacea erythema cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/22/13667\" title=\"picture 3\">",
"      Telangiectasia nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/32/514\" title=\"picture 4\">",
"      Rosacea rhinophyma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/58/34721\" title=\"picture 5\">",
"      Seborrheic dermatitis face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/39/32371\" title=\"picture 6A\">",
"      Acute cutaneous lupus erythematosus - malar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/47/3828\" title=\"picture 6B\">",
"      Acute cutaneous lupus erythematosus - malar eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/6/29793\" title=\"picture 7\">",
"      Dermatomyositis - heliotrope eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/18/5413\" title=\"picture 8\">",
"      Acne mixed type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/39/22131\" title=\"picture 9A\">",
"      Perioral dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/17/8469\" title=\"picture 9B\">",
"      Perioral dermatitis lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/23/19828\" title=\"picture 10\">",
"      Keratosis pilaris rubra faceii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/3/26672\" title=\"picture 11A\">",
"      Keratosis pilaris fair skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/26/18854\" title=\"picture 11B\">",
"      Keratosis pilaris dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/55/36724\" title=\"picture 12\">",
"      Pyoderma faciale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13621|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29066?source=related_link\">",
"      Management of rosacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34761?source=related_link\">",
"      Ocular rosacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_46_36585="Neurologic manifestations of hypothyroidism";
var content_f35_46_36585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic manifestations of hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36585/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36585/contributors\">",
"     Devon I Rubin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36585/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36585/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36585/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36585/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36585/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/46/36585/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism is a common medical condition in the general population. Common systemic manifestations include fatigue, constipation, cold intolerance, weight gain, hair loss, dry skin, and hoarseness. A variety of central and peripheral nervous system manifestations are common in patients with hypothyroidism (",
"    <a class=\"graphic graphic_table graphicRef72975 \" href=\"mobipreview.htm?31/18/32043\">",
"     table 1",
"    </a>",
"    ). In many cases, the neurologic manifestations occur in conjunction with the systemic features of the disease and may be noted only incidentally. However, symptoms and signs of neurologic dysfunction may be the presenting feature in some patients and can contribute significant disability. Most of these complications are partially or fully responsive to thyroid replacement.",
"   </p>",
"   <p>",
"    This topic reviews the common neurologic manifestations of hypothyroidism. Other clinical manifestations of hypothyroidism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERSISTENT AFFECTS OF CONGENITAL HYPOTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cretinism refers to the sequelae of hypothyroidism in the development of the fetus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    young infant. Although the effects of postnatal hypothyroidism can be ameliorated by prompt treatment, the sequelae of gestational hypothyroidism, particularly in the first trimester, persist throughout life. A common cause of congenital hypothyroidism is maternal and infant iodine deficiency, which is still endemic in some parts of Europe and elsewhere in the world.",
"   </p>",
"   <p>",
"    Neurologic sequelae include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mental retardation. The severity of cognitive impairments is associated with both the degree and duration of thyroid (or iodine) deficiency in utero and early life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/1\">",
"       1",
"      </a>",
"      ]. Severe deficiency in the first trimester of pregnancy in particular is associated with severe irreversible intellectual as well as motor impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Even children exposed to mild degrees of iodine deficiency in gestation and those with postnatal congenital hypothyroidism that is promptly recognized at birth, are likely to have mild, often subclinical, neuropsychiatric deficits when compared with siblings and other control groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/4\">",
"       4",
"      </a>",
"      ]. Studies suggest that in postnatal hypothyroidism, earlier administration of higher-dose thyroxine treatment is associated with less severe deficits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=see_link\">",
"       \"Treatment and prognosis of congenital hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Impaired motor development. Severe gestational and postnatal hypothyroidism are associated with dysfunction of pyramidal and extrapyramidal motor systems. Typical deficits include rigidity and spasticity of the trunk and proximal extremities, with relative sparing of the distal arms and legs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/6\">",
"       6",
"      </a>",
"      ]. Neuroimaging studies have revealed calcification in the basal ganglia and subcortical areas on computed tomography (CT), as well as magnetic resonance imaging (MRI) signal abnormalities in the globus pallidus and substantia nigra [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Up to 40 percent of children and adolescents with congenital hypothyroidism have been shown to demonstrate mild findings of cerebellar dysfunction, such as intention tremor, difficulty with tandem gait, clumsy running, fine motor dysfunction, and unsteady stance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The findings were more prominent in those diagnosed with hypothyroidism during the first few months of life compared with those diagnosed after the first year of life. A delay to treatment also influences the severity of findings in these children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/10\">",
"       10",
"      </a>",
"      ]. Animal studies have shown that hypothyroidism interferes with cerebellar development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other deficits can include strabismus and sensorineural hearing loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Iodine deficiency and congenital hypothyroidism are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39864?source=see_link\">",
"     \"Iodine deficiency disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=see_link\">",
"     \"Treatment and prognosis of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MYXEDEMA COMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coma is a rare manifestation of severe hypothyroidism and usually occurs in conjunction with hypothermia and other symptoms and signs (hypotension, bradycardia, hyponatremia, hypoglycemia, and hypoventilation). Seizures are common. Myxedema coma is a medical emergency with a high mortality rate. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8566?source=see_link\">",
"     \"Myxedema coma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COGNITIVE IMPAIRMENT AND DEMENTIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features and associations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Myxedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive dysfunction is a common feature of clinical hypothyroidism or myxedema, occurring in 66 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive impairment in hypothyroidism is most often manifest by slowed mentation, poor concentration, and decreased short-term memory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Also common are social withdrawal, psychomotor retardation, depressed mood, and apathy. Cortical features (aphasia, apraxia) are generally absent. Less commonly, hypothyroidism presents with other neuropsychological symptoms including psychosis, confusion, and disorientation; this syndrome has been called \"myxedema madness.\"",
"   </p>",
"   <p>",
"    When neuropsychological testing is performed, deficits may be most pronounced in tests of attention and executive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Memory retrieval, learning, verbal fluency, and motor speed are also often particularly impaired. Electroencephalography (EEG) may show generalized background slowing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive change in overt hypothyroidism is commonly accompanied by other clinical features associated with this condition, including lethargy, fatigue, cold intolerance, dry skin, constipation, and decreased exercise tolerance. These symptoms may occur concurrently with, or precede cognitive decline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Subclinical hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accepted definition of subclinical hypothyroidism is an elevated thyrotropin (TSH) level with a normal level of free thyroxine (T4). Subclinical hypothyroidism is common in the adult population, in about 8 percent of women and 3.5 percent of men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The prevalence increases with age; in those over 60 years, the prevalence is about 15 percent in women and 8 percent in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigations of the association between subclinical hypothyroidism and dementia or cognitive impairment have had somewhat conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In case control studies, some investigators have found between a two to four-fold higher incidence of elevated TSH in individuals with dementia compared with nondemented controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. The cross-sectional nature of this study precludes a cause and effect interpretation of this finding.",
"     </li>",
"     <li>",
"      In contrast, some investigators have found low TSH to be associated with Alzheimer disease, perhaps as a secondary phenomenon of neurodegeneration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Alzheimer disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Two population-based, cross-sectional studies, each with more than 800 elderly participants, found no association between TSH and cognitive status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. However, the cognitive assessments in these studies were somewhat crude. In a series of 15 patients with more detailed cognitive evaluations, slower reaction time, reduced verbal fluency, impaired visual memory, and decreased selective attention were seen in patients with subclinical hypothyroidism compared with normal controls matched for age, education, and premorbid intelligence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 464 euthyroid older women, the investigators found that low normal baseline T4 level, while unassociated with baseline cognitive status, did correlate with greater cognitive decline over three years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/26\">",
"       26",
"      </a>",
"      ]. TSH levels were unrelated to cognitive status either at baseline or at follow-up. A relationship between T4 level and cognitive performance has been found in other elderly euthyroid populations, with and without dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another prospective, population-based cohort, 599 persons, age 85 years, were evaluated with thyroid function tests and a variety of cognitive assessments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/29\">",
"       29",
"      </a>",
"      ]. Most were euthyroid; 7 percent had subclinical hypothyroidism, and 7 percent had overt hypothyroidism. At baseline, and after two years of untreated follow-up, there was no correlation between TSH and cognitive status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Alzheimer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have linked thyroid disease and Alzheimer disease (AD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], but the bulk of evidence does not support an etiologic relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/30,32-35\">",
"     30,32-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case control study of 646 patients with AD found no relationship between thyroid disease and AD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A long-term follow-up study of 198 patients with Hashimoto's thyroiditis found no increased risk of subsequent dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Rotterdam study, 1843 older participants (mean age of 69 years) had TSH levels measured at study onset. At an average 2.1 years, the investigators reported that patients with low TSH had an increased risk of dementia overall and of AD in particular: adjusted relative risk 3.5 (95% CI: 1.1 to 11.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/30\">",
"       30",
"      </a>",
"      ]. Participants had normal T4 levels. A relationship between low TSH and AD was also found in a case control study of 178 AD patients and 291 controls (OR 2.4; 95% CI:1.2 to 4.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/36\">",
"       36",
"      </a>",
"      ]. The investigators speculated that AD-related neurodegeneration might lead to reduced thyrotropin-releasing hormone and low TSH on that basis. However, in an independent subset of 489 study participants in the Rotterdam study with a longer follow-up, baseline TSH was not associated with incident dementia or AD at 5.5 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of 829 consecutive outpatients in a geriatrics practice, there was no significant difference in TSH levels between patients with AD and those without dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal cerebrospinal fluid levels of thyroid hormones were found in an analysis of 21 euthyroid AD patients compared with controls, suggesting abnormal cerebral hormone metabolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hashimoto's encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune or Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient areas of the world. Hashimoto's encephalopathy describes a syndrome of altered mental status and seizures that occurs in individuals with serologic manifestations of Hashimoto's thyroiditis. Unlike the syndromes described above, the clinical manifestations are believed to result from autoimmunity, not from hypothyroidism. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33527?source=see_link\">",
"     \"Hashimoto's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of cognitive dysfunction in hypothyroidism is unknown. Decreased cerebral blood flow and decreased cerebral oxygen and glucose metabolism as seen on single photon emission computed tomography (SPECT) and positron-emission tomography (PET) studies have been implicated in some patients, but not in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/15,38-40\">",
"     15,38-40",
"    </a>",
"    ]. Animal studies suggest that hypothyroidism can produce alterations in the synaptic plasticity of neural pathways mediated by the dorsal hippocampus, which are important for many higher cognitive functions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild cognitive impairment in hypothyroidism may be mediated by anxiety and depression, both of which have been linked to hypothyroidism. Depression and anxiety can impair attention and executive function, the same cognitive spheres that are most often and earliest affected in hypothyroidism. Studies of post-thyroidectomy patients who undergo induced hypothyroidism (for the purpose of cancer assessment) find that patients exhibit symptoms of anxiety and depression with proportionate disturbances in attention and executive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism is generally understood to be a \"treatable\" dementia. However, studies of the efficacy of thyroid replacement on cognitive function are somewhat limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with more severe hypothyroidism, replacement to a euthyroid state can improve cognition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the degree of recovery is variable and may be incomplete in patients with more severe and longer duration of hypothyroidism. Cognitive recovery may also be delayed for several months following a return to a euthyroid state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/15\">",
"     15",
"    </a>",
"    ]. Studies that report either no or limited improvement often had short follow-up times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/14,45\">",
"     14,45",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Few randomized, placebo-controlled studies have assessed the effect of thyroid replacement on cognitive performance in patients with subclinical hypothyroidism. In these studies, which had relatively small numbers of patients, replacement with thyroxine led to objective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subjective improvements in memory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Several uncontrolled trials have also indicated that a significant improvement in attention, memory, verbal fluency, and executive functions occurs with thyroid replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/16,46,50\">",
"     16,46,50",
"    </a>",
"    ]. Most of these patients were not demented. A randomized, placebo controlled trial in 94 patients, aged 65 years and older with subclinical hypothyroidism demonstrated no significant improvement in mini-mental status examinations and other tests of cognition following six months of thyroid replacement; however only one subject was cognitively impaired at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these studies are not conclusive, we suggest considering a treatment trial with thyroid replacement for patients with subclinical hypothyroidism and cognitive impairment. Treatment can be stopped in patients who don't appear to have a clinical benefit, and have a TSH &lt;10",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    Thyroid replacement is recommended for subclinical hypothyroidism with TSH &gt;10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    regardless of cognitive status, as well as for patients with overt hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=see_link&amp;anchor=H25#H25\">",
"     \"Subclinical hypothyroidism\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Screening for hypothyroidism in cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The yield of screening for hypothyroidism in unselected patients with dementia is very low. In a community-based series of the 560 patients with dementia, no cases were felt to be attributable to hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/52\">",
"     52",
"    </a>",
"    ]. In the 1 percent of patients with TSH &gt;20",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    thyroid supplementation resulted in normalization of TSH levels but no improvement in dementia. However, the efficacy of thyroid replacement in improving mild cognitive impairment and ameliorating dementia has not been well studied and may be beneficial.",
"   </p>",
"   <p>",
"    Given the high prevalence of hypothyroidism in the elderly population and the potential for treatment benefit, we suggest screening for hypothyroidism with a serum TSH in patients with cognitive impairment and dementia as recommended by the Quality Standards Subcommittee of the American Academy of Neurology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MOVEMENT DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Parkinson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between hypothyroidism and Parkinson disease (PD) has not been defined. Although the incidence of hypothyroidism was shown in one small study to be slightly higher in patients with Parkinson disease compared with controls (6.6 versus 2.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/55\">",
"     55",
"    </a>",
"    ], other studies have found no difference in thyroid hormone levels in patients compared with the normal population or a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, many clinical features are common to both hypothyroidism and PD, including general slowness (bradykinesia), rigidity, decreased facial expression, monotonous voice, apathy, and depression. Because identification of hypothyroidism may be masked by PD, some suggest that thyroid function studies be performed in patients with PD who do not respond to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testing for hypothyroidism may be complicated in the setting of PD. L-dopa suppresses the thyrotropin-releasing hormone response. A small reduction in serum thyrotropin (TSH) levels has been shown to occur two hours after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/59\">",
"     59",
"    </a>",
"    ]. Serum TSH screening may produce false-negative results if the serum is drawn during the first few hours following administration of a dopaminergic medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cerebellar ataxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early case series of patients with adult-onset hypothyroidism, a wide-based gait ataxia was a prominent feature in a significant number (10 to 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In many cases, this was the presenting feature, and variably included limb ataxia (clumsiness, intention tremor, dysmetria) and dysarthria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Treatment of the hypothyroid state led to improvement or resolution of the cerebellar features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/8,62\">",
"     8,62",
"    </a>",
"    ]. Subsequent reports have challenged the association of cerebellar dysfunction and hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebellar dysfunction is also a feature of congenital hypothyroidism. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Persistent affects of congenital hypothyroidism'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hemichorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single case of reversible hemichorea has been reported in association with other features of hypothyroidism. The chorea resolved after several weeks of thyroid replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PERIPHERAL NEUROPATHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome (CTS) refers to compression of the median nerve within the carpal tunnel or bony canal in the wrist. CTS is a common symptom in the general population, with a reported prevalence of 3.0 to 5.8 percent in women and 0.6 to 2.1 percent in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CTS is a common complication of hypothyroidism. In small case series of patients with newly diagnosed hypothyroidism, CTS is present in 25 to 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In the majority of these patients, the findings were bilateral. No correlation between the severity of hypothyroidism and the presence of CTS has been reported.",
"   </p>",
"   <p>",
"    The reported prevalence of hypothyroidism in patients with CTS varies widely in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/67,70-73\">",
"     67,70-73",
"    </a>",
"    ]. A systematic review of the literature found that reported prevalence of hypothyroidism in CTS patients ranged from 1.3 percent to 10.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/67\">",
"     67",
"    </a>",
"    ]. The highest associations between CTS and hypothyroidism were in studies of patients undergoing surgical therapy, suggesting that hypothyroidism may be associated with more severe CTS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of CTS in hypothyroidism is believed to be due to mucinous infiltration of the perineurium and endoneurium of the median nerve within the carpal tunnel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Mucopolysaccharide protein complexes with synovial thickening have been identified in tendons and synovial sheaths. The deposition of mucin material leads to increased compartmental pressure within the carpal tunnel, producing direct pressure on the median nerve and causing focal demyelination. The pathologic findings improve or resolve with treatment of the hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of CTS symptoms may precede other clinical features of hypothyroidism.",
"   </p>",
"   <p>",
"    The symptoms and signs of CTS in hypothyroidism do not differ from CTS in other patients. Patients classically present with numbness, tingling, or pain in the hand, which is particularly bothersome at night. Sensory loss is demonstrable in the first three fingers and half of the fourth finger. Weakness and atrophy of the thenar muscles occur in severe cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CTS in hypothyroid patients is similar to other settings. Nerve conduction studies (NCS) are a useful diagnostic tool and can guide treatment decisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of screening for hypothyroidism in patients presenting with CTS has not been well studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/67\">",
"     67",
"    </a>",
"    ]. Most studies associating hypothyroidism in CTS do not indicate whether the diagnosis of hypothyroid disease was made before or after the diagnosis of CTS. One study that did so reported that 13 of 18 hypothyroid diagnoses were made after presentation with CTS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/70\">",
"     70",
"    </a>",
"    ]. Given the potential health risk of undiagnosed hypothyroidism, its relatively high prevalence in CTS, the relative ease of screening for the disease, and the altered treatment approach to CTS in the setting of hypothyroidism, we suggest screening for hypothyroidism with a serum thyrotropin level (TSH) in patients with CTS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical observations report clinical and electrodiagnostic improvement or resolution of the CTS following thyroid replacement and return to a euthyroid state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/69,76,77\">",
"     69,76,77",
"    </a>",
"    ]. With thyroid replacement, symptoms may improve within weeks to months. However, one study found that among 21 treated patients with hypothyroidism, symptoms and electrophysiologic signs of CTS were common (73 and 29 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/78\">",
"     78",
"    </a>",
"    ]. Unsystematic observations suggest that a longer duration of CTS prior to treatment is associated with poorer response to hormone replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other treatments used in CTS, such as wrist splinting, corticosteroid injection, and surgical carpal tunnel release are also options in these patients, although they have not been specifically studied in hypothyroid-related CTS. Since improvement with return to the euthyroid state is common, surgical intervention is often unnecessary and should probably await a treatment trial of hormone replacement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44008?source=see_link\">",
"     \"Treatment of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of polyneuropathy in hypothyroid patients is not precisely known. In various studies, distal sensory complaints occur in 29 to 64 percent, clinical signs of polyneuropathy are seen in 25 to 42 percent, and electrophysiologic evidence of polyneuropathy is reported in 17 to 72 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/68,69,79-81\">",
"     68,69,79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the hypothyroid neuropathy is incompletely understood. Pathologic descriptions have varied and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mucopolysaccharide-protein complexes within the endoneurium and perineurium",
"     </li>",
"     <li>",
"      Reduction in the number of large, myelinated fibers with segmental demyelination and remyelination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aggregates of glycogen granules, mitochondria, lipid droplets, and lamellar bodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/75,82\">",
"       75,82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Axonal degeneration with shrinkage of axons, and disruption of neurotubules and neurofilaments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some believe that the primary pathology in hypothyroid neuropathy is demyelination, perhaps as a result of metabolic abnormalities of the Schwann cells, with secondary axonal degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/75,84\">",
"     75,84",
"    </a>",
"    ]. Others propose a primary axonal pathology with secondary demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/82,85\">",
"     82,85",
"    </a>",
"    ]. Hypothyroidism may affect slow axonal transport due to a disturbance in microtubule assembly, thereby contributing to nerve damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical manifestation of hypothyroid neuropathy is a sensory disturbance in a symmetric, distal-predominant distribution, affecting the feet earlier and more severely than the hands. Sensory loss, tingling, and painful dysesthesias are common complaints. Findings on neurologic examination include loss or reduction of deep tendon reflexes and a symmetric \"stocking-glove\" distribution of sensory loss. Delayed relaxation of the reflexes is a characteristic feature of hypothyroidism. Rarely, in more severe cases, distal weakness and atrophy may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset and duration of neuropathic symptoms is generally correlated to the onset and duration of hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/83\">",
"     83",
"    </a>",
"    ]. However, symptoms of neuropathy may be present for years before the diagnosis of hypothyroidism is made. The severity of neuropathic symptoms does not directly correlate with the degree of thyroid deficiency, but may be associated with the duration of hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various findings on nerve conduction studies have been reported, including low amplitude or absent sensory nerve action potentials, mild slowing of motor and sensory conduction velocities, and mild prolongation of distal motor latencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/75,82,83\">",
"     75,82,83",
"    </a>",
"    ]. These findings suggest a combination of axonal and demyelinating features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical neurophysiology\", section on 'Nerve conduction studies'",
"    </a>",
"    .) These abnormalities can be seen in patients with subclinical as well as overt hypothyroidism and in patients without symptoms of neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of patients with hypothyroidism complains of typical neuropathic pain, but have normal nerve conduction studies. This suggests that some patients may have an isolated small fiber polyneuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of distal sensory loss and reduced or absent deep tendon reflexes suggests a sensory polyneuropathy in a patient with known hypothyroidism. Electrophysiologic tests help to confirm as well as characterize the polyneuropathy. There are no specific clinical or electrophysiologic features that distinguish hypothyroid polyneuropathy from neuropathy due to other causes.",
"   </p>",
"   <p>",
"    In one report, skin biopsy demonstrated a reduction in the intraepidermal nerve fiber density in neurologically asymptomatic patients with overt or subclinical hypothyroidism; the clinical utility of this evaluation is not established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone replacement is effective in the treatment of hypothyroid polyneuropathy. With a return to euthyroid state, clinical and electrophysiologic improvement occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/69,75,89\">",
"     69,75,89",
"    </a>",
"    ]. In one case series, nerve conduction studies normalized in four of seven patients examined three months after initiation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/69\">",
"     69",
"    </a>",
"    ]. The nonresponders had a longer duration of symptoms and more axonal features on nerve conduction studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Autoimmune demyelinating neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of Guillain-Barr&eacute; syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy of autoimmune origin have been reported in patients with Hashimoto's thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. These likely reflect an underlying predisposition to autoimmune disease. The presence of progressive weakness and prominent demyelinating features (conduction block) on nerve conduction studies should suggest these diagnoses. It is important to consider and recognize these syndromes, as the appropriate treatment is immunosuppressive therapy, rather than thyroid replacement alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Tarsal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report describes three patients with hypothyroidism and carpal tunnel syndrome who experienced unilateral tingling on the medial sole and heel of the foot, suggesting a clinical diagnosis of tarsal tunnel syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/93\">",
"     93",
"    </a>",
"    ]. Nerve conduction studies demonstrated prolonged tibial motor distal latencies, consistent with this diagnosis. However, more complete electrophysiologic studies were not performed, and a more generalized peripheral neuropathy was not excluded. At the same time, it seems plausible that hypothyroidism might be associated with entrapment neuropathies other than carpal tunnel syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle involvement in a variety of forms is a frequent problem in both congenital and adult-onset hypothyroidism. Typically, patients complain of myalgias and muscle stiffness and have mild proximal muscle weakness and elevated serum muscle enzymes. The myopathy resolves with thyroid replacement. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=see_link\">",
"     \"Hypothyroid myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual fields are restricted in most patients with hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/94\">",
"     94",
"    </a>",
"    ]. This occurs as a result of pituitary hyperplasia, itself a consequence of decreased negative feedback from thyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/95\">",
"     95",
"    </a>",
"    ]. These deficits are usually subtle and subclinical, and improve with thyroid replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss, which may be subclinical, and tinnitus are also common in hypothyroid patients and improve with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/96\">",
"     96",
"    </a>",
"    ]. The hearing loss is usually sensorineural rather than conductive. The pathogenesis is unknown; in some studies, a cochlear pathology or an endolymphatic hydrops have been implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical hoarseness of hypothyroidism is believed to result from myxedematous changes in the larynx rather than from neurologic involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of myasthenia gravis (MG) is somewhat higher in patients with hypothyroidism than in patients without thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/99\">",
"     99",
"    </a>",
"    ]. This likely reflects a shared autoimmune pathogenesis between MG and Hashimoto's thyroiditis, a common cause of hypothyroidism. MG is also associated with Graves' disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30057?source=see_link\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relationship between headache and hypothyroidism is not established. An association between hypothyroidism and migraine headache has been suggested in one small case control study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/100\">",
"     100",
"    </a>",
"    ]. In an uncontrolled case series, mild, diffuse headaches reported by 31 of 102 patients with new hypothyroidism resolved within two weeks of thyroid replacement treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/101\">",
"     101",
"    </a>",
"    ]. However, other small studies have found that hypothyroidism is not prevalent among patients with chronic headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/102\">",
"     102",
"    </a>",
"    ], that elevated thyroid-stimulating hormone is protective for headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/103\">",
"     103",
"    </a>",
"    ], and that there is no association between thyroid status and headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36585/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea can be caused or exacerbated by hypothyroidism, usually as a result of macroglossia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of hypothyroidism\", section on 'Respiratory system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic manifestations of hypothyroidism are both common and protean, affecting both the central and peripheral nervous system. Although usually occurring in the setting of other clinical manifestations of hypothyroidism, they may be the presenting feature, and can cause significant disability. Most of these complications are partially or fully responsive to thyroid replacement. The more common disorders are summarized in the Table. (",
"    <a class=\"graphic graphic_table graphicRef72975 \" href=\"mobipreview.htm?31/18/32043\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/1\">",
"      Glinoer D, Delange F. The potential repercussions of maternal, fetal, and neonatal hypothyroxinemia on the progeny. Thyroid 2000; 10:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/2\">",
"      Halpern JP, Boyages SC, Maberly GF, et al. The neurology of endemic cretinism. A study of two endemias. Brain 1991; 114 ( Pt 2):825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/3\">",
"      Cao XY, Jiang XM, Dou ZH, et al. Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. N Engl J Med 1994; 331:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/4\">",
"      Lazarus JH. Thyroid hormone and intellectual development: a clinician's view. Thyroid 1999; 9:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/5\">",
"      Oerbeck B, Sundet K, Kase BF, Heyerdahl S. Congenital hypothyroidism: no adverse effects of high dose thyroxine treatment on adult memory, attention, and behaviour. Arch Dis Child 2005; 90:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/6\">",
"      Arii J, Tanabe Y, Makino M, et al. Children with irreversible brain damage associated with hypothyroidism and multiple intracranial calcifications. J Child Neurol 2002; 17:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/7\">",
"      Ma T, Lian ZC, Qi SP, et al. Magnetic resonance imaging of brain and the neuromotor disorder in endemic cretinism. Ann Neurol 1993; 34:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/8\">",
"      Hagberg B, Westphal O. Ataxic syndrome in congenital hypothyroidism. Acta Paediatr Scand 1970; 59:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/9\">",
"      Wiebel J. Cerebellar-ataxic syndrome in children and adolescents with hypothyroidism under treatment. Acta Paediatr Scand 1976; 65:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/10\">",
"      Gauchard GC, Deviterne D, Leheup B, Perrin PP. Effect of age at thyroid stimulating hormone normalization on postural control in children with congenital hypothyroidism. Dev Med Child Neurol 2004; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/11\">",
"      Nicholson JL, Altman J. The effects of early hypo- and hyperthyroidism on the development of rat cerebellar cortex. I. Cell proliferation and differentiation. Brain Res 1972; 44:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/12\">",
"      Koibuchi N, Jingu H, Iwasaki T, Chin WW. Current perspectives on the role of thyroid hormone in growth and development of cerebellum. Cerebellum 2003; 2:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/13\">",
"      Leigh H, Kramer SI. The psychiatric manifestations of endocrine disease. Adv Intern Med 1984; 29:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/14\">",
"      Osterweil D, Syndulko K, Cohen SN, et al. Cognitive function in non-demented older adults with hypothyroidism. J Am Geriatr Soc 1992; 40:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/15\">",
"      Haupt M, Kurz A. Reversibility of dementia in hypothyroidism. J Neurol 1993; 240:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/16\">",
"      del Ser Quijano T, Delgado C, Mart&iacute;nez Espinosa S, V&aacute;zquez C. [Cognitive deficiency in mild hypothyroidism]. Neurologia 2000; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/17\">",
"      Miller KJ, Parsons TD, Whybrow PC, et al. Memory improvement with treatment of hypothyroidism. Int J Neurosci 2006; 116:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/18\">",
"      Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/19\">",
"      Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med 1990; 150:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/20\">",
"      Sawin CT, Chopra D, Azizi F, et al. The aging thyroid. Increased prevalence of elevated serum thyrotropin levels in the elderly. JAMA 1979; 242:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/21\">",
"      Ganguli M, Burmeister LA, Seaberg EC, et al. Association between dementia and elevated TSH: a community-based study. Biol Psychiatry 1996; 40:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/22\">",
"      Larson EB, Reifler BV, Sumi SM, et al. Diagnostic evaluation of 200 elderly outpatients with suspected dementia. J Gerontol 1985; 40:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/23\">",
"      L&ouml;pp&ouml;nen MK, Isoaho RE, R&auml;ih&auml; IJ, et al. Undiagnosed diseases in patients with dementia--a potential target group for intervention. Dement Geriatr Cogn Disord 2004; 18:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/24\">",
"      Luboshitzky R, Oberman AS, Kaufman N, et al. Prevalence of cognitive dysfunction and hypothyroidism in an elderly community population. Isr J Med Sci 1996; 32:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/25\">",
"      Lindeman RD, Schade DS, LaRue A, et al. Subclinical hypothyroidism in a biethnic, urban community. J Am Geriatr Soc 1999; 47:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/26\">",
"      Volpato S, Guralnik JM, Fried LP, et al. Serum thyroxine level and cognitive decline in euthyroid older women. Neurology 2002; 58:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/27\">",
"      Prinz PN, Scanlan JM, Vitaliano PP, et al. Thyroid hormones: positive relationships with cognition in healthy, euthyroid older men. J Gerontol A Biol Sci Med Sci 1999; 54:M111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/28\">",
"      Stern RA, Davis JD, Rogers BL, et al. Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer dementia. Cogn Behav Neurol 2004; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/29\">",
"      Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/30\">",
"      Kalmijn S, Mehta KM, Pols HA, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000; 53:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/31\">",
"      Lathe R. Hormones and the hippocampus. J Endocrinol 2001; 169:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/32\">",
"      Small GW, Matsuyama SS, Komanduri R, et al. Thyroid disease in patients with dementia of the Alzheimer type. J Am Geriatr Soc 1985; 33:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/33\">",
"      Yoshimasu F, Kokmen E, Hay ID, et al. The association between Alzheimer's disease and thyroid disease in Rochester, Minnesota. Neurology 1991; 41:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/34\">",
"      de Jong FJ, den Heijer T, Visser TJ, et al. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 2006; 91:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/35\">",
"      van der Cammen TJ, Mattace-Raso F, van Harskamp F, de Jager MC. Lack of association between thyroid disorders and Alzheimer's disease in older persons: a cross-sectional observational study in a geriatric outpatient population. J Am Geriatr Soc 2003; 51:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/36\">",
"      van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology 2004; 62:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/37\">",
"      Sampaolo S, Campos-Barros A, Mazziotti G, et al. Increased cerebrospinal fluid levels of 3,3',5'-triiodothyronine in patients with Alzheimer's disease. J Clin Endocrinol Metab 2005; 90:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/38\">",
"      Kinuya S, Michigishi T, Tonami N, et al. Reversible cerebral hypoperfusion observed with Tc-99m HMPAO SPECT in reversible dementia caused by hypothyroidism. Clin Nucl Med 1999; 24:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/39\">",
"      Constant EL, de Volder AG, Ivanoiu A, et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. J Clin Endocrinol Metab 2001; 86:3864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/40\">",
"      Smith CD, Ain KB. Brain metabolism in hypothyroidism studied with 31P magnetic-resonance spectroscopy. Lancet 1995; 345:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/41\">",
"      Sui L, Wang F, Li BM. Adult-onset hypothyroidism impairs paired-pulse facilitation and long-term potentiation of the rat dorsal hippocampo-medial prefrontal cortex pathway in vivo. Brain Res 2006; 1096:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/42\">",
"      Constant EL, Adam S, Seron X, et al. Anxiety and depression, attention, and executive functions in hypothyroidism. J Int Neuropsychol Soc 2005; 11:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/43\">",
"      Clarnette RM, Patterson CJ. Hypothyroidism: does treatment cure dementia? J Geriatr Psychiatry Neurol 1994; 7:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/44\">",
"      Cunha UG. An investigation of dementia among elderly outpatients. Acta Psychiatr Scand 1990; 82:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/45\">",
"      Wekking EM, Appelhof BC, Fliers E, et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005; 153:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/46\">",
"      Davis JD, Stern RA, Flashman LA. Cognitive and neuropsychiatric aspects of subclinical hypothyroidism: significance in the elderly. Curr Psychiatry Rep 2003; 5:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/47\">",
"      Bono G, Fancellu R, Blandini F, et al. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. Acta Neurol Scand 2004; 110:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/48\">",
"      Nystr&ouml;m E, Caidahl K, Fager G, et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol (Oxf) 1988; 29:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/49\">",
"      Jaeschke R, Guyatt G, Gerstein H, et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996; 11:744.",
"     </a>",
"    </li>",
"    <li>",
"     De-Fa Zhu, Brain 2006; 129:2923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/51\">",
"      Parle J, Roberts L, Wilson S, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab 2010; 95:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/52\">",
"      Knopman DS, Petersen RC, Cha RH, et al. Incidence and causes of nondegenerative nonvascular dementia: a population-based study. Arch Neurol 2006; 63:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/53\">",
"      Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/54\">",
"      Larson EB, Reifler BV, Sumi SM, et al. Diagnostic tests in the evaluation of dementia. A prospective study of 200 elderly outpatients. Arch Intern Med 1986; 146:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/55\">",
"      Munhoz RP, Teive HA, Troiano AR, et al. Parkinson's disease and thyroid dysfunction. Parkinsonism Relat Disord 2004; 10:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/56\">",
"      Berger JR, Kelley RE. Thyroid function in Parkinson disease. Neurology 1981; 31:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/57\">",
"      Johannessen AC, Boye A, Pakkenberg H. Thyroid function in patients with Parkinson's disease. Acta Neurol Scand 1987; 75:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/58\">",
"      Garc&iacute;a-Moreno JM, Chac&oacute;n-Pe&ntilde;a J. Hypothyroidism and Parkinson's disease and the issue of diagnostic confusion. Mov Disord 2003; 18:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/59\">",
"      Wingert TD, Hershman JM. Sinemet and thyroid function in Parkinson disease. Neurology 1979; 29:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/60\">",
"      NICKEL SN, FRAME B. Neurologic manifestations of myxedema. Neurology 1958; 8:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/61\">",
"      JELLINEK EH, KELLY RE. Cerebellar syndrome in myxoedema. Lancet 1960; 2:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/62\">",
"      Sandyk R. Cerebellar dysfunction in hypothyroidism. S Afr Med J 1982; 62:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/63\">",
"      Cremer GM, Goldstein NP, Paris J. Myxedema and ataxia. Neurology 1969; 19:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/64\">",
"      Pinelli P, Pisano F, Miscio G. Ataxia in myxoedema: a neurophysiological reassessment. J Neurol 1990; 237:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/65\">",
"      Quinn N, Barnard RO, Kelly RE. Cerebellar syndrome in myxoedema revisited: a published case with carcinomatosis and multiple system atrophy at necropsy. J Neurol Neurosurg Psychiatry 1992; 55:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/66\">",
"      Chotmongkol V, Bhuripanyo P. Movement disorder in hypothyroidism: a case report. J Med Assoc Thai 1989; 72:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/67\">",
"      van Dijk MA, Reitsma JB, Fischer JC, Sanders GT. Indications for requesting laboratory tests for concurrent diseases in patients with carpal tunnel syndrome: a systematic review. Clin Chem 2003; 49:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/68\">",
"      Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000; 68:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/69\">",
"      Kececi H, Degirmenci Y. Hormone replacement therapy in hypothyroidism and nerve conduction study. Neurophysiol Clin 2006; 36:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/70\">",
"      Atcheson SG, Ward JR, Lowe W. Concurrent medical disease in work-related carpal tunnel syndrome. Arch Intern Med 1998; 158:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/71\">",
"      Solomon DH, Katz JN, Bohn R, et al. Nonoccupational risk factors for carpal tunnel syndrome. J Gen Intern Med 1999; 14:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/72\">",
"      Karpitskaya Y, Novak CB, Mackinnon SE. Prevalence of smoking, obesity, diabetes mellitus, and thyroid disease in patients with carpal tunnel syndrome. Ann Plast Surg 2002; 48:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/73\">",
"      Cakir M, Samanci N, Balci N, Balci MK. Musculoskeletal manifestations in patients with thyroid disease. Clin Endocrinol (Oxf) 2003; 59:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/74\">",
"      PURNELL DC, DALY DD, LIPSCOMB PR. Carpal-tunnel syndrome associated with myxedema. Arch Intern Med 1961; 108:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/75\">",
"      Dyck PJ, Lambert EH. Polyneuropathy associated with hypothyroidism. J Neuropathol Exp Neurol 1970; 29:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/76\">",
"      Chisholm JC Jr. Hypothyroidism: a rare cause of the bilateral carpal tunnel syndrome--a case report and a review of the literature. J Natl Med Assoc 1981; 73:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/77\">",
"      Wood KA, Jacoby RJ. Lithium induced hypothyroidism presenting with carpal tunnel syndrome. Br J Psychiatry 1986; 149:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/78\">",
"      Palumbo CF, Szabo RM, Olmsted SL. The effects of hypothyroidism and thyroid replacement on the development of carpal tunnel syndrome. J Hand Surg Am 2000; 25:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/79\">",
"      Beghi E, Delodovici ML, Bogliun G, et al. Hypothyroidism and polyneuropathy. J Neurol Neurosurg Psychiatry 1989; 52:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/80\">",
"      Laycock MA, Pascuzzi RM. The neuromuscular effects of hypothyroidism. Semin Neurol 1991; 11:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/81\">",
"      Rao SN, Katiyar BC, Nair KR, Misra S. Neuromuscular status in hypothyroidism. Acta Neurol Scand 1980; 61:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/82\">",
"      Pollard JD, McLeod JG, Honnibal TG, Verheijden MA. Hypothyroid polyneuropathy. Clinical, electrophysiological and nerve biopsy findings in two cases. J Neurol Sci 1982; 53:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/83\">",
"      Nemni R, Bottacchi E, Fazio R, et al. Polyneuropathy in hypothyroidism: clinical, electrophysiological and morphological findings in four cases. J Neurol Neurosurg Psychiatry 1987; 50:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/84\">",
"      Shirabe T, Tawara S, Terao A, Araki S. Myxoedematous polyneuropathy: a light and electron microscopic study of the peripheral nerve and muscle. J Neurol Neurosurg Psychiatry 1975; 38:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/85\">",
"      Sidenius P, Nagel P, Larsen JR, et al. Axonal transport of slow component a in sciatic nerves of hypo- and hyperthyroid rats. J Neurochem 1987; 49:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/86\">",
"      Misiunas A, Niepomniszcze H, Ravera B, et al. Peripheral neuropathy in subclinical hypothyroidism. Thyroid 1995; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/87\">",
"      &Oslash;rstavik K, Norheim I, J&oslash;rum E. Pain and small-fiber neuropathy in patients with hypothyroidism. Neurology 2006; 67:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/88\">",
"      Magri F, Buonocore M, Oliviero A, et al. Intraepidermal nerve fiber density reduction as a marker of preclinical asymptomatic small-fiber sensory neuropathy in hypothyroid patients. Eur J Endocrinol 2010; 163:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/89\">",
"      Dick DJ, Lane RJ, Nogues MA, Fawcett PR. Polyneuropathy in occult hypothyroidism. Postgrad Med J 1983; 59:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/90\">",
"      Toscano A, Rodolico C, Benvenga S, et al. Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of an association. Neuromuscul Disord 2002; 12:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/91\">",
"      Polizzi A, Ruggieri M, Vecchio I, et al. Autoimmune thyroiditis and acquired demyelinating polyradiculoneuropathy. Clin Neurol Neurosurg 2001; 103:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/92\">",
"      Kohli RS, Bleibel W, Bleibel H. Concurrent immune thrombocytopenic purpura and Guillain-Barre syndrome in a patient with Hashimoto's thyroiditis. Am J Hematol 2007; 82:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/93\">",
"      Schwartz MS, Mackworth-Young CG, McKeran RO. The tarsal tunnel syndrome in hypothyroidism. J Neurol Neurosurg Psychiatry 1983; 46:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/94\">",
"      Yamamoto K, Saito K, Takai T, et al. Visual field defects and pituitary enlargement in primary hypothyroidism. J Clin Endocrinol Metab 1983; 57:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/95\">",
"      Khawaja NM, Taher BM, Barham ME, et al. Pituitary enlargement in patients with primary hypothyroidism. Endocr Pract 2006; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/96\">",
"      Anand VT, Mann SB, Dash RJ, Mehra YN. Auditory investigations in hypothyroidism. Acta Otolaryngol 1989; 108:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/97\">",
"      Meyerhoff WL. Hypothyroidism and the ear: electrophysiological, morphological, and chemical considerations. Laryngoscope 1979; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/98\">",
"      Brenner M, Hoistad DL, Hain TC. Prevalence of thyroid dysfunction in patients with M&eacute;ni&egrave;re's disease. Arch Otolaryngol Head Neck Surg 2004; 130:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/99\">",
"      T&eacute;llez-Zenteno JF, Cardenas G, Esta&ntilde;ol B, et al. Associated conditions in myasthenia gravis: response to thymectomy. Eur J Neurol 2004; 11:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/100\">",
"      Singh SK. Prevalence of migraine in hypothyroidism. J Assoc Physicians India 2002; 50:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/101\">",
"      Moreau T, Manceau E, Giroud-Baleydier F, et al. Headache in hypothyroidism. Prevalence and outcome under thyroid hormone therapy. Cephalalgia 1998; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/102\">",
"      Iwasaki Y, Kinoshita M, Ikeda K, et al. Thyroid function in patients with chronic headache. Int J Neurosci 1991; 57:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/103\">",
"      Hagen K, Bj&oslash;ro T, Zwart JA, et al. Low headache prevalence amongst women with high TSH values. Eur J Neurol 2001; 8:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/104\">",
"      Amy JR. Tests of thyroid function in chronic headache patients. Headache 1987; 27:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36585/abstract/105\">",
"      Larner AJ. Thyroid dysfunction and headache. J Headache Pain 2006; 7:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4841 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-77C9F1D2D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36585=[""].join("\n");
var outline_f35_46_36585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERSISTENT AFFECTS OF CONGENITAL HYPOTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MYXEDEMA COMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COGNITIVE IMPAIRMENT AND DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features and associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Myxedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hashimoto's encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Screening for hypothyroidism in cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MOVEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cerebellar ataxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hemichorea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PERIPHERAL NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Autoimmune demyelinating neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Tarsal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Visual loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Dysphonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4841|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/18/32043\" title=\"table 1\">",
"      Neuro complications of hypothy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33527?source=related_link\">",
"      Hashimoto's encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39864?source=related_link\">",
"      Iodine deficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=related_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_46_36586="Vitamin supplementation in disease prevention";
var content_f35_46_36586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vitamin supplementation in disease prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36586/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36586/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36586/contributors\">",
"     Kathleen M Fairfield, MD, DrPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36586/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36586/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/46/36586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/46/36586/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/46/36586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamins are chemically unrelated families of organic compounds that are essential in small amounts for normal metabolism. Because vitamins (with the exception of vitamin D) cannot be synthesized by humans, they need to be ingested in the diet to prevent disorders of metabolism. They should be distinguished from minerals (such as calcium and iron), some of which are also essential micronutrients.",
"   </p>",
"   <p>",
"    When vitamin deficiency is defined as low blood levels, or levels associated with reversible metabolic changes, the prevalence of vitamin deficiency on typical Western diets is higher than generally believed, especially in older adults. Pregnancy and alcohol consumption may increase requirements for some vitamins. Subtle deficiencies in several vitamins, at levels below those causing classic vitamin deficiency syndromes (eg, scurvy or pellagra), have been associated with chronic diseases such as atherosclerosis, cancer, and osteoporosis in observational studies. However, it is less well established that the vitamins in supplements can prevent or reverse chronic diseases.",
"   </p>",
"   <p>",
"    The evidence for using vitamin supplementation to prevent chronic disease is reviewed here. Overviews of individual vitamins, dietary minerals, and dietary supplements are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39226?source=see_link\">",
"     \"Overview of dietary trace minerals\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VITAMIN DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of vitamin deficiency has evolved since vitamins were first discovered, from obvious vitamin deficiency syndromes to the subtle effects of suboptimal vitamin intake on chronic diseases.",
"   </p>",
"   <p>",
"    Gross vitamin deficiency may be recognized by obvious clinical syndromes (",
"    <a class=\"graphic graphic_table graphicRef79983 \" href=\"mobipreview.htm?35/46/36589\">",
"     table 1",
"    </a>",
"    ). These syndromes are still seen in areas of the world with very poor diets. In Western societies, they occur mainly in special populations, including the elderly, vegans, new immigrants, the very poor, patients with alcoholism, malabsorption, little sun exposure, history of gastric bypass surgery, or inborn errors of metabolism, and in those undergoing hemodialysis or receiving parenteral nutrition (",
"    <a class=\"graphic graphic_table graphicRef81037 \" href=\"mobipreview.htm?9/39/9851\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dietary reference intakes (DRIs) represent four concepts: the Recommended Dietary Allowance (RDA); Adequate Intake (AI); Estimated Average Requirement (EAR); and Tolerable Upper Level (UL). DRIs are established in the United States (US) by the National Academy of Sciences, National Research Council, and the Institute of Medicine (IOM) (",
"    <a class=\"graphic graphic_table graphicRef72514 \" href=\"mobipreview.htm?29/45/30416\">",
"     table 3",
"    </a>",
"    ). For clinical purposes, we still refer to the RDA, which is the average daily intake that is sufficient to meet the dietary requirement of nearly all healthy people. The AI is used when the RDA cannot be determined (as is still the case for vitamin supplementation in infants &lt;12 months and for vitamin K) (",
"    <a class=\"graphic graphic_table graphicRef72514 \" href=\"mobipreview.htm?29/45/30416\">",
"     table 3",
"    </a>",
"    ). However, these intake levels may not be adequate for preventing chronic disease in some people. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74132943\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum levels of several vitamins is widely available. Fueled by popular belief in the importance of vitamins and by commercial interests, testing is being promoted to screen for unrecognized deficiency and to tailor supplements to individual needs. This practice seems unwarranted in most patients for two main reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is insufficient information about the optimum blood levels of vitamins, making it difficult to interpret subtle deficiency states.",
"     </li>",
"     <li>",
"      There is a lack of evidence that vitamin supplements prevent disease in many healthy adults with low blood levels of vitamins, apart from those with specific diets or medical conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tests are useful if clearly high or low to diagnose or rule out gross deficiency. However, the meaning of a \"normal\" value is uncertain; it is defined as the range of usual values in the general population, but many of these people may have suboptimal intake (just as, for example, commonly occurring levels of cholesterol or blood pressure may be harmful).",
"   </p>",
"   <p>",
"    Inadequate intake or low serum levels of some vitamins can be associated with biochemical abnormalities. As examples, the serum concentration of homocysteine rises with diets low in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , methylmalonic acid rises with low intake of vitamin B12, and parathyroid hormone rises with low intake of vitamin D. These biochemical abnormalities generally improve with increasing intake and reach a plateau beyond which more intake causes no further improvement, suggesting a correctable metabolic disorder. Testing for specific deficiencies remains appropriate in clinical situations where deficiencies are suspected (eg, vitamin D in elderly patients with osteoporosis or vitamin B12 in patients with cognitive decline of unknown etiology).",
"   </p>",
"   <p>",
"    Additional information about genetic polymorphisms, which increase requirements for specific vitamins, is likely to become available. This appears to be the case for certain genes, such as those controlling the metabolism of folate and vitamin D. However, there is currently not enough understanding of individual risk to warrant routine testing for vitamin levels or testing for polymorphisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link&amp;anchor=H14954217#H14954217\">",
"     \"Pathogenesis of osteoporosis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current interest in vitamins centers on whether optimizing the daily ingestion of vitamins can prevent chronic disease (eg, vitamin D supplementation and osteoporotic fractures; vitamin B12 and dementia). The remainder of this topic review will address the effectiveness of individual vitamin supplements in preventing specific diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FOLIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate is the natural form of the vitamin found in food and is present in green, leafy vegetables, fruits, cereals, grains, nuts, and meats.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    is the synthetic form of the vitamin that is included in supplements and food fortification, has many of the same biologic effects as folate, but is more bioavailable and therefore more effective dose for dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/1\">",
"     1",
"    </a>",
"    ]. Some evidence suggests that the metabolism of folic acid differs from folate and may have toxicities under certain circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/2\">",
"     2",
"    </a>",
"    ]. Gross deficiency of folate leads to megaloblastic anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    has been studied for prevention of many disease states. Overall, the only well established benefit of folic acid supplementation is the prevention of neural tube defects. The optimal dose of folic acid to prevent neural tube defects is not precisely known. For most women at average risk, 400 to 800 mcg daily is adequate. Thus, women of childbearing potential should take a daily supplement of 400 to 800 micrograms in addition to a varied diet. Women who have had a previous child with a neural tube defect typically are supplemented with a higher dose. Folic acid supplementation for the prevention of neural tube defects is reviewed briefly below and in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aside from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation to prevent neural tube defects, we do not recommend folic acid for disease prevention given the lack of proven efficacy for other conditions and the possible increased risk of cancer. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    supplementation reduces the risk of neural tube defects, probably because folate is required for normal cell division. This has been shown in multiple observational studies and confirmed by randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of women from two areas of China, one with a high and one with a low rate of neural tube defects, periconceptional intake of 400 mcg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    per day significantly reduced the incidence of neural tube defects in both regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/7\">",
"     7",
"    </a>",
"    ]. In the high incidence region, the rate of neural tube defects was 1.0 per 1000 among the fetuses or infants of women who were asked to take a pill containing 400 mcg of folic acid daily from the time of their premarital examination until the end of the first trimester of pregnancy, compared with 4.8 per 1000 among the fetuses or infants of women who did not take any folic acid. Comparable numbers for treated and untreated women in the low incidence region were 0.6 and 1.0 per 1000, respectively.",
"   </p>",
"   <p>",
"    Prior to a national grain fortification program in the US, only one in three women consumed a sufficient amount of folate to prevent neural tube defects. Mainly for this reason, the US Food and Drug Administration (FDA) mandated in 1998 that cereal grain products be fortified with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . The concentration of folic acid added, 140",
"    <span class=\"nowrap\">",
"     mcg/100",
"    </span>",
"    grams of cereal grain products, would give the average woman an extra 100",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of neural tube defect rates before and after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    fortification in various regions of the world and at various times have consistently shown reductions of 25 to 50 percent after supplementation, while rates in countries without fortification have not changed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/8\">",
"     8",
"    </a>",
"    ]. In setting the level of fortification, policy makers feared that folic acid supplements would mask vitamin B12 related neurologic disease in the elderly by preventing B12 related anemias that might otherwise cause symptoms leading to diagnosis of B12 deficiency. This phenomenon is theoretically possible but rarely observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women trying to conceive should take a daily supplement of 400 to 800 micrograms of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    daily. This is in agreement with the US Preventive Services Task Force (USPSTF) recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/10\">",
"     10",
"    </a>",
"    ]. Similarly, the US National Academies recommend a 400 microgram supplement for such women in addition to the folate in a varied diet (approximately 200",
"    <span class=\"nowrap\">",
"     micrograms/day",
"    </span>",
"    for an average woman). However, doses well above this amount may be necessary to maximally reduce the risk of neural tube defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link&amp;anchor=H7#H7\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'Folic acid supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate deficiency may contribute to aberrant DNA synthesis and carcinogenesis by decreasing methionine availability and interfering with normal DNA methylation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23782?source=see_link\">",
"     \"Physiology of vitamin B12 and folate deficiency\"",
"    </a>",
"    ). Biologic and observational evidence suggest that sufficient folate intake might prevent cancers in certain populations at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/12-15\">",
"     12-15",
"    </a>",
"    ], but randomized trials have not confirmed any benefits of folic acid supplementation and have raised the possibility of harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2013 meta-analysis of randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    in patients with colorectal adenoma (3 trials) or for prevention of cardiovascular disease (10 trials), during an average of 5.2 years of treatment, there was no significant difference in overall cancer incidence for patients assigned to folic acid or placebo (1904 versus 1809 cancers in placebo group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/20\">",
"     20",
"    </a>",
"    ]. There was also no significant effect on the incidence of specific cancers, including cancers of the large intestine, prostate, lung, or breast. The doses of folic acid in the included trials ranged from 0.5 to 5 mg daily, which is greater than the amount of folic acid in fortified cereal products and flour. One limitation of the included trials is that the average duration of intervention (five years) is short and may not be sufficient to characterize long-term benefits or harm of folic acid supplementation. In addition, the trials do not address underlying nutrition status and other preventive measures. Since the evidence is inconclusive, we recommend not taking folic acid supplementation for the sole purpose of reducing cancer risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64967839\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of homocysteine are associated with an increased risk of cardiovascular disease. Supplementation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B6, and vitamin B12 can lower homocysteine levels. However, meta-analyses of randomized trials of supplementation for secondary prevention do not support the hypothesis that these vitamins are beneficial for cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;High folate intake may reduce the risk of hypertension. In multivariate analyses from the large prospective Nurses' Health Study, compared with women who consumed diets with less than 200 mcg folate per day, the risk of hypertension was reduced in young women age 27 to 44 years consuming diets with more than 1000 mcg per day (RR 0.54, 95% CI 0.45-0.66) and to a lesser extent in older women age 43 to 70 years (RR 0.82, 0.69-0.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/26\">",
"     26",
"    </a>",
"    ]. There are insufficient evidence to recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation to reduce the risk of hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether folate intake is associated with hearing loss. There is conflicting observational evidence about whether increased serum folate levels are associated with a decreased risk of age-related hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation (800 mcg daily for three years) versus placebo in adults age 50 to 70 years with elevated homocysteine, those randomly assigned to folic acid had a slightly slower decline in low frequency hearing than those receiving placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/27\">",
"     27",
"    </a>",
"    ]. No such difference was seen for decline in hearing in the high frequencies. The trial was performed in the Netherlands at a time when food was not supplemented with folic acid.",
"   </p>",
"   <p>",
"    Additional studies are needed before folate supplementation can be recommended for the purpose of preventing hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated homocysteine levels have been associated with osteoporosis and dementia. It is not known whether these associations are causal and whether lowering homocysteine levels with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation would affect risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Folate/vitamin B12'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VITAMIN D",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intake of vitamin D in older adults should be the equivalent of at least 800 units daily, provided in the diet or as a vitamin D3 supplement (cholecalciferol) dosed daily, weekly, or monthly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/29\">",
"     29",
"    </a>",
"    ]. Dietary vitamin D intake is often low in older adults. Thus, for older adults, we suggest supplementation with 600 to 800 units of vitamin D daily. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subclinical vitamin D deficiency or insufficiency is extremely common and may contribute to the development of osteoporosis, falls, and fractures. We do not routinely measure serum 25-hydroxyvitamin D levels in most individuals. However, serum 25-hydroxyvitamin D should be measured in patients who are at risk for inadequate serum vitamin D concentrations, including institutionalized individuals, patients being evaluated for osteoporosis, and patients with malabsorption (eg, Crohn&rsquo;s disease and celiac disease). The evaluation and supplementation of vitamin D in patients with vitamin D deficient states and in patients with osteoporosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intake at which the dose of vitamin D becomes toxic is not clear. The Institute of Medicine (IOM) has defined the upper limit for vitamin D as 4000 units daily for healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/29\">",
"     29",
"    </a>",
"    ]. This is also the upper limit for pregnant and lactating women. It is important to inquire about additional dietary supplements (some of which contain vitamin D) that patients may be taking before prescribing supplemental vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic doses of vitamin D attenuate bone loss and may decrease fracture rate. Evidence regarding the efficacy and necessary dose of vitamin D to prevent osteoporosis and reduce fracture risk, as well as the possible need for concurrent calcium therapy, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As is the case with other vitamins, there is evidence that host factors such as genetic polymorphisms strongly influence fracture risk and may determine the host response to vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link&amp;anchor=H14954217#H14954217\">",
"     \"Pathogenesis of osteoporosis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Falls",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several meta-analyses showing a reduction in risk of falls (relative risk reduction as high as 20 percent) following vitamin D supplementation, particularly when the baseline vitamin D status is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\", section on 'Vitamin D supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link&amp;anchor=H651654#H651654\">",
"     \"Vitamin D and extraskeletal health\", section on 'Falls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64967914\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are biologic reasons why vitamin D may protect against cancer, evidence for this effect in humans is mixed and expert groups have not recommended vitamin D supplements for the specific purpose of preventing cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link&amp;anchor=H651662#H651662\">",
"     \"Vitamin D and extraskeletal health\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217626177\">",
"    <span class=\"h2\">",
"     All-cause mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In observational studies, the relationship between serum 25-hydroxyvitamin D and mortality was defined by a U or reverse J-shaped curve, indicating higher mortality at very low (&lt;20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and high (&gt;30 to 50",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    75 to 125",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    serum 25-hydroxyvitamin D concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/38\">",
"     38",
"    </a>",
"    ]. A meta-analysis of randomized trials of vitamin D supplementation did not find any statistically significant association with all-cause mortality (relative risk 0.96, 95% CI 0.93-1.00) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/39\">",
"     39",
"    </a>",
"    ]. The underlying trials were mainly designed to assess fractures, bone density, and falls in older patients. Since mortality was not reported in all such trials, there is the possibility of reporting bias where trials showing a mortality effect would be more likely to include results on mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link&amp;anchor=H651704#H651704\">",
"     \"Vitamin D and extraskeletal health\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64968013\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its role in calcium and bone homeostasis, vitamin D potentially regulates many cellular functions. Vitamin D deficiency has been implicated as a risk factor for many diseases. However, a causal association between poor vitamin D status and nearly all major diseases (infections, autoimmune disorders, cardiovascular and metabolic diseases) has not been established. This is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANTIOXIDANT VITAMINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antioxidant vitamins include total vitamin A, consisting of preformed vitamin A (retinol) and the carotenoids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , as well as vitamins C and E. Many other compounds found in food, especially vegetables and fruits, also have antioxidant properties. A number of studies have examined the hypothesis that antioxidants can prevent cancer and cardiovascular disease by augmenting the body's ability to dispose of toxic free radicals, thereby retarding oxidative damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies have consistently shown that diets high in vegetables and fruits (that are rich in antioxidants) are associated with a reduced risk of cancer and cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/41\">",
"     41",
"    </a>",
"    ]. Others have shown associations between specific vitamins and cancers or cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/42\">",
"     42",
"    </a>",
"    ]. However, observational studies may be misleading. The effect may be due to the vitamins themselves, other non-vitamin antioxidants, other compounds in vegetables and fruits such as flavonoids, substitution of dietary meat and fat with vegetables and fruits, or healthy lifestyles in people taking fruits and vegetables.",
"   </p>",
"   <p>",
"    Randomized trials that have examined the role of antioxidant supplements in reducing the risk of cancer and cardiovascular disease have generally not found positive effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. As an example, a systematic review and meta-analysis of randomized trials of antioxidant supplements for the prevention of gastrointestinal cancers found no decreased risk with supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While antioxidants are often grouped, specific antioxidant vitamins (including different forms of some vitamins) might be expected to have distinct effects. Individual responses may vary based upon genetic predisposition and other exposures including smoking, dose, and tissue of interest. We will consider the antioxidant vitamins separately in this section, since findings suggest that the specific types of antioxidant vitamins affect cancer and cardiovascular disease differently. Overall, there is a lack of evidence that antioxidant vitamins are beneficial in disease prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vitamin A and the carotenoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total vitamin A consists of preformed vitamin A (retinol) and the carotenoids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    . Retinol is only found in animal products and supplements, while carotenoids that can be converted into vitamin A (provitamin A carotenoids) are found in fruits and vegetables. In addition to antioxidant properties, retinol may also decrease cancer risk via other mechanisms such as inducing cellular differentiation.",
"   </p>",
"   <p>",
"    Most diets in developed countries contain adequate amounts of retinol and carotenoids. Vegetarians, including vegans, do not need to take vitamin A supplements if they eat an adequate variety of vegetables containing carotenoids. Supplementation with vitamin A at the community level in poor countries is recommended by the World Health Organization to prevent blindness. In the industrialized countries where dietary intake of vitamin A is generally adequate, we do not recommend vitamin A or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    supplementation given lack of proven efficacy and the possibility of harm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating vitamin",
"    <span class=\"nowrap\">",
"     A/carotenoid",
"    </span>",
"    supplementation and risk of cancer have provided mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/48-58\">",
"     48-58",
"    </a>",
"    ]. Results of observational studies and clinical trials have not been consistent, limiting the ability to make conclusive recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two large, randomized trials assessed the effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      supplementation on risk of lung cancer among men at increased risk for lung cancer because of smoking or asbestos exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. Both trials showed statistically significant increases in lung cancer risk among men who received the supplements. The excess risk appeared to resolve over time once supplements were stopped [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8902?source=see_link&amp;anchor=H5#H5\">",
"       \"Chemoprevention of lung cancer\", section on 'Primary chemoprevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Physicians Health Study found that 12 years of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      supplements (50 mg every other day) produced neither benefit nor harm with respect to the incidence of malignant neoplasms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/51\">",
"       51",
"      </a>",
"      ]. Overall, the cohort was at low risk for lung cancer since few smoked. The Women's Health Study also found no effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ATBC Cancer Prevention Study showed an increase in both prostate cancer incidence and mortality (23 and 15 percent, respectively) among subjects randomized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/44\">",
"       44",
"      </a>",
"      ]. The excess risk appeared to resolve over time once supplements were stopped [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of 7627 women who were free of cancer at random assignment in the Women's Antioxidant Cardiovascular Study found that after a mean follow-up of 9.4 years,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      50 mg every other day had no effect on the incidence of cancer (RR 1.00, 95% CI 0.85-1.17) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Observational studies of vitamin A (or carotenoid) intake and breast cancer have yielded varying results. In the Iowa Women's Health Study, no association between dietary vitamin A and breast cancer was observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/54\">",
"       54",
"      </a>",
"      ]. In contrast, evidence from the Nurses' Health Study suggested that high intake of carotenoids may decrease the risk of breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. This association may be strongest in premenopausal women with a positive family history who appear to have significant reductions in breast cancer risk with increasing dietary alpha- and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       lutein/zeaxanthin,",
"      </span>",
"      and total vitamin A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/56\">",
"       56",
"      </a>",
"      ]. Similarly, another report from the Nurses' Health Study found a decreased risk of breast cancer in women with higher plasma levels of carotenoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/57\">",
"       57",
"      </a>",
"      ]. There are no clinical trials of vitamin A intake and breast cancer.",
"     </li>",
"     <li>",
"      Results from a four-year randomized trial of antioxidants to prevent colorectal adenoma found no benefit to supplementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/58\">",
"       58",
"      </a>",
"      ]. The Polyp Prevention Study Group reported no reduction in adenoma risk in 864 patients randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      (25 mg daily), vitamin C (1 g daily) and E (400 mg daily), or both beta-carotene and vitamins C and E.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible explanations for discordant results for observational and experimental studies with regard to vitamin A and carotenoids and cancer risk include the inability of observational data to completely control for confounding by other healthy behaviors, differences in form or dose of vitamins, and interaction with other exposures such as tobacco [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/59\">",
"     59",
"    </a>",
"    ]. The increase in risk of lung cancer in two randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    has dampened enthusiasm for further clinical trials of antioxidants to prevent cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. There is currently no strong evidence that vitamin A and carotenoid supplements reduce the risk of cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of vitamin A and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    have shown no benefit for primary or secondary prevention of coronary heart disease (CHD) and one trial suggested potential harm with regard to cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/44\">",
"     44",
"    </a>",
"    ]. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A improves immunity in children living in developing countries where dietary intake is inadequate and life-threatening infectious diseases are common. A meta-analysis of 12 randomized trials of vitamin A showed a 30 percent reduction in overall mortality, with a 61 percent reduction in mortality among hospitalized patients with measles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/60\">",
"     60",
"    </a>",
"    ]. One US study of children with measles showed more severe illness in children with more depressed serum retinol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/61\">",
"     61",
"    </a>",
"    ]. The World Health Organization recommends community-based Vitamin A supplementation in developing countries even in the absence of signs and symptoms of deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/60\">",
"     60",
"    </a>",
"    ]. There is no reason to expect an improvement in immunity with vitamin A supplementation in people who already have adequate dietary intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is consistent evidence from observational studies that higher vitamin A intake (specifically retinol), within the range taken by many people in Western societies, is a risk factor for osteopenia and fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. As an example, 72,337 postmenopausal women age 34 to 77 years were followed for 18 years in the Nurses&rsquo; Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/63\">",
"     63",
"    </a>",
"    ]. Women in the highest quintile of total vitamin A intake had a relative risk for hip fracture of 1.48 compared with women in the lowest quintile. This increased risk was attributed primarily to retinol. An earlier Finnish cohort study had similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, patients should be cautioned against diets high in retinol (preformed vitamin A), especially if they have other risk factors for osteopenia, and should avoid vitamin A supplements, including multivitamins containing preformed vitamin A, if their dietary intake is high. Common food sources of preformed vitamin A include liver, milk, egg yolk, and butter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link&amp;anchor=H9#H9\">",
"     \"Drugs that affect bone metabolism\", section on 'Vitamin A and synthetic retinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cataracts and macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have found no benefit of vitamin A or carotenoid supplementation for the prevention of cataracts or macular degeneration. These trials are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link&amp;anchor=H8#H8\">",
"     \"Cataract in adults\", section on 'Vitamin supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=see_link&amp;anchor=H21#H21\">",
"     \"Age-related macular degeneration: Treatment and prevention\", section on 'Nutritional and vitamin supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9268837\">",
"    <span class=\"h2\">",
"     Vitamin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin C is commonly found in citric fruits and many types of vegetables. Vitamin C is thought to stimulate the immune system, strengthen connective tissues, and promote wound healing. Vitamin C may have a minor role in preventing the common cold, specifically for persons involved in high-intensity physical activity in extreme cold climates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link&amp;anchor=H20#H20\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Vitamin C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence does not support the use of vitamin C supplementation for disease prevention. In particular, vitamin C supplementation does not appear to be beneficial for the primary or secondary prevention of cancer or CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9268896\">",
"    <span class=\"h3\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large randomized trials have found no reduction in cancer in patients given vitamin C supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Physicians' Health Study II randomly assigned 14,641 male physicians ages 50 and older to vitamin C 500 mg daily or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/66\">",
"       66",
"      </a>",
"      ]. After an average follow-up of 8.0 years, vitamin C had no effect on the incidence of cancer (HR 1.01, 95% 95% CI 0.92-1.10).",
"     </li>",
"     <li>",
"      An analysis of 7627 women who were free of cancer at random assignment in the Women's Antioxidant Cardiovascular Study found that after a mean follow-up of 9.4 years, vitamin C 500 mg daily had no effect on the incidence of cancer (RR 1.11, 95% CI 0.95-1.30) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9268903\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have shown no benefit of vitamin C for primary or secondary prevention of coronary heart disease (CHD). This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Health Professionals Follow-up Study, an observational study including 43,738 men, showed no association between supplemental vitamin C (700 mg or more daily) and stroke risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9268910\">",
"    <span class=\"h3\">",
"     Cataracts and macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have found no benefit to vitamin C supplementation for the prevention of cataracts or macular degeneration. These trials are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link&amp;anchor=H8#H8\">",
"     \"Cataract in adults\", section on 'Vitamin supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=see_link&amp;anchor=H21#H21\">",
"     \"Age-related macular degeneration: Treatment and prevention\", section on 'Nutritional and vitamin supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E is a family of related chemicals. There are a number of biologically active vitamin E compounds in nature, including alpha-, beta-, gamma-, and delta- tocopherol. Vitamin E compounds are commonly found in sunflowers, wheat germ oil, corn, and nuts.",
"   </p>",
"   <p>",
"    Current evidence does not support a role for vitamin E supplementation in the prevention or treatment of cancers, cardiovascular disease, dementia, and infection. Since the best available evidence, while not conclusive, suggests that high-dose vitamin E (&ge;400",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    might increase all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/67\">",
"     67",
"    </a>",
"    ], patients without special indications should not take vitamin E supplements for disease prevention. In addition, individuals taking anticoagulants should be particularly advised against high doses of vitamin E because of the synergistic action of vitamin E with these drugs. Vitamin E supplementation is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have found variable effects of vitamin E on certain cancers, particularly within subgroups such as smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/54-56,68-70\">",
"     54-56,68-70",
"    </a>",
"    ], but most randomized trials do not support a protective effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/53,58,66,71-73\">",
"     53,58,66,71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the Women's Health Study was a randomized trial that followed 39,876 apparently healthy women ages 45 and older for a mean of 10.1 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/71\">",
"     71",
"    </a>",
"    ]. Compared with placebo, supplementation with 600 units of natural-source vitamin E on alternate days had no effect on the incidence of all cancer (RR 1.01, 95% CI 0.94-1.08) or on breast cancer (RR 1.00), lung cancer (RR 1.09), colon cancer (RR 1.00), or cancer death (RR 1.12).",
"   </p>",
"   <p>",
"    Randomized trials of vitamin E for prevention of prostate cancer have found conflicting results. The ATBC Cancer Prevention Study observed a 32 percent decrease in prostate cancer incidence and 41 percent decrease in prostate cancer mortality among male smokers randomly assigned to 50 mg (75 units) of alpha-tocopherol (vitamin E) for five to eight years compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/74\">",
"     74",
"    </a>",
"    ]. However, subsequent large randomized trials found no reduction, and possible harm, with vitamin E supplementation in prostate cancer incidence (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link&amp;anchor=H14#H14\">",
"     \"Chemoprevention strategies in prostate cancer\", section on 'Vitamin E'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SELECT trial followed 35,533 men (ages 50 and older for African American men and ages 55 and older for other men) for a median of seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/75\">",
"       75",
"      </a>",
"      ]. Compared with placebo, vitamin E supplementation (400 units daily) was associated with an increased risk of prostate cancer (HR 1.17, 99% CI 1.004-1.36).",
"     </li>",
"     <li>",
"      The Physicians' Health Study II followed 14,641 male physicians ages 50 and older for an average of 8.0 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/66\">",
"       66",
"      </a>",
"      ]. Compared with placebo, vitamin E supplementation (400 units every other day) had no effect on the incidence of prostate cancer (HR 0.97, 95% CI 0.85-1.09) or total cancer (HR 1.04, 95% CI 0.95-1.13).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supplementation with vitamin E does not appear to be beneficial in preventing cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all randomized trials of vitamin E have shown no benefit for primary or secondary prevention of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/44\">",
"     44",
"    </a>",
"    ]. Additionally, vitamin E supplementation may increase the risk of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/72\">",
"     72",
"    </a>",
"    ]. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials have not found convincing benefit of vitamin E supplementation for stroke prevention. In a meta-analysis of nine randomized trials of vitamin E supplementation versus placebo, vitamin E had no significant effect on risk of total stroke (RR 0.98, 95% CI 0.91-1.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/45\">",
"     45",
"    </a>",
"    ]. Findings were similar for patients with and without previous cardiovascular disease. Vitamin E supplementation was associated with an increased risk of hemorrhagic stroke (RR 1.22, 95% CI 1.00-1.48); however, it was also associated with a decreased risk of ischemic stroke (RR 0.90, 95% CI 0.82-0.99).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although observational studies suggested that increased dietary intake of vitamin E or vitamin E supplementation might protect against the development of Alzheimer disease and vascular dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/76-78\">",
"     76-78",
"    </a>",
"    ], randomized trials have found no benefit of vitamin E supplementation for the prevention of dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention of dementia\", section on 'Antioxidant vitamins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of dementia\", section on 'Vitamin E and selegiline'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have reported that supplementation with vitamin E improves the immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Such an effect is of particular interest in elderly people, in whom an age-related decline in immune response may increase the risk of infections and their complications. However, randomized trials that have examined the use of vitamin E to prevent infections in the elderly have not found clinical benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. Large trials found no reduction in the incidence of respiratory infections when either institutionalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/83,84\">",
"     83,84",
"    </a>",
"    ] or noninstitutionalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/85\">",
"     85",
"    </a>",
"    ] older adult patients received daily vitamin E supplements. Furthermore, in the study of noninstitutionalized elderly, among patients experiencing a respiratory infection, those who received vitamin E (200 units per day) had a significantly longer total illness duration (19 versus 14 days), more symptoms, and a higher frequency of fever and activity restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of vitamin E may interfere with vitamin K and affect coagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of vitamin E\", section on 'Excess and toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A secondary analysis from the Women's Health Study found that women randomly assigned to receive 600 units vitamin E every other day had a lower risk of venous thromboembolism than women receiving placebo (HR 0.79, 95% CI 0.66-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This effect needs to be confirmed in other randomized trials before vitamin E can be recommended for prevention of venous thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418486\">",
"    <span class=\"h3\">",
"     Cataracts and macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have found no benefit to vitamin E supplementation for the prevention of cataracts or macular degeneration. These trials are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link&amp;anchor=H8#H8\">",
"     \"Cataract in adults\", section on 'Vitamin supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=see_link&amp;anchor=H21#H21\">",
"     \"Age-related macular degeneration: Treatment and prevention\", section on 'Nutritional and vitamin supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     All-cause mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of randomized trials of vitamin E supplementation (many of which are discussed individually above) examined the effects of supplementation on all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/67\">",
"     67",
"    </a>",
"    ]. There was no significant effect on mortality across all trials; however, mortality was increased in patients who received high-dose vitamin E supplementation (&ge;400",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    (increase in mortality of 39 per 10,000 persons, 95% CI 3-74 per 10,000 persons). There appeared to be a dose-response relationship. As a whole, patients treated with low-dose supplementation had a decrease in mortality; however, trials of these doses were often performed in malnourished populations or used other supplements in combination with vitamin E. A number of the trials of high-dose supplementation were performed in patients with chronic diseases, and it is unclear whether the observed harm from such supplementation would carry over to a healthier population.",
"   </p>",
"   <p>",
"    Similar to the overall results of the above analysis, a meta-analysis that did not stratify trials by dose of vitamin E found no significant effect of supplementation on all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9052545\">",
"    <span class=\"h1\">",
"     VITAMIN B2 (RIBOFLAVIN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin B2 is found in many commonly consumed foods, including milk, meat, eggs, cereal, and green leafy vegetables. This may explain why overt riboflavin deficiency is rare. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link&amp;anchor=H22#H22\">",
"     \"Preventive treatment of migraine in adults\", section on 'Riboflavin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no strong evidence that supplemental vitamin B2 is helpful in healthy people eating a balanced diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     VITAMIN B6 (PYRIDOXINE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin B6 is found in bananas, nuts, and many common vegetables such as potatoes, green beans, cauliflower, and carrots. Vitamin B6 is thought to reduce the risk of cardiovascular disease and cancer. However, it has been difficult to separate out the effects of vitamin B6 from that of other vitamins and of other substances in fruits and vegetables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/87\">",
"     87",
"    </a>",
"    ]. Furthermore, the optimal dose is not well-characterized.",
"   </p>",
"   <p>",
"    High levels of homocysteine are associated with an increased risk of cardiovascular disease. Supplementation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B6, and vitamin B12 can lower homocysteine levels. However, randomized trials of supplementation for secondary prevention do not support the hypothesis that these vitamins prevent cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin B6 theoretically may lower risk of cancer. Possible mechanisms include preventing abnormalities in DNA synthesis, repair, and methylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/88\">",
"     88",
"    </a>",
"    ]. Higher levels of vitamin B6 and their metabolites are associated with a lower risk of cancer. In a meta-analysis of nine prospective cohort studies, vitamin B6 intake and blood levels of pyridoxal 5'-phosphate (the active form of vitamin B6) were inversely associated with risk of colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, a nested case-control analysis from the Nurses' Health Study found a trend toward a lower risk of breast cancer in women with higher plasma levels of vitamin B6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/90\">",
"     90",
"    </a>",
"    ]. Comparing the highest with the lowest quintile of plasma vitamin B6 levels, the relative risk was 0.70 (95% CI 0.48-1.02). Although higher plasma levels of vitamin B6 are associated with lower cancer risk, it is unclear whether supplementation with vitamin B6 is beneficial in cancer risk reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     VITAMIN B12 (COBALAMIN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suboptimal vitamin B12 level is most commonly caused by poor absorption and inadequate intake of vitamin B12-containing food sources (eg, liver, milk, fish, meat). Malabsorption of cobalamin is primarily the result of inability to release cobalamin from dietary proteins, especially in the presence of autoimmune antibodies against intrinsic factor or reduced gastric acid secretion. In older adults, gastric atrophy and hypochlorhydria result in reduced gastric acid and inefficient vitamin B12 absorption. Vitamin B12 deficiency can also be seen among people following a vegan diet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H54\">",
"     'Special diets'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a population-based cross-sectional analysis of 3511 elderly people from the United Kingdom, the age-specific prevalence of cobalamin deficiency was approximately 5 and 10 percent in those ages 65 to 74 years and those &ge;75 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin B12 deficiency is associated with several disease states: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe vitamin B12 deficiency causes neurologic disease and megaloblastic anemia. Subtle B12 deficiency, even without anemia, is associated with dementia and low cognitive function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/92\">",
"       92",
"      </a>",
"      ]. However, there is no solid evidence that taking vitamin B12 supplements prevents dementia. In addition, B12 deficiency may lead to deteriorating balance in some older adults, but this has not been well studied. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention of dementia\", section on 'Vitamins B6, B12, and folate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin B12 deficiency may also be an important cause of hyperhomocysteinemia, particularly in the elderly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/93\">",
"       93",
"      </a>",
"      ]. High levels of homocysteine are associated with an increased risk of cardiovascular disease. Supplementation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      , vitamin B6, and vitamin B12 can lower homocysteine levels, but randomized trial data do not support the hypothesis that these vitamins prevent cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/21-25\">",
"       21-25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"       \"Overview of homocysteine\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperhomocysteinemia is also associated with osteoporosis. It is not known whether this association is causal or whether lowering homocysteine levels would affect risk. Similarly it is unknown whether supplementation with folate and vitamin B12 in high risk groups would reduce the risk of fractures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Folate/vitamin B12'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals at risk for poor vitamin B12 intake, including vegans, alcoholics, and people with little dietary variation (such as some older adults) may require testing of vitamin B12 levels. Vitamin B12 supplementation in healthy adults and in those with vitamin B12 deficiency is well-tolerated without significant adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. The diagnostic approach and treatment of B12 deficiency is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no strong evidence that supplemental vitamin B12 is beneficial in healthy people eating a balanced diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     MULTIVITAMINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most generic and brand-name multivitamins contain 50 to 150 percent of the RDA for all vitamins, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and vitamins A, C, D, E, B2, B6, and B12. However, there are several variations of multivitamins, such as B vitamins alone, multivitamins with minerals, and multivitamins for specific groups (eg, women, men, younger and older populations). The proposed rationale for taking a daily multivitamin for adults includes known or potential effectiveness for some of the component vitamins, relative safety in low doses, low cost (one multivitamin per day costs $15 to $35 per year in the US), and efficiency of taking one pill rather than multiple vitamin pills. &nbsp;",
"   </p>",
"   <p>",
"    Multivitamin supplementation should be considered in patients at risk for vitamin deficiency, such as those with alcoholism, malabsorption, a vegan diet, a history of gastric bypass surgery, or some inborn errors of metabolism, as well as those being treated with hemodialysis or parenteral nutrition. In addition, in patients with a specific vitamin deficiency, a multivitamin may be a reasonable choice over supplementation with individual vitamins if a multivitamin is less costly and the formulation contains an appropriate dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Nutritional deficiencies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/8/9353?source=see_link\">",
"     \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unless there is a specific indication, however, we do not suggest multivitamin supplementation for primary prevention of chronic diseases because of evidence that they are not effective. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The health effects of multivitamins could be greater than the sum of their component vitamins if the component vitamins interacted. An example is the combined effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B6, and vitamin B12 on homocysteine metabolism.",
"   </p>",
"   <p>",
"    Several randomized trials and systematic reviews have evaluated the effect of individual and various combinations of vitamins on a variety of disease outcomes, including cancer, cardiovascular disease, and eye disease, as well as on total mortality. A 2006 systematic review of randomized trials and observational studies found insufficient evidence to determine the presence or absence of benefit of various vitamin combinations in preventing chronic disease (including cancer, cardiovascular disease, and certain eye diseases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/96\">",
"     96",
"    </a>",
"    ]. Subsequent studies of multivitamin supplementation have not shown benefit for cancer or cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. As an example, the Women&rsquo;s Health Initiative, a prospective observational study of nearly 162,000 women with a median follow-up of eight years, found no association between multivitamin use and risk of the following: breast cancer (HR 0.98, 95% CI 0.91-1.05), colorectal cancer (HR 0.99, CI 0.88-1.11), endometrial cancer (HR 1.05, CI 0.90-1.21), lung cancer (HR 1.00, CI 0.88-1.13), ovarian cancer (HR 1.07, CI 0.88-1.29), myocardial infarction (HR 0.96, CI 0.89-1.03), stroke (HR 0.99, CI 0.91-1.07), venous thromboembolism (HR 1.05, CI 0.85-1.29), or mortality (HR 1.02, CI 0.97-1.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first large randomized trial of multivitamin use, involving over 14,000 men, the Physicians&rsquo; Health Study II (PHS II), demonstrated a small, statistically-significant reduction in total cancer risk (HR 0.92, 95% CI 0.86-0.998) for the multivitamin group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/101\">",
"     101",
"    </a>",
"    ]. The study population was male physicians 50 years and older at recruitment, and thus generally well nourished and highly educated. With a mean follow-up of 11.2 years, there was a reduction in total cancer from 18.3 to 17.0 events per 1000 person-years, comparing groups assigned to multivitamins and placebo, respectively. No difference was found in the secondary outcome of decreased incidence of specific cancers, and there was no impact on cancer mortality. For men with a baseline history of cancer, multivitamin use was associated with a reduction in total cancer (HR 0.73, 95% CI 0.56-0.96).",
"   </p>",
"   <p>",
"    In addition, the PHS II trial showed no reduction in the rates of major cardiovascular events in men taking a daily multivitamin compared to placebo (11.0 versus 10.8 events per 1000 person-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/102\">",
"     102",
"    </a>",
"    ]. Cardiovascular events included myocardial infarction, stroke, and other vascular events. There was no difference in results between men with or without a history of cardiovascular disease. Multivitamin use also was not associated significantly with all-cause mortality. &nbsp;",
"   </p>",
"   <p>",
"    Given the variability of study findings, with only marginal benefit in some and no benefit in others, we suggest that healthy adults not take a daily multivitamin. It has not been established that multivitamin and mineral supplements provide added benefit to a balanced, healthful diet for most individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, the federal government does not regulate food supplements (vitamins, minerals, and herbs) to assure safety and efficacy. Multivitamins are sold in a variety of combinations and doses. However, manufacturers are required to list contents in a standard way, making it easier for consumers to compare brands.",
"   </p>",
"   <p>",
"    Individual vitamin doses in multivitamins are apparently safe for most adults. The dose of vitamin E is well below the levels reported to cause an increase in overall mortality, and the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , usually a part of the total vitamin A activity, is well below levels associated with lung cancer. The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is also lower than that found to potentially increase cancer risk. Some formulations of vitamins sold over-the-counter may contain several times the RDA of vitamin B12, which is harmless even at much higher doses.",
"   </p>",
"   <p>",
"    Some individuals may be harmed by even ordinary doses of vitamin A. Vitamin A has been shown in observational studies to be a risk factor for osteopenia and fractures in the range ingested by a substantial proportion of the adult population in the US. People at increase risk of osteopenia, or with relatively high dietary intake of vitamin A, should not take additional supplements containing vitamin A until further research clarifies whether the association between vitamin A and osteopenia is causal. Additionally, vitamin A is teratogenic starting at doses of only 10,000",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    of supplementation. Manufacturers have been reducing the amount of vitamin A in multivitamins, but supplementation, even at less than 100 percent of the RDA, does not seem prudent in people who are otherwise at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link&amp;anchor=H23#H23\">",
"     \"Screening for osteoporosis\", section on 'Risk factor screening'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Fractures'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H74132982\">",
"     'Toxicity at high doses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many multivitamins contain minerals as well, but the dose of minerals such as calcium and iron is well below one daily value (DV). DVs are reference values that provide recommended dietary nutrient intakes that appear on package labels. Toxicities of individual minerals are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39226?source=see_link\">",
"     \"Overview of dietary trace minerals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74132982\">",
"    <span class=\"h1\">",
"     TOXICITY AT HIGH DOSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially toxic levels of individual vitamins can be achieved easily in people who take very high potency vitamins, which can be obtained in specialty stores, over the internet, and even in pharmacies. High doses can also be achieved by taking a large number of pills even if the dose per pill is not high. The US Institute of Medicine and the Office of Dietary Supplements has suggested Tolerable Upper Intake Levels for specific vitamins, which is the highest daily dose that is unlikely to cause adverse health effects in the general population (",
"    <a class=\"graphic graphic_table graphicRef86660 \" href=\"mobipreview.htm?17/52/18253\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Water soluble vitamins (folate, vitamin C, B vitamins) can generally be tolerated at high doses, with toxicity occurring only at doses thousands of times the RDA. It has been hypothesized that large doses of vitamin C may increase the risk of kidney stones by increasing oxalate excretion, but this remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fat soluble vitamins (vitamins A, D, E, K) are generally more toxic than water soluble vitamins. Vitamin D may cause hypercalcemia at doses as low as 4000",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    (recommended upper limit) in some people. Vitamin A in pregnancy is teratogenic at doses as low as several times the RDA (with an apparent threshold at 10,000",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    of supplemental vitamin A) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/103\">",
"     103",
"    </a>",
"    ]. Beta-carotene appears to increase the risk of lung cancer in adults who are otherwise at high risk because of smoking or exposure to asbestos. As discussed above, there are concerns that vitamin E supplementation above 400 units per day may be associated with increased all-cause mortality. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Cancer'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H33\">",
"     'All-cause mortality'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     SPECIAL DIETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A balanced diet with fruits and vegetables promotes health not only by providing known vitamins, but also because it contains fiber and thousands of other less well-defined micronutrients and replaces meat and animal fat. However, people on restricted or special diets may have additional needs for vitamin supplementation. As an example, adequate vitamin B12 levels are strongly affected by dietary intake in addition to absorption. In younger adults, low consumption of animal-source food is the main cause of low vitamin B12 levels; in older adults, malabsorption of vitamin B12 from food is the most common cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/104\">",
"     104",
"    </a>",
"    ]. The lowest intakes of vitamin B12 are seen in those who eat no animal products, and vitamin B12 intake increases with increasing intake of animal source foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some special diets include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8266?source=see_link\">",
"     \"Vegetarian diets for children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Semivegetarian &mdash; Meat occasionally is included in the diet. Some people who follow such a diet may not eat red meat but may eat fish and perhaps chicken.",
"     </li>",
"     <li>",
"      Lactoovovegetarian &mdash; Eggs, milk, and milk products (lacto = dairy; ovo = eggs) are included, but no meat is consumed.",
"     </li>",
"     <li>",
"      Lactovegetarian &mdash; Milk and milk products are included in the diet, but no eggs or meat are consumed.",
"     </li>",
"     <li>",
"      Macrobiotic &mdash; Whole grains, especially brown rice, are emphasized and vegetables, fruits, legumes, and seaweeds are included in the diet. Locally-grown fruits are encouraged. Animal foods limited to white meat or fish may be included in the diet once or twice a week.",
"     </li>",
"     <li>",
"      Vegan &mdash; All animal products, including eggs, milk, and milk products, are excluded from the diet. Some vegans do not use honey and may refrain from using animal products such as leather or wool. They also may avoid foods that are processed or not organically grown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    People who consume a vegan diet should be supplemented with vitamin B12 (at the RDA of 2.4",
"    <span class=\"nowrap\">",
"     micrograms/day)",
"    </span>",
"    if they do not consume other fortified food products (such as cereals). They are also at risk for inadequate vitamin D status and should consider a supplement, particularly during winter months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lactoovovegetarians and lactovegetarians should also consider supplementation with vitamin B12.",
"   </p>",
"   <p>",
"    There are many other specialized diets that have not been adequately researched for their nutritional effects. Because most of the vitamins are available in a variety of foods, diets excluding one specific food generally would not be expected to result in deficiency or need for supplementation. In contrast, people who restrict entire categories of foods or consume only a few types of specific foods or groups may be at risk for deficiency of specific vitamins. Reasonable options in such patients are to recommend a daily multivitamin or consider specific testing (eg, 25-hydroxyvitamin D levels) based on the expected nutrient deficiencies in the diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Preventive Services Task Force (USPSTF) clinical practice guideline provides several recommendations for vitamin supplementation and can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <span class=\"nowrap\">",
"     www.ahrq.gov/clinic/uspstfix.htm.",
"    </span>",
"    The USPSTF recommends a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplement of 400 to 800",
"    <span class=\"nowrap\">",
"     micrograms/day",
"    </span>",
"    for all women planning or capable of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/10\">",
"     10",
"    </a>",
"    ]. The USPSTF found insufficient evidence to recommend for or against the use of supplements of vitamins A, C, E, multivitamins with folate, or antioxidant combinations for the prevention of cancer or cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/107\">",
"     107",
"    </a>",
"    ]. The USPSTF also recommend against the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    supplements for the prevention of cancer or cardiovascular disease.",
"   </p>",
"   <p>",
"    The US National Institutes of Health (NIH) consensus statement reports that there is insufficient evidence to recommend either for or against the use of multivitamins for chronic disease prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/46/36586/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/45/10962?source=see_link\">",
"       \"Patient information: Vitamin D deficiency (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/15/6387?source=see_link\">",
"       \"Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/38/40546?source=see_link\">",
"       \"Patient information: Vitamin supplements (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63268677\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, vitamin supplementation is not necessary for most adults who eat a balanced diet and get regular sun exposure or drink vitamin D&ndash;fortified dairy products. However, many people take multivitamins, and common formulations, generally containing 0.5- to 1.5-times the daily reference intakes of individual vitamins, are likely safe in nearly all people. Because some vitamins in larger doses can be harmful in some people, high-dose vitamin recommendations should be tailored to individual patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A balanced diet with fruits and vegetables promotes health not only by providing known vitamins, but also because it contains fiber and other less well-defined nutrients and replaces meat and animal fat. People on restricted or special diets may have additional needs for vitamin supplementation. (See",
"      <a class=\"local\" href=\"#H54\">",
"       'Special diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation in women who might become pregnant (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Supplementation in women reduces the incidence of neural tube defects in their children. While the optimal dose is unclear, women of childbearing potential should take a vitamin supplement containing at least 400 micrograms of folic acid per day. In all others, we recommend NOT taking folic acid for disease prevention (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This recommendation is based on evidence that it is not effective, the possibility that folic acid might mask vitamin B12 deficiency in older adults, and that folic acid might stimulate the progression of some cancers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link\">",
"       \"Folic acid for prevention of neural tube defects\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prevent osteoporosis and falls, the intake of vitamin D in older adults should be the equivalent of at least 800 units daily, provided in the diet or as a supplement dosed daily, weekly, or monthly. Dietary vitamin D intake is often low in older adults. Thus, for older adults, we suggest supplementation with 600 to 800 units of vitamin D daily depending on dietary intake (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Specific recommendations for vitamin D supplementation are discussed elsewhere. A causal association between poor vitamin D status and many major diseases (cancer, infections, autoimmune diseases, cardiovascular and metabolic diseases) has been suggested but not established. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      administering vitamin D supplements above and beyond what is required for osteoporosis or fall prevention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link&amp;anchor=H6#H6\">",
"       \"Prevention of falls and complications of falls in community-dwelling older persons\", section on 'Vitamin D supplementation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"       \"Treatment of vitamin D deficiency in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link\">",
"       \"Vitamin D and extraskeletal health\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=see_link\">",
"       \"Overview of vitamin D\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Vitamin D'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In industrialized countries where dietary intake of vitamin A is generally adequate, we recommend NOT supplementing with vitamin A for disease prevention (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Pregnant women should avoid vitamin A supplementation because it is teratogenic in doses easily achieved by high-dose supplementation. In addition, people with diets high in vitamin A and those who are at increased risk for fractures or osteopenia should avoid supplements that contain vitamin A, including multivitamin supplements, because relatively high intake, even from diet alone, has been associated with osteoporosis. Vitamin A supplementation may have other possible harmful effects, including increased risk of cancer, cardiovascular disease, and hip fracture. Therapeutic use of vitamin A in other populations, including in those at risk for vitamin A deficiency, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21736?source=see_link\">",
"       \"Overview of vitamin A\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H19\">",
"       'Vitamin A and the carotenoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H52\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients without special indications",
"      <strong>",
"       not",
"      </strong>",
"      take vitamin E supplements for preventive health care (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The best available evidence, which has limitations, suggests that high-dose vitamin E (&ge;400",
"      <span class=\"nowrap\">",
"       units/day)",
"      </span>",
"      increases all-cause mortality. Specific recommendations for vitamin E supplementation are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link\">",
"       \"Overview of vitamin E\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H26\">",
"       'Vitamin E'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      taking vitamin C supplementation for prevention of disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Such supplementation is safe but not effective. We also suggest",
"      <strong>",
"       not",
"      </strong>",
"      taking vitamin B2 or B6 supplementation for disease prevention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9268837\">",
"       'Vitamin C'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9052545\">",
"       'Vitamin B2 (riboflavin)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H41\">",
"       'Vitamin B6 (pyridoxine)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In young, healthy adults we suggest",
"      <strong>",
"       not",
"      </strong>",
"      taking vitamin B12 supplementation for disease prevention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some experts favor supplementation in older populations given the high prevalence of vitamin B12 deficiency and the safety of administration. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Vitamin B12 (cobalamin)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals at high risk of vitamin deficiency may benefit from a multivitamin supplement: those with alcoholism, malabsorption, a vegan diet, a history of gastric bypass surgery, or some inborn errors of metabolism, as well as those on hemodialysis. In addition, in patients with a specific vitamin deficiency, taking a multivitamin could be a reasonable choice over supplementing with individual vitamins if a multivitamin is less expensive and offers sufficient repletion. We suggest that healthy adults not take a daily multivitamin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Adults who are particularly concerned about minimizing their risk of developing cancer and are willing to accept a preventive therapy that is unlikely to cause harm, and where there is some evidence to suggest a small reduction in cancer risk, could reasonably choose to take a daily multivitamin. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Multivitamins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H54\">",
"       'Special diets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/1\">",
"      Oakley GP Jr. Eat right and take a multivitamin. N Engl J Med 1998; 338:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/2\">",
"      Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr 2008; 87:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/3\">",
"      Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C Semin Med Genet 2004; 125C:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/4\">",
"      Czeizel AE, Medveczky E. Periconceptional multivitamin supplementation and multimalformed offspring. Obstet Gynecol 2003; 102:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/5\">",
"      Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006; 28:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/6\">",
"      Botto LD, Mulinare J, Erickson JD. Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps. Am J Med Genet A 2003; 121A:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/7\">",
"      Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999; 341:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/8\">",
"      Eichholzer M, T&ouml;nz O, Zimmermann R. Folic acid: a public-health challenge. Lancet 2006; 367:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/9\">",
"      Tucker KL, Mahnken B, Wilson PW, et al. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 1996; 276:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/10\">",
"      U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/11\">",
"      Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001; 358:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/12\">",
"      Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 1998; 129:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/13\">",
"      Giovannucci E, Rimm EB, Ascherio A, et al. Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 1995; 87:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/14\">",
"      Lewis SJ, Harbord RM, Harris R, Smith GD. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Inst 2006; 98:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/15\">",
"      Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 2007; 99:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/16\">",
"      Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/17\">",
"      Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/18\">",
"      Ebbing M, B&oslash;naa KH, Nyg&aring;rd O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009; 302:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/19\">",
"      Zhang SM, Cook NR, Albert CM, et al. Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA 2008; 300:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/20\">",
"      Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50���000 individuals. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/21\">",
"      Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/22\">",
"      Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/23\">",
"      Mart&iacute;-Carvajal AJ, Sol&agrave; I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009; :CD006612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/24\">",
"      Miller ER 3rd, Juraschek S, Pastor-Barriuso R, et al. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol 2010; 106:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/25\">",
"      Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. Stroke 2010; 41:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/26\">",
"      Forman JP, Rimm EB, Stampfer MJ, Curhan GC. Folate intake and the risk of incident hypertension among US women. JAMA 2005; 293:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/27\">",
"      Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. Am J Clin Nutr 1999; 69:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/28\">",
"      Berner B, Odum L, Parving A. Age-related hearing impairment and B vitamin status. Acta Otolaryngol 2000; 120:633.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Report at a Glance, Report Brief: Dietary Reference Intakes for Calcium and Vitamin D, released 11/30/2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/30\">",
"      Marriott BM. Vitamin D supplementation: a word of caution. Ann Intern Med 1997; 127:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/31\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/32\">",
"      Jackson C, Gaugris S, Sen SS, Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM 2007; 100:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/33\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339:b3692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/34\">",
"      Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009; :CD007146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/35\">",
"      Cameron ID, Murray GR, Gillespie LD, et al. Interventions for preventing falls in older people in nursing care facilities and hospitals. Cochrane Database Syst Rev 2010; :CD005465.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine Dietary reference intakes of calcium and vitamin D, National Academy Press, Washington, DC 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/37\">",
"      Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer--ready for prime time? N Engl J Med 2011; 364:1385.",
"     </a>",
"    </li>",
"    <li>",
"     file://books.nap.edu/openbook.php?record_id=13050&amp;page=366 (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/39\">",
"      Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/40\">",
"      Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/41\">",
"      Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med 1995; 123:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/42\">",
"      Stanner SA, Hughes J, Kelly CN, Buttriss J. A review of the epidemiological evidence for the 'antioxidant hypothesis'. Public Health Nutr 2004; 7:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/43\">",
"      Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004; 364:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/44\">",
"      Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/45\">",
"      Sch&uuml;rks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010; 341:c5702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/46\">",
"      Ascherio A, Rimm EB, Hern&aacute;n MA, et al. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann Intern Med 1999; 130:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/47\">",
"      Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; 3:CD007176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/48\">",
"      The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/49\">",
"      Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/50\">",
"      Virtamo J, Pietinen P, Huttunen JK, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003; 290:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/51\">",
"      Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/52\">",
"      Lee IM, Cook NR, Manson JE, et al. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/53\">",
"      Lin J, Cook NR, Albert C, et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 2009; 101:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/54\">",
"      Kushi LH, Fee RM, Sellers TA, et al. Intake of vitamins A, C, and E and postmenopausal breast cancer. The Iowa Women's Health Study. Am J Epidemiol 1996; 144:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/55\">",
"      Hunter DJ, Manson JE, Colditz GA, et al. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 1993; 329:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/56\">",
"      Zhang S, Hunter DJ, Forman MR, et al. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst 1999; 91:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/57\">",
"      Tamimi RM, Hankinson SE, Campos H, et al. Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol 2005; 161:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/58\">",
"      Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 1994; 331:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/59\">",
"      Marshall JR. Beta-carotene: a miss for epidemiology. J Natl Cancer Inst 1999; 91:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/60\">",
"      Fawzi WW, Chalmers TC, Herrera MG, Mosteller F. Vitamin A supplementation and child mortality. A meta-analysis. JAMA 1993; 269:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/61\">",
"      Butler JC, Havens PL, Sowell AL, et al. Measles severity and serum retinol (vitamin A) concentration among children in the United States. Pediatrics 1993; 91:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/62\">",
"      Melhus H, Micha&euml;lsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med 1998; 129:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/63\">",
"      Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002; 287:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/64\">",
"      Micha&euml;lsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med 2003; 348:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/65\">",
"      Coulter ID, Hardy ML, Morton SC, et al. Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer. J Gen Intern Med 2006; 21:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/66\">",
"      Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/67\">",
"      Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/68\">",
"      Chan JM, Stampfer MJ, Ma J, et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/69\">",
"      Kirsh VA, Hayes RB, Mayne ST, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006; 98:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/70\">",
"      Woodson K, Tangrea JA, Barrett MJ, et al. Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers. J Natl Cancer Inst 1999; 91:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/71\">",
"      Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/72\">",
"      Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/73\">",
"      Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/74\">",
"      Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/75\">",
"      Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/76\">",
"      Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/77\">",
"      Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287:3223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/78\">",
"      Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/79\">",
"      Yaffe K, Clemons TE, McBee WL, et al. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 2004; 63:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/80\">",
"      Kang JH, Cook N, Manson J, et al. A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 2006; 166:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/81\">",
"      Meydani SN, Meydani M, Blumberg JB, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA 1997; 277:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/82\">",
"      Serafini M. Dietary vitamin E and T cell-mediated function in the elderly: effectiveness and mechanism of action. Int J Dev Neurosci 2000; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/83\">",
"      Girodon F, Galan P, Monget AL, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. MIN. VIT. AOX. geriatric network. Arch Intern Med 1999; 159:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/84\">",
"      Meydani SN, Leka LS, Fine BC, et al. Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial. JAMA 2004; 292:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/85\">",
"      Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. JAMA 2002; 288:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/86\">",
"      Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation 2007; 116:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/87\">",
"      Omenn GS, Beresford SA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. Circulation 1998; 97:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/88\">",
"      Selhub J. Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging 2002; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/89\">",
"      Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA 2010; 303:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/90\">",
"      Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003; 95:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/91\">",
"      Clarke R, Grimley Evans J, Schneede J, et al. Vitamin B12 and folate deficiency in later life. Age Ageing 2004; 33:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/92\">",
"      Vogel T, Dali-Youcef N, Kaltenbach G, Andr&egrave;s E. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract 2009; 63:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/93\">",
"      Stabler SP, Lindenbaum J, Allen RH. Vitamin B-12 deficiency in the elderly: current dilemmas. Am J Clin Nutr 1997; 66:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/94\">",
"      Dary O. Establishing safe and potentially efficacious fortification contents for folic acid and vitamin B12. Food Nutr Bull 2008; 29:S214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/95\">",
"      Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008; :CD004514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/96\">",
"      Huang HY, Caballero B, Chang S, et al. The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health state-of-the-science conference. Ann Intern Med 2006; 145:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/97\">",
"      Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med 2009; 169:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/98\">",
"      Lawson KA, Wright ME, Subar A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 2007; 99:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/99\">",
"      McNeill G, Avenell A, Campbell MK, et al. Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial. Nutr J 2007; 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/100\">",
"      Liu BA, McGeer A, McArthur MA, et al. Effect of multivitamin and mineral supplementation on episodes of infection in nursing home residents: a randomized, placebo-controlled study. J Am Geriatr Soc 2007; 55:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/101\">",
"      Gaziano JM, Sesso HD, Christen WG, et al.. Multivitamins in the prevention of cancer in men. The Physicians' Health Study II randomized controlled trial. JAMA online first 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/102\">",
"      Sesso HD, Christen WG, Bubes V, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/103\">",
"      Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/104\">",
"      Allen LH. How common is vitamin B-12 deficiency? Am J Clin Nutr 2009; 89:693S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/105\">",
"      Davey GK, Spencer EA, Appleby PN, et al. EPIC-Oxford: lifestyle characteristics and nutrient intakes in a cohort of 33 883 meat-eaters and 31 546 non meat-eaters in the UK. Public Health Nutr 2003; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/106\">",
"      Outila TA, K&auml;rkk&auml;inen MU, Sepp&auml;nen RH, Lamberg-Allardt CJ. Dietary intake of vitamin D in premenopausal, healthy vegans was insufficient to maintain concentrations of serum 25-hydroxyvitamin D and intact parathyroid hormone within normal ranges during the winter in Finland. J Am Diet Assoc 2000; 100:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/107\">",
"      U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale. Ann Intern Med 2003; 139:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/46/36586/abstract/108\">",
"      NIH State-of-the-Science Conference Statement on Multivitamin/Mineral Supplements and Chronic Disease Prevention. NIH Consens State Sci Statements 2006; 23:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5368 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36586=[""].join("\n");
var outline_f35_46_36586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H63268677\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VITAMIN DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74132943\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FOLIC ACID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64967839\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VITAMIN D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Falls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64967914\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H217626177\">",
"      All-cause mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64968013\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANTIOXIDANT VITAMINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vitamin A and the carotenoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cataracts and macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9268837\">",
"      Vitamin C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9268896\">",
"      - Cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9268903\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9268910\">",
"      - Cataracts and macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Dementia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H418486\">",
"      - Cataracts and macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - All-cause mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9052545\">",
"      VITAMIN B2 (RIBOFLAVIN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      VITAMIN B6 (PYRIDOXINE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      VITAMIN B12 (COBALAMIN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      MULTIVITAMINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74132982\">",
"      TOXICITY AT HIGH DOSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      SPECIAL DIETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63268677\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/5368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/5368|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/46/36589\" title=\"table 1\">",
"      Vitamin deficiency syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/39/9851\" title=\"table 2\">",
"      Clinical situations associated with vitamin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/45/30416\" title=\"table 3\">",
"      Dietary Reference Intakes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/52/18253\" title=\"table 4\">",
"      Tolerable upper intake levels for vitamins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=related_link\">",
"      Age-related macular degeneration: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8902?source=related_link\">",
"      Chemoprevention of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/8/9353?source=related_link\">",
"      Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/15/6387?source=related_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/45/10962?source=related_link\">",
"      Patient information: Vitamin D deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/38/40546?source=related_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23782?source=related_link\">",
"      Physiology of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_46_36587="Characteristic grief depres";
var content_f35_46_36587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of grief versus depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grief",
"       </td>",
"       <td class=\"subtitle1\">",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definition",
"       </td>",
"       <td>",
"        Feelings and behaviors that result from a particular loss",
"       </td>",
"       <td>",
"        Depressed mood, decreased interest and pleasure, appetite and sleep disturbance, psychomotor agitation or retardation, decreased concentration, loss of energy, feelings of worthlessness, guilt, hopelessness, helplessness, and thoughts of death with impairment of functioning lasting at least two weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Symptoms and signs",
"       </td>",
"       <td rowspan=\"2\">",
"        Somatic distress, sleep and appetite disturbance, diminished concentration, social withdrawal, sighing",
"       </td>",
"       <td>",
"        Hopelessness, helplessness, anhedonia, worthlessness, guilt, suicidal ideation most useful diagnostic clues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatic distress, sleep and appetite disturbance, diminished concentration, social withdrawal, sighing are also common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Other differentiating factors",
"       </td>",
"       <td>",
"        Patient retains capacity for pleasure",
"       </td>",
"       <td>",
"        Nothing is enjoyable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comes in waves",
"       </td>",
"       <td>",
"        Constant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Passive wishes for death",
"       </td>",
"       <td>",
"        Intense, persistent suicidal thoughts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Able to look forward to the future",
"       </td>",
"       <td>",
"        No sense of anything to look forward to",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Block, SD. Psychological issues in end of life care. Journal of Palliative Medicine 2006; 9:751. Copyright &copy;2006 Mary Ann Liebert, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36587=[""].join("\n");
var outline_f35_46_36587=null;
var title_f35_46_36588="Initial management of patients with suspected aortic dissection";
var content_f35_46_36588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guidelines: Initial management of patients with suspected aortic dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Detailed medical history and complete physical examination (whenever possible)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Intravenous line, blood sample (CK, troponin I, myoglobin, WBC, D-dimer, hematocrit, LDH)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. ECG: documentation of ischemia",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Heart rate and blood pressure (BP) monitoring",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Pain relief (morphine sulphate)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Reduction of systolic blood pressure using beta blockers (IV propranolol, metoprolol, esmolol, or labetalol)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Transfer to intensive care unit",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. In patients with severe hypertension additional vasodilator (IV sodium nitroprusside to titrate BP to 100-120 mmHg)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. In patients with obstructive pulmonary disease, blood pressure lowering with calcium channel blockers",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Imaging in patients with ECG signs of ischemia before thrombolysis if aortic pathology is suspected",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Chest x-ray",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Erbel, R, Alfonso, F, Boileau, C, et al, Eur Heart J 2001; 22:1642.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36588=[""].join("\n");
var outline_f35_46_36588=null;
var title_f35_46_36589="Vitamin deficiency syndromes";
var content_f35_46_36589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vitamin deficiency syndromes and dietary sources of common vitamins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deficiency syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Water-soluble",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         B1",
"        </p>",
"        <p>",
"         (thiamine)",
"        </p>",
"       </td>",
"       <td>",
"        Thiamine pyrophosphate",
"       </td>",
"       <td>",
"        Beriberi - dry (peripheral neuropathy) or wet (heart failure), Wernicke encephalopathy (nystagmus,",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         ophthalmoplegia",
"        </span>",
"        , ataxia)",
"       </td>",
"       <td>",
"        Wheat germ, whole grains, dried beans, oatmeal,&nbsp;brown rice, pork, liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         B2",
"        </p>",
"        <p>",
"         (riboflavin)",
"        </p>",
"       </td>",
"       <td>",
"        Flavine adenine dinucleotide",
"       </td>",
"       <td>",
"        Nonspecific symptoms including edema of mucus membranes, angular stomatitis, glossitis, and seborrheic dermatitis",
"       </td>",
"       <td>",
"        Milk products, meat, cheese, eggs, liver, ocean fish, dark green leafy vegetables, whole grains, whey powder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         B3",
"        </p>",
"        <p>",
"         (niacin, nicotinic acid)",
"        </p>",
"       </td>",
"       <td>",
"        Nicotinamide adenine dinucleotide",
"       </td>",
"       <td>",
"        Pellagra (dermatitis, diarrhea, dementia)",
"       </td>",
"       <td>",
"        Peanuts, peas, liver, poultry, fish, lean meat, bran",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         B6",
"        </p>",
"        <p>",
"         (proxidine, pyridoxal)",
"        </p>",
"       </td>",
"       <td>",
"        Transaminase cofactor",
"       </td>",
"       <td>",
"        Anemia, weakness, insomnia, difficulty walking, nasolabial seborrheic dermatitis, cheilosis, stomatitis",
"       </td>",
"       <td>",
"        Bananas, chick peas, fortified cereals, yeast,&nbsp;potatoes, brown rice, salmon, chicken, tuna, liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         B12",
"        </p>",
"        <p>",
"         (cobalamin)",
"        </p>",
"       </td>",
"       <td>",
"        One carbon transfer",
"       </td>",
"       <td>",
"        Megaloblastic anemia (pernicious anemia), neurologic symptoms (subacute combined degeneration)",
"       </td>",
"       <td>",
"        Clams, salmon, liver, egg yolk, meat, lentils, spinach, fortified cereals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folate",
"       </td>",
"       <td>",
"        One carbon transfer",
"       </td>",
"       <td>",
"        Megaloblastic anemia",
"       </td>",
"       <td>",
"        Liver, spinach, avocado, lentils, fortified cereals, enriched rice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biotin",
"       </td>",
"       <td>",
"        Pyruvate carboxylase cofactor",
"       </td>",
"       <td>",
"        Nonspecific symptoms including altered mental status, myalgia, dysesthesias, anorexia, maculosquamous dermatitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pantothenate",
"       </td>",
"       <td>",
"        Coenzyme A",
"       </td>",
"       <td>",
"        Nonspecific symptoms including paresthesias, dysesthesias (\"burning feet\"), anemia, gastrointestinal symptoms",
"       </td>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         Fortified cereals, shiitake mushrooms, white mushrooms, sunflower seeds, salmon, beef, chicken",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         C",
"        </p>",
"        <p>",
"         (ascorbate)",
"        </p>",
"       </td>",
"       <td>",
"        Antioxidant, collagen synthesis",
"       </td>",
"       <td>",
"        Scurvy - fatigue, petechiae, ecchymoses, bleeding gums, depression, dry skin, impaired wound healing",
"       </td>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         Citric fruits, peppers, papaya, broccoli, brussel sprouts, strawberries, paprika, kohlrabi",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fat-soluble",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         A",
"        </p>",
"        <p>",
"         (retinol, retinal, retinoic acid)",
"        </p>",
"       </td>",
"       <td>",
"        Vision, epithelial differentiation, antioxidant",
"       </td>",
"       <td>",
"        Night blindness, xerophthalmia, keratomalacia, Bitot's spot, follicular hyperkeratosis",
"       </td>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         Cod-liver oil, milk products, carrots, sweet potatoes, spinach, pumpkin, dark leafy green vegetables, butter, egg yolk",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         D",
"        </p>",
"        <p>",
"         (cholecalciferol, ergocalciferol)",
"        </p>",
"       </td>",
"       <td>",
"        Prohormone for calcium regulation",
"       </td>",
"       <td>",
"        Rickets, osteomalacia, craniotabes",
"       </td>",
"       <td>",
"        Cod-liver oil,",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         fatty fish, milk, egg yolk, liver, maitake mushrooms, fortified cereals",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         E",
"        </p>",
"        <p>",
"         (tocopherols)",
"        </p>",
"       </td>",
"       <td>",
"        Antioxidant",
"       </td>",
"       <td>",
"        Sensory and motor neuropathy, ataxia, retinal degeneration, hemolytic anemia",
"       </td>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         Sunflower seeds, almonds, fortified cereals, sunflower oil, safflower oil, spinach, turnip greens",
"        </span>",
"        ,&nbsp;collard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         K",
"        </p>",
"        <p>",
"         (phylloquinone, menaquinone, menadione)",
"        </p>",
"       </td>",
"       <td>",
"        Clotting factors, bone proteins",
"       </td>",
"       <td>",
"        Hemorrhagic disease",
"       </td>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         Cooked collard greens, spinach, kale, mustard greens, raw spinach, cooked brussel sprouts, asparagus, green leaf lettuce, kiwi, dried prunes",
"        </span>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36589=[""].join("\n");
var outline_f35_46_36589=null;
var title_f35_46_36590="Cortical cataract";
var content_f35_46_36590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cortical cataract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Slit lamp photo of a cortical cataract reveals white spoke-like opacities in the outer layers of the lens (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah S Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36590=[""].join("\n");
var outline_f35_46_36590=null;
var title_f35_46_36591="Mitral valvuloplasty using the Inoue balloon catheter";
var content_f35_46_36591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1195px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/75997/mitrvlvp_conv.mp4?title=Mitral+valvuloplasty+using+the+Inoue+balloon+catheter\" style=\"width:224px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    Mitral valvuloplasty using the Inoue balloon catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a balloon inflation-deflation sequence during a percutanous mitral commissurotomy using the Inoue balloon. The balloon catheter has been introduced from the right femoral vein, crosses the interatrial septum after a transeptal catheterization, and has been manipulated across the mitral valve into the left ventricle with the balloon deflated. During inflation the distal portion of the balloon expands first and the catheter is pulled back slightly with resistance being felt from the stenotic valve. Additional inflation then expands the rear or proximal portion of the balloon, thus locking the balloon within the stenotic valve. The final inflation expands the mid-portion resulting in a controlled transmission of force resulting in a splitting of the fused commissures. The rapid inflation-deflation sequence shown here results in no important period of hypotension; most patients have little awareness of the inflation. The other catheters seen in the image are a pigtail catheter in the left ventricle and a pulmonary artery thermodilution cardiac output catheter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John D Carroll, MD. This type of movie will be part of The Multimedia Textbook of Coronary Arteriography and Interventions, Williams &amp; Wilkins, Baltimore, Fall, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_46_36591=[""].join("\n");
var outline_f35_46_36591=null;
